

Glivec (STI571, imatinib), a rationally developed, targeted

Nature Reviews Drug Discovery

1, 493-502

DOI: 10.1038/nrd839

Citation Report

#	ARTICLE	IF	CITATIONS
1	Emerging cancer-targeted therapies. <i>Pediatric Clinics of North America</i> , 2002, 49, 1339-1368.	0.9	7
2	A paradigm for therapy-induced microenvironmental changes in solid tumors leading to drug resistance. <i>Differentiation</i> , 2002, 70, 599-609.	1.0	61
3	Structures of the Cancer-Related Aurora-A, FAK, and EphA2 Protein Kinases from Nanovolume Crystallography. <i>Structure</i> , 2002, 10, 1659-1667.	1.6	193
5	Selective anticancer drugs. <i>Nature Reviews Cancer</i> , 2002, 2, 645-646.	12.8	32
6	Selective anticancer drugs. <i>Nature Reviews Drug Discovery</i> , 2002, 1, 491-492.	21.5	81
8	Dual-specificity phosphatases as targets for antineoplastic agents. <i>Nature Reviews Drug Discovery</i> , 2002, 1, 961-976.	21.5	132
9	NF- κ B and breast cancer. <i>Current Problems in Cancer</i> , 2002, 26, 282-309.	1.0	62
10	Molecular pathology of tumor metastasis III. <i>Pathology and Oncology Research</i> , 2003, 9, 49-72.	0.9	10
11	Response to imatinib mesylate of a gastrointestinal stromal tumor with very low expression of KIT. <i>Cancer Chemotherapy and Pharmacology</i> , 2003, 51, 261-265.	1.1	73
12	Exposing oncogenic dependencies for cancer drug target discovery and validation using RNAi. <i>Seminars in Cancer Biology</i> , 2003, 13, 293-300.	4.3	17
13	Protein structure: discovering selective protein kinase inhibitors. <i>Targets</i> , 2003, 2, 101-108.	0.3	9
14	One step closer to specific cancer drugs?. <i>Targets</i> , 2003, 2, 73-74.	0.3	0
15	Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. <i>Cancer Cell</i> , 2003, 3, 285-296.	7.7	973
16	PDGF receptors as cancer drug targets. <i>Cancer Cell</i> , 2003, 3, 439-443.	7.7	449
17	PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFR α -induced myeloproliferative disease. <i>Cancer Cell</i> , 2003, 3, 459-469.	7.7	223
18	Advancing drug discovery through systems biology. <i>Drug Discovery Today</i> , 2003, 8, 175-183.	3.2	95
19	The emergence of Ph ψ , trisomy -8+ cells in patients with chronic myeloid leukemia treated with imatinib mesylate. <i>Experimental Hematology</i> , 2003, 31, 702-707.	0.2	37
20	Mechanisms involved in the induced differentiation of leukemia cells. , 2003, 100, 257-290.		135

#	ARTICLE	IF	CITATIONS
21	Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-? in ovarian serous carcinoma and normal ovarian surface epithelium. <i>Cancer</i> , 2003, 98, 758-764.	2.0	104
22	Medicines in the 21st century Or pills, politics, potions, and profits: <i>Where is public policy?</i> . <i>Drug Development Research</i> , 2003, 59, 269-291.	1.4	19
23	Die chemische Genetik entdeckt das (Zebra)-Fischen. <i>Angewandte Chemie</i> , 2003, 115, 1116-1118.	1.6	1
24	Mechanism of Action in Model Organisms: Interfacing Chemistry, Genetics and Genomics. , 0, , 153-183.		1
25	Chemical Genetics Goes (Zebra) Fishing. <i>Angewandte Chemie - International Edition</i> , 2003, 42, 1086-1087.	7.2	5
26	An aminopyridazine-based inhibitor of a pro-apoptotic protein kinase attenuates hypoxia-ischemia induced acute brain injury. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2003, 13, 3465-3470.	1.0	89
27	Rhenium tricarbonyl core complexes with ligands derived from arylpiperazines. The structures of [Re(CO) ₃ {NC ₅ H ₄ CH ₂ N(H)CH ₂ CH ₂ â€“Fphenpip}]Br, [Re(CO) ₃ {(NC ₅ H ₄ CH ₂) ₂ N(CH ₂) ₃ â€“CH ₃ OphenpipH}]Br ₂ and [Re(CO) ₃ {(CH ₃ N ₂ C ₃ H ₂ CH ₂)(O ₂ CCH ₂)N(CH ₂) ₃ â€“CH ₃ OphenpipH ₂ }]BrCl. <i>Inorganic Chemistry Communication</i> , 2003, 6, 1099-1103.	1.8	17
28	Overview of the clinical efficacy of investigational anticancer drugs. <i>Journal of Internal Medicine</i> , 2003, 253, 46-75.	2.7	75
29	Imatinib mesylate (STI571) inhibits multiple myeloma cell proliferation and potentiates the effect of common antimyeloma agents. <i>British Journal of Haematology</i> , 2003, 123, 858-868.	1.2	53
30	Molecular imaging in drug discovery and development. <i>Nature Reviews Drug Discovery</i> , 2003, 2, 123-131.	21.5	721
32	Tyrosine kinases as targets in cancer therapy â€“ successes and failures. <i>Expert Opinion on Therapeutic Targets</i> , 2003, 7, 215-234.	1.5	200
33	Pharmacogenetics and clinical gastroenterology. <i>Gastroenterology</i> , 2003, 125, 240-248.	0.6	22
34	STI-571: an anticancer protein-tyrosine kinase inhibitor. <i>Biochemical and Biophysical Research Communications</i> , 2003, 309, 709-717.	1.0	101
35	Immunoreactivity of Stat5 phosphorylated on tyrosine as a cell-based measure of Bcr/Abl kinase activity. <i>Cytometry</i> , 2003, 54A, 75-88.	1.8	52
36	Dissecting the genetic alterations involved in lung carcinogenesis. <i>Lung Cancer</i> , 2003, 40, 111-121.	0.9	32
37	Tyrosine kinase inhibition and grey hair. <i>Lancet, The</i> , 2003, 361, 1056.	6.3	50
38	Management of chronic myeloid leukemia: Targets for molecular therapy. <i>Seminars in Hematology</i> , 2003, 40, 34-49.	1.8	13
39	Imatinib: A targeted clinical drug development. <i>Seminars in Hematology</i> , 2003, 40, 15-20.	1.8	24

#	ARTICLE	IF	CITATIONS
40	The use of cyclin-dependent kinase inhibitors alone or in combination with established cytotoxic drugs in cancer chemotherapy. <i>Drug Resistance Updates</i> , 2003, 6, 15-26.	6.5	54
41	Classifying human cancer by analysis of gene expression. <i>Trends in Molecular Medicine</i> , 2003, 9, 5-10.	3.5	29
42	Lysophosphatidic acid acyltransferase- β : a novel target for induction of tumour cell apoptosis. <i>Expert Opinion on Therapeutic Targets</i> , 2003, 7, 643-661.	1.5	37
43	An efficient proteomics method to identify the cellular targets of protein kinase inhibitors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 15434-15439.	3.3	329
44	Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Promotes Mitochondrial Dysfunction and Apoptosis Induced by 7-Hydroxystaurosporine and Mitogen-Activated Protein Kinase Kinase Inhibitors in Human Leukemia Cells That Ectopically Express Bcl-2 and Bcl-xL. <i>Molecular Pharmacology</i> , 2003, 64, 1402-1409.	1.0	25
45	Determination of the substrate-docking site of protein tyrosine kinase C-terminal Src kinase. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 14707-14712.	3.3	87
46	Interstitial Cells in the Musculature of the Gastrointestinal Tract: Cajal and Beyond. <i>International Review of Cytology</i> , 2003, 229, 115-208.	6.2	91
47	The ATPases: a new family for a family-based drug design approach. <i>Expert Opinion on Therapeutic Targets</i> , 2003, 7, 453-461.	1.5	12
48	Fluorescence Assays for High-Throughput Screening of Protein Kinases. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2003, 6, 313-320.	0.6	47
49	Organische Chemie 2002. <i>Nachrichten Aus Der Chemie</i> , 2003, 51, 286-315.	0.0	3
50	Functional consequence of MDR1 expression on imatinib intracellular concentrations. <i>Blood</i> , 2003, 102, 1142-1142.	0.6	66
51	Imatinib mesylate elicits positive clinical response in atypical chronic myeloid leukemia involving the platelet-derived growth factor receptor beta. <i>Blood</i> , 2003, 102, 2699-2700.	0.6	33
52	Tuberous sclerosis complex (TSC) gene involvement in sporadic tumours. <i>Biochemical Society Transactions</i> , 2003, 31, 597-602.	1.6	39
53	Imatinib: A targeted clinical drug development. <i>Seminars in Hematology</i> , 2003, 40, 15-20.	1.8	17
55	The Structural Perspective on CDK5. <i>NeuroSignals</i> , 2003, 12, 164-172.	0.5	25
56	Chemical Libraries Towards Protein Kinase Inhibitors. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2003, 6, 661-672.	0.6	7
59	Development and possible clinical use of antagonists for PDGF and TGF- β . <i>Upsala Journal of Medical Sciences</i> , 2004, 109, 165-178.	0.4	20
60	Development of a Fluorescence Polarization Bead-Based Coupled Assay to Target Different Activity/Conformation States of a Protein Kinase. <i>Journal of Biomolecular Screening</i> , 2004, 9, 309-321.	2.6	12

#	ARTICLE	IF	CITATIONS
61	Development and Use of Biomarkers in Oncology Drug Development. <i>Toxicologic Pathology</i> , 2004, 32, 106-115.	0.9	51
62	Imatinib-Mesylate Blocks Recombinant T-Type Calcium Channels Expressed in Human Embryonic Kidney-293 Cells by a Protein Tyrosine Kinase-Independent Mechanism. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004, 309, 208-215.	1.3	26
63	Long-Term Treatment With a Specific Rho-Kinase Inhibitor Suppresses Cardiac Allograft Vasculopathy in Mice. <i>Circulation Research</i> , 2004, 94, 46-52.	2.0	267
64	Chemical Proteomic Analysis Reveals Alternative Modes of Action for Pyrido[2,3-d]pyrimidine Kinase Inhibitors. <i>Molecular and Cellular Proteomics</i> , 2004, 3, 1181-1193.	2.5	74
65	The Tyrosine Kinase Inhibitor STI571 Induces Cellular Clearance of PrPSc in Prion-infected Cells. <i>Journal of Biological Chemistry</i> , 2004, 279, 41918-41927.	1.6	114
66	Oral Imatinib Mesylate (STI571/Gleevec) Improves the Efficacy of Local Intravascular Vascular Endothelial Growth Factor-C Gene Transfer in Reducing Neointimal Growth in Hypercholesterolemic Rabbits. <i>Circulation</i> , 2004, 109, 1140-1146.	1.6	47
67	Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study. <i>Blood</i> , 2004, 104, 2655-2660.	0.6	204
68	Simultaneous Blockade of Platelet-Derived Growth Factor-Receptor and Epidermal Growth Factor-Receptor Signaling and Systemic Administration of Paclitaxel as Therapy for Human Prostate Cancer Metastasis in Bone of Nude Mice. <i>Cancer Research</i> , 2004, 64, 4201-4208.	0.4	103
69	Roles of Stem Cell Factor/c-Kit and Effects of Glivec®/STI571 in Human Uveal Melanoma Cell Tumorigenesis. <i>Journal of Biological Chemistry</i> , 2004, 279, 31769-31779.	1.6	75
70	Characterization of a Peptide Inhibitor of Janus Kinase 2 That Mimics Suppressor of Cytokine Signaling 1 Function. <i>Journal of Immunology</i> , 2004, 172, 7510-7518.	0.4	85
71	Evaluation of Kinase Inhibitor Selectivity by Chemical Proteomics. <i>Assay and Drug Development Technologies</i> , 2004, 2, 215-224.	0.6	45
72	Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2004, 36, 1084-1089.	9.4	393
73	VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. <i>Nature Medicine</i> , 2004, 10, 262-267.	15.2	920
74	Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. <i>Nature Reviews Drug Discovery</i> , 2004, 3, 391-400.	21.5	2,211
76	The role of the medicinal chemist in drug discovery "then and now". <i>Nature Reviews Drug Discovery</i> , 2004, 3, 853-862.	21.5	286
77	Strategies to overcome resistance to targeted protein kinase inhibitors. <i>Nature Reviews Drug Discovery</i> , 2004, 3, 1001-1010.	21.5	305
78	Clonal chromosomal abnormalities in the Philadelphia chromosome negative cells of chronic myeloid leukemia patients treated with imatinib. <i>Leukemia</i> , 2004, 18, 1140-1142.	3.3	12
79	A narrow deletion of 7q is common to HCL, and SMZL, but not CLL. <i>European Journal of Haematology</i> , 2004, 72, 390-402.	1.1	35

#	ARTICLE	IF	CITATIONS
80	Assessment of the response to imatinib in chronic myeloid leukemia patients - comparison between the FISH, multiplex and RT-PCR methods. <i>European Journal of Haematology</i> , 2004, 73, 243-250.	1.1	23
81	Targeted therapies in myeloid leukemia. <i>Seminars in Cancer Biology</i> , 2004, 14, 41-62.	4.3	45
82	Synthetic lethal targeting of MYC by activation of the DR5 death receptor pathway. <i>Cancer Cell</i> , 2004, 5, 501-512.	7.7	152
83	Role of KIT and platelet-derived growth factor receptors as oncoproteins. <i>Seminars in Oncology</i> , 2004, 31, 4-11.	0.8	75
84	Inhibitors of JAKs/STATs and the kinases: a possible new cluster of drugs. <i>Drug Discovery Today</i> , 2004, 9, 268-275.	3.2	73
85	Is pharmaceutical R&D just a game of chance or can strategy make a difference?. <i>Drug Discovery Today</i> , 2004, 9, 18-26.	3.2	40
86	Monitor-chemistry. <i>Drug Discovery Today</i> , 2004, 9, 459-460.	3.2	0
87	Monitor " Chemistry. <i>Drug Discovery Today</i> , 2004, 9, 619-620.	3.2	0
88	Sulfotransferase structural biology and inhibitor discovery. <i>Drug Discovery Today</i> , 2004, 9, 1003-1011.	3.2	65
89	Expression of imatinib mesylate-targeted kinases in endometrial carcinoma. <i>Gynecologic Oncology</i> , 2004, 95, 32-36.	0.6	59
90	Evolutionary relationships of Aurora kinases: implications for model organism studies and the development of anti-cancer drugs. <i>BMC Evolutionary Biology</i> , 2004, 4, 39.	3.2	102
91	Use of new biotechnology to design rational drugs against newly defined targets. <i>Best Practice and Research in Clinical Rheumatology</i> , 2004, 18, 81-95.	1.4	12
92	NMR resonance assignment of selectively labeled proteins by the use of paramagnetic ligands. <i>Journal of Biomolecular NMR</i> , 2004, 30, 205-210.	1.6	9
93	Apoptosis in the development and treatment of cancer. <i>Carcinogenesis</i> , 2004, 26, 263-270.	1.3	324
94	Protein NMR in biomedical research. <i>Cellular and Molecular Life Sciences</i> , 2004, 61, 580-599.	2.4	67
95	Synthesis and evaluation of the antitumor agent TMC-69-6H and a focused library of analogs. <i>Tetrahedron</i> , 2004, 60, 9543-9558.	1.0	51
96	Determination of imatinib (Gleevec®) in human plasma by solid-phase extraction"liquid chromatography"ultraviolet absorbance detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2004, 803, 285-292.	1.2	52
97	Characterization of a Conserved Structural Determinant Controlling Protein Kinase Sensitivity to Selective Inhibitors. <i>Chemistry and Biology</i> , 2004, 11, 691-701.	6.2	130

#	ARTICLE	IF	CITATIONS
98	Use of moving optical gradient fields for analysis of apoptotic cellular responses in a chronic myeloid leukemia cell model. <i>Analytical Biochemistry</i> , 2004, 327, 14-22.	1.1	13
99	Solid-Phase Synthesis of an Alkylaminobenzanilide Library. <i>ACS Combinatorial Science</i> , 2004, 6, 789-795.	3.3	8
100	Screening for Enzyme Inhibitors by Surface Plasmon Resonance Combined with Mass Spectrometry. <i>Analytical Chemistry</i> , 2004, 76, 5243-5248.	3.2	60
101	Platelet-Derived Growth Factor Production by B16 Melanoma Cells Leads to Increased Pericyte Abundance in Tumors and an Associated Increase in Tumor Growth Rate. <i>Cancer Research</i> , 2004, 64, 2725-2733.	0.4	174
102	Solid-Phase Synthesis of 2,4-Diaminopyrimidines via Lewis Acid-Mediated Aromatic Nucleophilic Substitution. <i>ACS Combinatorial Science</i> , 2004, 6, 414-419.	3.3	13
103	Primer on Medical Genomics Part XIV: Introduction to Systems Biology—A New Approach to Understanding Disease and Treatment. <i>Mayo Clinic Proceedings</i> , 2004, 79, 651-658.	1.4	72
104	Increasing tumor uptake of anticancer drugs with imatinib. <i>Seminars in Oncology</i> , 2004, 31, 18-23.	0.8	69
105	Chemical kinomics — a target gene family approach in chemical biology. <i>Drug Discovery Today: Technologies</i> , 2004, 1, 25-34.	4.0	6
106	Cancer metastasis therapeutic targets and drug discovery: emerging small-molecule protein kinase inhibitors. <i>Expert Opinion on Investigational Drugs</i> , 2004, 13, 1-19.	1.9	48
107	Tumour-stroma interaction: cancer-associated fibroblasts as novel targets in anti-cancer therapy?. <i>Lung Cancer</i> , 2004, 45, S163-S175.	0.9	297
108	Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neuin a murine mammary carcinoma model. <i>Breast Cancer Research</i> , 2004, 6, R275-83.	2.2	80
109	Enzyme Inhibition and Inactivation. , 2004, , 227-321.		2
110	Systemic chemotherapy for patients with bladder cancer — current controversies and future directions. <i>Cancer Treatment Reviews</i> , 2004, 30, 343-358.	3.4	49
111	Altered Notch signaling resulting from expression of a WAMTP1-MAML2 gene fusion in mucoepidermoid carcinomas and benign Warthin's tumors. <i>Experimental Cell Research</i> , 2004, 292, 21-28.	1.2	150
112	Expression of a Truncated Form of the c-Kit Tyrosine Kinase Receptor and Activation of Src Kinase in Human Prostatic Cancer. <i>American Journal of Pathology</i> , 2004, 164, 1243-1251.	1.9	70
113	Inhibition of Platelet-Derived Growth Factor Promotes Pericyte Loss and Angiogenesis in Ischemic Retinopathy. <i>American Journal of Pathology</i> , 2004, 164, 1263-1273.	1.9	108
114	Activation of the neuronal c-Abl tyrosine kinase by amyloid- β -peptide and reactive oxygen species. <i>Neurobiology of Disease</i> , 2004, 17, 326-336.	2.1	114
115	Gene expression profiles in hepatocellular carcinoma: not yet there. <i>Journal of Hepatology</i> , 2004, 41, 336-339.	1.8	18

#	ARTICLE	IF	CITATIONS
116	Toward a Pharmacophore for Kinase Frequent Hitters. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 5616-5619.	2.9	59
117	Natural Product-Based Drug Discovery – Epithilones as Lead Structures for the Discovery of New Anticancer Agents. <i>Chimia</i> , 2004, 58, 686-690.	0.3	20
118	The FIP1L1-PDGFR?? kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia. <i>Current Opinion in Hematology</i> , 2004, 11, 51-57.	1.2	70
119	The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFR?? positive chronic eosinophilic leukemia. <i>Blood</i> , 2004, 103, 2802-2805.	0.6	88
120	Early prediction of response in patients with relapsed or refractory Philadelphia chromosome?? positive acute lymphoblastic leukemia (Ph+ALL) treated with imatinib. <i>Blood</i> , 2004, 103, 1495-1498.	0.6	49
121	Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib. <i>Blood</i> , 2004, 103, 2929-2935.	0.6	57
122	Convergence and Divergence, a Concept for Explaining Drug Actions. <i>Journal of Pharmacological Sciences</i> , 2004, 96, 95-100.	1.1	4
123	Mutational Analysis of the c-KIT AND PDGFR?? in a Series of Molecularly Well-Characterized Synovial Sarcomas. <i>Diagnostic Molecular Pathology</i> , 2005, 14, 134-139.	2.1	18
124	Chemical Proteomics in Drug Development. , 2005, , 109-122.		2
125	Autocrine- and paracrine-activated receptor tyrosine kinases in classic Hodgkin lymphoma. <i>Blood</i> , 2005, 105, 4051-4059.	0.6	116
126	PEP005, a selective small-molecule activator of protein kinase C, has potent antileukemic activity mediated via the delta isoform of PKC. <i>Blood</i> , 2005, 106, 1362-1368.	0.6	127
127	Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32). <i>Blood</i> , 2005, 105, 4849-4852.	0.6	119
128	Nanotechnology, nanomedicine, and the development of new, effective therapies for cancer. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2005, 1, 101-109.	1.7	316
129	3D-QSAR studies on c-Src kinase inhibitors and docking analyses of a potent dual kinase inhibitor of c-Src and c-Abl kinases. <i>Bioorganic and Medicinal Chemistry</i> , 2005, 13, 4704-4712.	1.4	57
130	Direct synthesis of hetero-biaryl compounds containing an unprotected NH2 group via Suzuki?? Miyaura reaction. <i>Tetrahedron Letters</i> , 2005, 46, 3573-3577.	0.7	115
131	Exploiting structural principles to design cyclin-dependent kinase inhibitors. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2005, 1754, 58-64.	1.1	27
132	High yield bacterial expression of active c-Abl and c-Src tyrosine kinases. <i>Protein Science</i> , 2005, 14, 3135-3139.	3.1	206
133	Novel Eicosanoid Pathways: The Discovery of Prostacyclin/6-keto Prostaglandin F_{1??} and the Hepoxilins. <i>Molecular Neurobiology</i> , 2005, 32, 019-026.	1.9	6

#	ARTICLE	IF	CITATIONS
134	Chemical approaches to the discovery and development of cancer therapies. <i>Nature Reviews Cancer</i> , 2005, 5, 285-296.	12.8	205
135	Automated synthesis of oligosaccharides as a basis for drug discovery. <i>Nature Reviews Drug Discovery</i> , 2005, 4, 751-763.	21.5	227
136	Multiple, PKA-dependent and PKA-independent, signals are involved in cAMP-induced PRL expression in the eosinophilic cell line Eo1-1. <i>Cellular Signalling</i> , 2005, 17, 901-909.	1.7	22
137	Using imaging biomarkers to accelerate drug development and clinical trials. <i>Drug Discovery Today</i> , 2005, 10, 259-266.	3.2	103
138	The Crystal Structure of a c-Src Complex in an Active Conformation Suggests Possible Steps in c-Src Activation. <i>Structure</i> , 2005, 13, 861-871.	1.6	304
139	cDNA microarray-based translational research in soft tissue sarcoma. <i>Journal of Surgical Oncology</i> , 2005, 92, 267-271.	0.8	9
140	Patupilone (epothilone B, EPO906) and imatinib (STI571, Glivec) in combination display enhanced antitumour activity in vivo against experimental rat C6 glioma. <i>Cancer Chemotherapy and Pharmacology</i> , 2005, 55, 307-317.	1.1	30
141	Pharmacokinetics of imatinib mesylate in end stage renal disease. A case study. <i>Cancer Chemotherapy and Pharmacology</i> , 2005, 56, 358-360.	1.1	38
142	CD117 expression in glial tumors. <i>Journal of Neuro-Oncology</i> , 2005, 75, 195-202.	1.4	28
143	The Use of Tyrosine Kinase Inhibitors in Modifying the Response of Tumor Microvasculature to Radiotherapy. <i>Technology in Cancer Research and Treatment</i> , 2005, 4, 691-698.	0.8	16
144	Imatinib Mesylate Inhibits Leydig Cell Tumor Growth: Evidence for In vitro and In vivo Activity. <i>Cancer Research</i> , 2005, 65, 1897-1903.	0.4	39
145	Development of a Microplate-Based, Electrophoretic Fluorescent Protein Kinase A Assay: Comparison with Filter-Binding and Fluorescence Polarization Assay Formats. <i>Journal of Biomolecular Screening</i> , 2005, 10, 329-338.	2.6	8
146	Inhibition of the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Pathway but not the MEK/ERK Pathway Attenuates Laminin-Mediated Small Cell Lung Cancer Cellular Survival and Resistance to Imatinib Mesylate or Chemotherapy. <i>Cancer Research</i> , 2005, 65, 8423-8432.	0.4	113
147	The Paullones: A Family of Pharmacological Inhibitors of Cyclin-Dependent Kinases and Glycogen Synthase Kinase 3. , 2005, , 47-64.		6
148	Anaplastic Carcinoma of the Thyroidâ€”Will Aurora B Light a Path for Treatment?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 1243-1245.	1.8	16
149	Dendritic cells from patients with chronic myeloid leukemia: Functional and phenotypic features. <i>Leukemia and Lymphoma</i> , 2005, 46, 663-670.	0.6	18
150	Recent progress in the discovery and development of cyclin-dependent kinase inhibitors. <i>Expert Opinion on Investigational Drugs</i> , 2005, 14, 457-477.	1.9	112
151	Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines. <i>British Journal of Cancer</i> , 2005, 92, 1881-1891.	2.9	70

#	ARTICLE	IF	CITATIONS
152	The kinase inhibitor imatinib mesylate inhibits TNF- α production in vitro and prevents TNF-dependent acute hepatic inflammation. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 13622-13627.	3.3	121
153	KIT and Platelet-Derived Growth Factor Receptor Alpha Tyrosine Kinase Gene Mutations and KIT Amplifications in Human Solid Tumors. Journal of Clinical Oncology, 2005, 23, 49-57.	0.8	195
154	Hsp90 Inhibitor 17-Allylamino-17-Demethoxygeldanamycin Prevents Synovial Sarcoma Proliferation via Apoptosis in In vitro Models. Clinical Cancer Research, 2005, 11, 5631-5638.	3.2	48
155	Live Long and Prosper: Fig. 1.. Molecular Pharmacology, 2005, 68, 1193-1195.	1.0	0
156	Treatment of Mice with the Suppressor of Cytokine Signaling-1 Mimetic Peptide, Tyrosine Kinase Inhibitor Peptide, Prevents Development of the Acute Form of Experimental Allergic Encephalomyelitis and Induces Stable Remission in the Chronic Relapsing/Remitting Form. Journal of Immunology, 2005, 175, 5077-5086.	0.4	64
157	How Will RNAi Facilitate Drug Development?. Science Signaling, 2005, 2005, pe39-pe39.	1.6	20
159	Second-generation kinase inhibitors. Expert Opinion on Therapeutic Targets, 2005, 9, 975-993.	1.5	55
160	Exploring the tumour environment: cancer-associated fibroblasts as targets in cancer therapy. Expert Opinion on Therapeutic Targets, 2005, 9, 1217-1233.	1.5	137
161	Genomics and the second golden era of cancer drug development. Molecular BioSystems, 2005, 1, 17.	2.9	48
162	Improving pharmacotherapy outcomes by pharmacogenomics: from expectation to reality?. Pharmacogenomics, 2005, 6, 701-711.	0.6	11
163	High Affinity Targets of Protein Kinase Inhibitors Have Similar Residues at the Positions Energetically Important for Binding. Journal of Molecular Biology, 2005, 352, 1134-1156.	2.0	42
164	Resistance to tyrosine kinase inhibitors: Calling on extra forces. Drug Resistance Updates, 2005, 8, 119-129.	6.5	37
165	Strategies to improve oral drug bioavailability. Expert Opinion on Drug Delivery, 2005, 2, 419-433.	2.4	110
166	Rapid Computational Identification of the Targets of Protein Kinase Inhibitors. Journal of Medicinal Chemistry, 2005, 48, 4138-4152.	2.9	50
168	Profile and Molecular Modeling of 3-(Indole-3-yl)-4-(3,4,5-trimethoxyphenyl)-1H-pyrrole-2,5dione (1) as a Highly Selective VEGF-R2/3 Inhibitor. Journal of Medicinal Chemistry, 2006, 49, 7549-7553.	2.9	29
169	Case histories, magic bullets and the state of drug discovery. Nature Reviews Drug Discovery, 2006, 5, 635-640.	21.5	41
170	Elucidation of Characteristic Structural Features of Ligand Binding Sites of Protein Kinases: A Neural Network Approach. Journal of Chemical Information and Modeling, 2006, 46, 2158-2166.	2.5	9
171	[4-(Imidazol-1-yl)thiazol-2-yl]phenylamines. A Novel Class of Highly Potent Colchicine Site Binding Tubulin Inhibitors: Synthesis and Cytotoxic Activity on Selected Human Cancer Cell Lines. Journal of Medicinal Chemistry, 2006, 49, 5769-5776.	2.9	28

#	ARTICLE	IF	CITATIONS
172	Bcr-Abl Kinase Inhibitors. Topics in Medicinal Chemistry, 2006, , 407-444.	0.4	4
174	Investigating the Molecular Basis of Drug Action and Response: Chemocentric Genomics and Proteomics. Current Drug Targets, 2006, 7, 387-395.	1.0	5
175	Phosphoproteomics in Drug Discovery and Development. , 2006, , 265-278.		0
176	Signal Transduction Therapy with Rationally Designed Kinase Inhibitors. Current Signal Transduction Therapy, 2006, 1, 67-95.	0.3	43
177	Design and Development of Signal Transduction Inhibitors for Cancer Treatment: Experience and Challenges with Kinase Targets. Current Signal Transduction Therapy, 2006, 1, 13-23.	0.3	35
178	Dermatofibrosarcoma protuberans: a surgical disease with a molecular savior. Current Opinion in Oncology, 2006, 18, 341-346.	1.1	40
179	A Kinase-focused Compound Collection: Compilation and Screening Strategy. Chemical Biology and Drug Design, 2006, 67, 385-394.	1.5	18
180	Population pharmacokinetics of imatinib and the role of alpha1-acid glycoprotein. British Journal of Clinical Pharmacology, 2006, 62, 97-112.	1.1	161
181	Immunohistochemical and mutational analysis of PDGF and PDGFR in desmoid tumours: is there a role for tyrosine kinase inhibitors in c-kit-negative desmoid tumours?. Histopathology, 2006, 49, 576-581.	1.6	31
182	Smart drug discovery leveraging innovative technologies and predictive knowledge. , 2006, 2, 646-648.		2
183	Allosteric inhibitors of Bcr-ablâ€“dependent cell proliferation. Nature Chemical Biology, 2006, 2, 95-102.	3.9	349
184	New approaches to molecular cancer therapeutics. Nature Chemical Biology, 2006, 2, 689-700.	3.9	361
185	Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nature Reviews Drug Discovery, 2006, 5, 835-844.	21.5	1,525
186	Dasatinib. Nature Reviews Drug Discovery, 2006, 5, 717-718.	21.5	119
187	Positive immunohistochemical staining of KIT in solid-pseudopapillary neoplasms of the pancreas is not associated with KIT/PDGFR mutations. Modern Pathology, 2006, 19, 1157-1163.	2.9	45
188	Chronic myeloproliferative disorders: a tyrosine kinase tale. Leukemia, 2006, 20, 200-205.	3.3	63
189	Characterization of an imatinib-sensitive subset of high-grade human glioma cultures. Oncogene, 2006, 25, 4913-4922.	2.6	85
190	Discovery of substituted 4-anilino-2-(2-pyridyl)pyrimidines as a new series of apoptosis inducers using a cell- and caspase-based high throughput screening assay. Part 1: Structureâ€“activity relationships of the 4-anilino group. Bioorganic and Medicinal Chemistry, 2006, 14, 7761-7773.	1.4	37

#	ARTICLE	IF	CITATIONS
191	Efficient Pd-catalyzed synthesis of 2-arylaminoimidines via microwave irradiation. <i>Tetrahedron Letters</i> , 2006, 47, 4881-4884.	0.7	24
192	Src kinase activation: A switched electrostatic network. <i>Protein Science</i> , 2006, 15, 1051-1062.	3.1	71
193	Human Glioblastoma and Carcinoma Xenograft Tumors Treated by Combined Radiation and Imatinib (Gleevec®). <i>Strahlentherapie Und Onkologie</i> , 2006, 182, 400-407.	1.0	45
195	Targeting Loss-of-Function Mutations in Tumor-Suppressor Genes as a Strategy for Development of Cancer Therapeutic Agents. <i>Seminars in Oncology</i> , 2006, 33, 513-520.	0.8	27
196	Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application. , 2006, 110, 135-370.		483
197	A Highly Active Catalyst for Suzuki-Miyaura Cross-Coupling Reactions of Heteroaryl Compounds. <i>Angewandte Chemie - International Edition</i> , 2006, 45, 3484-3488.	7.2	345
199	Protein Kinases as Drug Targets in Cancer. <i>Current Cancer Drug Targets</i> , 2006, 6, 623-634.	0.8	76
200	Platelet-derived growth factor receptor family mutations in gastrointestinal stromal tumours. <i>Scandinavian Journal of Gastroenterology</i> , 2006, 41, 805-811.	0.6	12
201	Strategies for Delaying or Treating In vivo Acquired Resistance to Trastuzumab in Human Breast Cancer Xenografts. <i>Clinical Cancer Research</i> , 2006, 12, 904-916.	3.2	140
202	Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 1280-1289.	1.9	110
204	Phase I/II Study of Imatinib Mesylate for Recurrent Malignant Gliomas: North American Brain Tumor Consortium Study 99-08. <i>Clinical Cancer Research</i> , 2006, 12, 4899-4907.	3.2	404
205	Identification of an Agent Selectively Targeting DPC4 (Deleted in Pancreatic Cancer Locus 4) Deficient Pancreatic Cancer Cells. <i>Cancer Research</i> , 2006, 66, 9722-9730.	0.4	62
206	Therapeutics in Renal Disease: The Road Ahead for Antiproliferative Targets. <i>Nephron Experimental Nephrology</i> , 2006, 103, e6-e15.	2.4	12
207	Novel Aspects of Oxidative Stress-Associated Carcinogenesis. <i>Antioxidants and Redox Signaling</i> , 2006, 8, 1373-1377.	2.5	90
208	Novel therapies for meningiomas. <i>Expert Review of Neurotherapeutics</i> , 2006, 6, 1447-1464.	1.4	30
209	Autocrine Factors That Sustain Glioma Invasion and Paracrine Biology in the Brain Microenvironment. <i>Journal of the National Cancer Institute</i> , 2007, 99, 1583-1593.	3.0	339
210	Phosphatidylinositol Ether Lipid Analogues That Inhibit AKT Also Independently Activate the Stress Kinase, p38 β , through MKK3/6-independent and -dependent Mechanisms. <i>Journal of Biological Chemistry</i> , 2007, 282, 27020-27029.	1.6	49
211	Molecular Targeting of Protein Kinases to Optimize Selectivity and Resistance Profiles of Kinase Inhibitors. <i>Current Topics in Medicinal Chemistry</i> , 2007, 7, 1332-1335.	1.0	9

#	ARTICLE	IF	CITATIONS
212	Targeted drug therapy for meningiomas. <i>Neurosurgical Focus</i> , 2007, 23, E12.	1.0	46
213	Protein Kinases and Protein Phosphatases in Signal Transduction Pathways. , 2007, , 959-992.		2
214	Imatinib. <i>Oncologist</i> , 2007, 12, 1390-1394.	1.9	33
215	Selective cell death of oncogenic Akt-transduced brain cancer cells by etoposide through reactive oxygen species-mediated damage. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 2178-2187.	1.9	37
216	Nek2 as an Effective Target for Inhibition of Tumorigenic Growth and Peritoneal Dissemination of Cholangiocarcinoma. <i>Cancer Research</i> , 2007, 67, 9637-9642.	0.4	84
217	Design, Synthesis, and Performance of NTA-modified Lipids as Templates for Histidine-tagged Protein Crystallization. <i>Chemistry Letters</i> , 2007, 36, 956-975.	0.7	14
218	C-KIT, by interacting with the membrane-bound ligand, recruits endothelial progenitor cells to inflamed endothelium. <i>Blood</i> , 2007, 109, 4264-4271.	0.6	70
219	Novel strategies for inhibition of the p38 MAPK pathway. <i>Trends in Pharmacological Sciences</i> , 2007, 28, 286-295.	4.0	139
220	Imatinib interferes with survival of multi drug resistant Kaposi's sarcoma cells. <i>FEBS Letters</i> , 2007, 581, 5897-5903.	1.3	35
221	Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. <i>Nature Biotechnology</i> , 2007, 25, 1035-1044.	9.4	979
223	Microwave-Assisted Solution- and Solid-Phase Synthesis of 2-Amino-4-arylpyrimidine Derivatives. <i>ACS Combinatorial Science</i> , 2007, 9, 275-284.	3.3	102
224	Harnblasenkarzinom. , 2007, , 301-372.		0
225	A Pharmacophore Map of Small Molecule Protein Kinase Inhibitors. <i>Journal of Chemical Information and Modeling</i> , 2007, 47, 2374-2382.	2.5	45
226	Clinical Translation of Genotyping and Haplotyping Data. <i>Clinical Pharmacokinetics</i> , 2007, 46, 807-824.	1.6	26
227	PDGF Receptors as Targets in Tumor Treatment. <i>Advances in Cancer Research</i> , 2007, 97, 247-274.	1.9	187
228	Towards new tuberculosis drugs. <i>Biochemical Society Transactions</i> , 2007, 35, 1321-1324.	1.6	21
229	Chemogenomics. , 2007, , 921-937.		4
230	The Intersection of Strategy and Drug Research. , 2007, , 1-84.		5

#	ARTICLE	IF	CITATIONS
231	Platelet-Derived Growth Factor as a Therapeutic Target for Systemic Autoimmune Diseases. Drug Target Insights, 2007, 2, 117739280700200.	0.9	6
232	Diversity versus Focus in Choosing Targets and Therapeutic Areas. , 2007, , 753-770.		1
233	Determination of imatinib mesylate and its main metabolite (CGP74588) in human plasma and murine specimens by ion-pairing reversed-phase high-performance liquid chromatography. Biomedical Chromatography, 2007, 21, 747-754.	0.8	43
234	Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats. Hepatology, 2007, 46, 1208-1217.	3.6	166
235	Functional Classification of Protein Kinase Binding Sites Using Cavbase. ChemMedChem, 2007, 2, 1432-1447.	1.6	70
236	A critical appraisal of conventional and investigational drug therapy in patients with hypereosinophilic syndrome and clonal eosinophilia. Cancer, 2007, 110, 955-964.	2.0	30
237	PKC 412 small molecule tyrosine kinase inhibitor. Cancer, 2007, 110, 1457-1468.	2.0	26
238	An orthogonal protection strategy for the synthesis of 2-substituted piperazines. Tetrahedron, 2007, 63, 3057-3065.	1.0	7
239	Microwave-assisted solid phase synthesis of Imatinib, a blockbuster anticancer drug. Tetrahedron Letters, 2007, 48, 3455-3458.	0.7	36
240	Structural investigation of PAP derivatives by CoMFA and CoMSIA reveals novel insight towards inhibition of Bcr-Abl oncoprotein. Journal of Molecular Graphics and Modelling, 2007, 26, 482-493.	1.3	7
241	Identification of imatinib mesylate degradation products obtained under stress conditions. Journal of Pharmaceutical and Biomedical Analysis, 2007, 43, 1682-1691.	1.4	26
242	High-performance liquid chromatography method with ultraviolet detection for the quantification of the BCR-ABL inhibitor nilotinib (AMN107) in plasma, urine, culture medium and cell preparations. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 852, 208-216.	1.2	31
243	Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia. Acta Crystallographica Section D: Biological Crystallography, 2007, 63, 80-93.	2.5	215
244	PDGF essentially links TGF- β signaling to nuclear β -catenin accumulation in hepatocellular carcinoma progression. Oncogene, 2007, 26, 3395-3405.	2.6	136
245	Drug target network. Nature Biotechnology, 2007, 25, 1119-1126.	9.4	1,584
246	Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. Nature Reviews Drug Discovery, 2007, 6, 464-479.	21.5	376
247	Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nature Reviews Drug Discovery, 2007, 6, 287-293.	21.5	438
248	Different target range and cytotoxic specificity of adaphostin and 17-allylamino-17-demethoxygeldanamycin in imatinib-resistant and sensitive cell lines. Leukemia, 2007, 21, 421-426.	3.3	15

#	ARTICLE	IF	CITATIONS
249	Characterization of a reference material for BCR-ABL (M-BCR) mRNA quantitation by real-time amplification assays: towards new standards for gene expression measurements. <i>Leukemia</i> , 2007, 21, 1481-1487.	3.3	29
250	Imatinib mesylate inhibits cell invasion of malignant peripheral nerve sheath tumor induced by platelet-derived growth factor-BB. <i>Laboratory Investigation</i> , 2007, 87, 767-779.	1.7	33
251	Targeting stromal cells for the treatment of platelet-derived growth factor C-induced hepatocellular carcinogenesis. <i>Differentiation</i> , 2007, 75, 843-852.	1.0	37
252	Anaplasma phagocytophilum AnkA secreted by type IV secretion system is tyrosine phosphorylated by Abl-1 to facilitate infection. <i>Cellular Microbiology</i> , 2007, 9, 2644-2657.	1.1	174
253	Liposomal cytarabine for treatment of myeloid central nervous system relapse in chronic myeloid leukaemia occurring during imatinib therapy. <i>European Journal of Clinical Investigation</i> , 2007, 37, 808-813.	1.7	31
254	c-Src Binds to the Cancer Drug Imatinib with an Inactive Abl/c-Kit Conformation and a Distributed Thermodynamic Penalty. <i>Structure</i> , 2007, 15, 299-311.	1.6	203
255	The tyrosine kinase inhibitor imatinib mesylate delays prion neuroinvasion by inhibiting prion propagation in the periphery. <i>Journal of NeuroVirology</i> , 2007, 13, 328-337.	1.0	40
256	Anticancer drugs from nature – natural products as a unique source of new microtubule-stabilizing agents. <i>Natural Product Reports</i> , 2007, 24, 327-357.	5.2	230
257	Cartilage polysaccharide induces apoptosis in human leukemia K562 cells. <i>Cell Biology and Toxicology</i> , 2007, 23, 465-476.	2.4	24
258	An improved synthesis of pyrimidine- and pyrazole-based acyclo-C-nucleosides as carbohybrids. <i>Tetrahedron Letters</i> , 2008, 49, 5080-5083.	0.7	36
259	Constitutive Overexpression of P-glycoprotein, Rather than Breast Cancer Resistance Protein or Organic Cation Transporter 1, Contributes to Acquisition of Imatinib-Resistance in K562 Cells. <i>Pharmaceutical Research</i> , 2008, 25, 827-835.	1.7	41
260	Predictors of orphan drug approval in the European Union. <i>European Journal of Clinical Pharmacology</i> , 2008, 64, 545-552.	0.8	42
261	The expression and prognostic significance of platelet-derived growth factor receptor alpha in mature T- and natural killer-cell lymphomas. <i>Annals of Hematology</i> , 2008, 87, 985-990.	0.8	11
263	Small Molecule Inhibitors of PDK1. <i>ChemMedChem</i> , 2008, 3, 1810-1838.	1.6	113
264	Mycobacterial Ser/Thr protein kinases and phosphatases: Physiological roles and therapeutic potential. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2008, 1784, 193-202.	1.1	153
265	Inhibition of PDGFR tyrosine kinase activity by a series of novel N-(3-(4-(pyridin-3-yl)-1H-imidazol-2-ylamino)phenyl)amides – A SAR study on the bioisosterism of pyrimidine and imidazole. <i>European Journal of Medicinal Chemistry</i> , 2008, 43, 1444-1453.	2.6	8
266	Discovery of amido-benzisoxazoles as potent c-Kit inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 5115-5117.	1.0	11
267	Small Molecule Recognition of c-Src via the Imatinib-Binding Conformation. <i>Chemistry and Biology</i> , 2008, 15, 1015-1022.	6.2	84

#	ARTICLE	IF	CITATIONS
268	Epothilones as lead structures for new anticancer drugs – pharmacology, fermentation, and structure-activity-relationships. , 2008, 66, 273-334.		5
269	Platelet-derived Growth Factor: Impact on Physiological and Tumor Angiogenesis. , 2008, , 155-169.		2
270	Assessment of Chemical Coverage of Kinome Space and Its Implications for Kinase Drug Discovery. Journal of Medicinal Chemistry, 2008, 51, 7898-7914.	2.9	158
271	Anti-cancer PEG-enzymes: 30 years old, but still a current approach. Advanced Drug Delivery Reviews, 2008, 60, 69-78.	6.6	131
272	PDGFR-A is a therapeutic target in alveolar rhabdomyosarcoma. Oncogene, 2008, 27, 6550-6560.	2.6	80
273	Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke. Nature Medicine, 2008, 14, 731-737.	15.2	405
274	Molecular genetic insights in paediatric T-cell acute lymphoblastic leukaemia. British Journal of Haematology, 2008, 143, 153-168.	1.2	136
275	Expression, mutational analysis and in vitro response of imatinib mesylate and nilotinib target genes in ovarian granulosa cell tumors. Gynecologic Oncology, 2008, 108, 182-190.	0.6	30
276	Fifty years of Biochemical Pharmacology: The discipline and the journal. Biochemical Pharmacology, 2008, 76, 1-10.	2.0	3
277	Personalized Medicine for Cancer. , 2008, , 93-107.		0
278	Small-molecule inhibitors binding to protein kinase. Part II: the novel pharmacophore approach of type II and type III inhibition. Expert Opinion on Drug Discovery, 2008, 3, 1427-1449.	2.5	96
279	Silica-assisted Suzuki-Miyaura reactions of heteroaryl bromides in aqueous media. Green Chemistry, 2008, 10, 868.	4.6	55
280	ABC transporters and the accumulation of imatinib and its active metabolite CGP74588 in rat C6 glioma cells. Pharmacological Research, 2008, 57, 214-222.	3.1	27
281	An electrostatic network and long-range regulation of Src kinases. Protein Science, 2008, 17, 1871-1880.	3.1	54
282	CTi(O ⁱ) ₃ -Promoted Reductive Amination on the Solid Phase: Combinatorial Synthesis of a Biaryl-Based Sulfonamide Library. ACS Combinatorial Science, 2008, 10, 280-284.	3.3	10
283	Inhibition of casein kinase 1-epsilon induces cancer-cell-selective, PERIOD2-dependent growth arrest. Genome Biology, 2008, 9, R92.	13.9	77
284	Nilotinib: a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of leukemias. Expert Opinion on Investigational Drugs, 2008, 17, 1127-1136.	1.9	12
285	Imatinib therapy blocks cerebellar apoptosis and improves neurological symptoms in a mouse model of Niemann-Pick type C disease. FASEB Journal, 2008, 22, 3617-3627.	0.2	86

#	ARTICLE	IF	CITATIONS
286	The Drug Discovery Business to Come. , 2008, , 53-112.		0
287	Drugs That Inhibit Signalling Pathways for Tumor Cell Growth and Proliferation. , 2008, , 251-305.		9
288	Platelet-derived growth factor inhibitionâ€™a new treatment of pulmonary hypertension in congenital diaphragmatic hernia?. Journal of Pediatric Surgery, 2008, 43, 1928-1931.	0.8	20
289	Application of PET/CT in the Development of Novel Anticancer Drugs. Oncologist, 2008, 13, 25-38.	1.9	55
290	Evaluation of neoadjuvant inhibition of aromatase activity and signal transduction in breast cancer. Cancer Letters, 2008, 262, 232-238.	3.2	16
291	PLI expression is restored upon treatment of chronic myeloid leukemia patients. Cancer Letters, 2008, 270, 328-336.	3.2	18
292	Sunitinib in the management of gastrointestinal stromal tumours (GISTs). European Journal of Surgical Oncology, 2008, 34, 844-850.	0.5	39
293	Peptide Biosensors for the Electrochemical Measurement of Protein Kinase Activity. Analytical Chemistry, 2008, 80, 9395-9401.	3.2	86
295	Development and Experimental Validation of a Docking Strategy for the Generation of Kinase-Targeted Libraries. Journal of Medicinal Chemistry, 2008, 51, 3124-3132.	2.9	38
296	Pharmacophore Identification and Pseudo-Receptor Modeling. , 2008, , 572-586.		4
297	Protein Crystallography and Drug Discovery. , 2008, , 605-634.		3
298	Micellar Catalysis of Suzukiâ€™Miyaura Cross-Couplings with Heteroaromatics in Water. Organic Letters, 2008, 10, 5329-5332.	2.4	149
299	Stat5 as a diagnostic marker for leukemia. Expert Review of Molecular Diagnostics, 2008, 8, 73-82.	1.5	24
300	Modern cancer drug discovery: integrating targets, technologies and treatments. , 2008, , 3-38.		4
301	Redesigning Kinase Inhibitors to Enhance Specificity. Journal of Medicinal Chemistry, 2008, 51, 4890-4898.	2.9	31
302	An In vivo Model of Met-Driven Lymphoma as a Tool to Explore the Therapeutic Potential of Met Inhibitors. Clinical Cancer Research, 2008, 14, 2220-2226.	3.2	15
303	STI571 prevents apoptosis, tau phosphorylation and behavioural impairments induced by Alzheimer's Î²-amyloid deposits. Brain, 2008, 131, 2425-2442.	3.7	136
304	Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability. British Journal of Cancer, 2008, 98, 1633-1640.	2.9	106

#	ARTICLE	IF	CITATIONS
305	Structural Characterization of Novel Adenine Dinucleotide Phosphate Conjugates of Imatinib in Incubations with Rat and Human Liver Microsomes. <i>Drug Metabolism and Disposition</i> , 2008, 36, 2414-2418.	1.7	14
306	Combined Tyrosine and Serine/Threonine Kinase Inhibition by Sorafenib Prevents Progression of Experimental Pulmonary Hypertension and Myocardial Remodeling. <i>Circulation</i> , 2008, 118, 2081-2090.	1.6	139
307	Small molecules targeting histone H4 as potential therapeutics for chronic myelogenous leukemia. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 769-778.	1.9	34
308	<i>In vitro</i> differential sensitivity of melanomas to phenothiazines is based on the presence of codon 600 BRAF mutation. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 1337-1346.	1.9	14
309	Somatic pharmacogenomics in cancer. <i>Pharmacogenomics Journal</i> , 2008, 8, 305-314.	0.9	22
310	Report of an international expanded access program of imatinib in adults with Philadelphia chromosome positive leukemias. <i>Annals of Oncology</i> , 2008, 19, 1320-1326.	0.6	14
311	Alternative assay formats to identify diverse inhibitors of protein kinases. <i>Expert Opinion on Drug Discovery</i> , 2008, 3, 819-831.	2.5	4
312	Use of genome-wide high-throughput technologies in biomarker development. <i>Biomarkers in Medicine</i> , 2008, 2, 509-524.	0.6	13
313	Exploitation of the 3-Quinolonecarbonitrile Template for Src Tyrosine Kinase Inhibitors. <i>Current Topics in Medicinal Chemistry</i> , 2008, 8, 922-934.	1.0	15
314	Management of granulosa cell tumour of the ovary. <i>Current Opinion in Oncology</i> , 2008, 20, 560-564.	1.1	41
315	Growth Arrest of BCR-ABL Positive Cells with a Sequence-Specific Polyamide-Chlorambucil Conjugate. <i>PLoS ONE</i> , 2008, 3, e3593.	1.1	9
317	Chemical genetic screening of KRAS-based synthetic lethal inhibitors for pancreatic cancer. <i>Frontiers in Bioscience - Landmark</i> , 2009, Volume, 2904.	3.0	15
318	Anti-Hepatitis B Virus Activity of New Substituted Pyrimidine Acyclic Nucleoside Analogues. <i>Zeitschrift Fur Naturforschung - Section C Journal of Biosciences</i> , 2009, 64, 767-772.	0.6	4
319	What Is Cancer?. , 2009, , 323-327.		0
320	Combined Anti-Angiogenic Therapy Targeting PDGF and VEGF Receptors Lowers the Interstitial Fluid Pressure in a Murine Experimental Carcinoma. <i>PLoS ONE</i> , 2009, 4, e8149.	1.1	38
321	Mining free compound databases to identify candidates selected by virtual screening. <i>Expert Opinion on Drug Discovery</i> , 2009, 4, 901-906.	2.5	12
322	Systems biology in pharmacogenomic research: the way to personalized prescribing?. <i>Pharmacogenomics</i> , 2009, 10, 971-981.	0.6	19
323	Expression, mutation and copy number analysis of platelet-derived growth factor receptor A (PDGFRA) and its ligand PDGFA in gliomas. <i>British Journal of Cancer</i> , 2009, 101, 973-982.	2.9	104

#	ARTICLE	IF	CITATIONS
324	A Novel Phospha Sugar Analogue: Synthesis And Evaluation Of 2,3-Dibromo-3-Methyl-1-Phenylphospholane 1-Oxide As A New Class Of Potential Anti-Proliferative Materials For Leukemia Cells. <i>Heterocyclic Communications</i> , 2009, 15, .	0.6	1
325	Substrate Specificity, Inhibitors and Regulation of Human Cytochrome P450 2D6 and Implications in Drug Development. <i>Current Medicinal Chemistry</i> , 2009, 16, 2661-2805.	1.2	64
326	Global Effects of Kinase Inhibitors on Signaling Networks Revealed by Quantitative Phosphoproteomics. <i>Molecular and Cellular Proteomics</i> , 2009, 8, 2796-2808.	2.5	194
327	Synthetic and Natural Compounds that Interact with Human Cytochrome P450 1A2 and Implications in Drug Development. <i>Current Medicinal Chemistry</i> , 2009, 16, 4066-4218.	1.2	107
328	Substrates, Inducers, Inhibitors and Structure-Activity Relationships of Human Cytochrome P450 2C9 and Implications in Drug Development. <i>Current Medicinal Chemistry</i> , 2009, 16, 3480-3675.	1.2	142
329	Equally Potent Inhibition of c-Src and Abl by Compounds that Recognize Inactive Kinase Conformations. <i>Cancer Research</i> , 2009, 69, 2384-2392.	0.4	134
330	Platelet-Derived Growth Factor C Is Upregulated in Human Uterine Fibroids and Regulates Uterine Smooth Muscle Cell Growth1. <i>Biology of Reproduction</i> , 2009, 81, 749-758.	1.2	26
331	The Application of Phenotypic High-Throughput Screening Techniques to Cardiovascular Research. <i>Trends in Cardiovascular Medicine</i> , 2009, 19, 207-212.	2.3	16
332	HCT116 cells deficient in p21Waf1 are hypersensitive to tyrosine kinase inhibitors and adriamycin through a mechanism unrelated to p21 and dependent on p53. <i>DNA Repair</i> , 2009, 8, 390-399.	1.3	17
333	Translation of rare disease research into orphan drug development: disease matters. <i>Drug Discovery Today</i> , 2009, 14, 1166-1173.	3.2	67
334	Effects of imatinib mesylate in osteoblastogenesis. <i>Experimental Hematology</i> , 2009, 37, 461-468.	0.2	41
335	Protein kinases as antibacterial targets. <i>Current Opinion in Cell Biology</i> , 2009, 21, 325-330.	2.6	55
336	Cancer therapy targeted at cellular signal transduction mechanisms: Strategies, clinical results, and unresolved issues. <i>European Journal of Pharmacology</i> , 2009, 625, 6-22.	1.7	22
337	Exploring Kinase Cosubstrate Promiscuity: Monitoring Kinase Activity through Dansylation. <i>ChemBioChem</i> , 2009, 10, 234-237.	1.3	33
338	Off-Target Decoding of a Multitarget Kinase Inhibitor by Chemical Proteomics. <i>ChemBioChem</i> , 2009, 10, 1163-1174.	1.3	14
339	Palladium-catalyzed cross-coupling reaction of 2- and/or 5-substituted 4,6-dichloropyrimidines with arylboronic acids. <i>Journal of Heterocyclic Chemistry</i> , 2009, 46, 960-964.	1.4	14
341	Transition-Metal-Catalyzed Direct Arylation of (Hetero)Arenes by C-H Bond Cleavage. <i>Angewandte Chemie - International Edition</i> , 2009, 48, 9792-9826.	7.2	2,623
342	Synthesis of 4-substituted styrene compounds via palladium catalyzed Suzuki-Miyaura reaction using bidentate Schiff base ligands. <i>Applied Organometallic Chemistry</i> , 2009, 23, 476-480.	1.7	14

#	ARTICLE	IF	CITATIONS
343	Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2009, 877, 1982-1996.	1.2	172
344	The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib. <i>Investigational New Drugs</i> , 2009, 27, 31-40.	1.2	132
345	Awakening guardian angels: drugging the p53 pathway. <i>Nature Reviews Cancer</i> , 2009, 9, 862-873.	12.8	805
346	Targeting protein kinases in central nervous system disorders. <i>Nature Reviews Drug Discovery</i> , 2009, 8, 892-909.	21.5	244
348	Analysis of c-Met Kinase Domain Complexes: A New Specific Catalytic Site Receptor Model for Defining Binding Modes of ATP-Competitive Ligands. <i>Chemical Biology and Drug Design</i> , 2009, 74, 560-570.	1.5	14
349	Synthesis of novel benzoxazocino quinoliniums and quinolones under PTC conditions and their application in Suzuki cross coupling reaction for the construction of polynuclear heteroaromatics. <i>Tetrahedron</i> , 2009, 65, 6941-6949.	1.0	11
350	Aqueous Suzuki coupling reaction catalyzed by water-soluble diimine/Pd(II) systems. <i>Journal of Organometallic Chemistry</i> , 2009, 694, 697-702.	0.8	81
351	Molecular target therapy for gastroenteropancreatic endocrine tumours: Biological rationale and clinical perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 72, 110-124.	2.0	36
352	3-Amido-4-anilinoquinolines as CSF-1R kinase inhibitors 2: Optimization of the PK profile. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 701-705.	1.0	20
353	Synthesis of potent antitumor and antiviral benzofuran derivatives. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 2420-2428.	1.0	266
354	Evaluation of substituted 6-arylquinazolin-4-amines as potent and selective inhibitors of cdc2-like kinases (Clk). <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 6700-6705.	1.0	69
355	The Chemical Biology of Protein Phosphorylation. <i>Annual Review of Biochemistry</i> , 2009, 78, 797-825.	5.0	213
356	A Randomized, Phase II Study of Preoperative plus Postoperative Imatinib in GIST: Evidence of Rapid Radiographic Response and Temporal Induction of Tumor Cell Apoptosis. <i>Annals of Surgical Oncology</i> , 2009, 16, 910-919.	0.7	166
357	9-(Arenethenyl)purines as Dual Src/Abl Kinase Inhibitors Targeting the Inactive Conformation: Design, Synthesis, and Biological Evaluation. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 4743-4756.	2.9	41
358	Suzuki Cross-Coupling Reactions Catalyzed by an Aliphatic Phosphine-Based Pincer Complex of Palladium: Evidence for a Molecular Mechanism. <i>ChemCatChem</i> , 2009, 1, 393-400.	1.8	54
359	Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy. <i>Advanced Drug Delivery Reviews</i> , 2009, 61, 26-33.	6.6	122
360	Naturally-occurring shikonin analogues – A class of necroptotic inducers that circumvent cancer drug resistance. <i>Cancer Letters</i> , 2009, 274, 233-242.	3.2	113
361	Specific modulation of protein kinase activity via small peptides. <i>Regulatory Peptides</i> , 2009, 153, 11-18.	1.9	7

#	ARTICLE	IF	CITATIONS
362	Synthesis and In Vitro Antitumor Activity of New Substituted Thiopyrimidine Acyclic Nucleosides and Their Thioglycoside Analogs. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2009, 28, 261-274.	0.4	43
364	Development of a Fluorescent-Tagged Kinase Assay System for the Detection and Characterization of Allosteric Kinase Inhibitors. <i>Journal of the American Chemical Society</i> , 2009, 131, 13286-13296.	6.6	140
365	PDGFR α : a new therapeutic target in the treatment of hepatocellular carcinoma?. <i>Expert Opinion on Therapeutic Targets</i> , 2009, 13, 443-454.	1.5	42
366	Platelet-Derived Growth Factor Receptor Expression and Activation in Choroid Plexus Tumors. <i>American Journal of Pathology</i> , 2009, 175, 1631-1637.	1.9	40
367	Application-Specific R&D Capabilities and the Advantage of Incumbents: Evidence from the Anticancer Drug Market. <i>Management Science</i> , 2009, 55, 1409-1422.	2.4	63
368	Quantitative Assessment of Blood Volume and Permeability in Cerebral Mass Lesions using Dynamic Contrast-Enhanced Computed Tomography in the Dog. <i>Academic Radiology</i> , 2009, 16, 1187-1195.	1.3	14
369	Targeted Restoration of Down-regulated DAPK2 Tumor Suppressor Activity Induces Apoptosis in Hodgkin Lymphoma Cells. <i>Journal of Immunotherapy</i> , 2009, 32, 431-441.	1.2	38
370	Anti-Hepatitis B Virus Activity of New N ⁴ - β -D-Glycoside Pyrazolo[3,4-d]pyrimidine Derivatives. <i>Zeitschrift Fur Naturforschung - Section C Journal of Biosciences</i> , 2009, 64, 323-328.	0.6	21
371	Chimeric tyrosine kinase-HDAC inhibitors as antiproliferative agents. <i>Anti-Cancer Drugs</i> , 2010, 21, 759-765.	0.7	6
374	A flow-based synthesis of Imatinib: the API of Gleevec. <i>Chemical Communications</i> , 2010, 46, 2450.	2.2	175
375	2-Pyridyl Tosylate Derivatives Building Blocks for Structural Diversity via Transition Metal Catalysis. <i>Israel Journal of Chemistry</i> , 2010, 50, 558-567.	1.0	8
376	The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors: A structural analysis of the binding interactions of Gleevec $\text{\textcircled{R}}$, Nexavar $\text{\textcircled{R}}$, and BIRB-796. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 5738-5748.	1.4	143
377	Iterative and regioselective cross-couplings of 2-chloro-3,4-diiodopyridine leading to 2,3,4-triheteroarylpyridines. <i>Tetrahedron</i> , 2010, 66, 668-675.	1.0	27
378	Mastering chiral substituted 2-oxopiperazines. <i>Tetrahedron: Asymmetry</i> , 2010, 21, 255-274.	1.8	36
379	Antimicrobial activity of new 4,6-disubstituted pyrimidine, pyrazoline, and pyran derivatives. <i>Archives of Pharmacal Research</i> , 2010, 33, 647-654.	2.7	32
380	Synthesis and anti-hepatitis B activity of new substituted uracil and thiouracil glycosides. <i>Archives of Pharmacal Research</i> , 2010, 33, 797-805.	2.7	10
381	Sulfur-Ligand/Pd-Catalyzed Cross-Coupling Reactions of Aryl Halides with Arylboronic Acids Under Aerobic Conditions. <i>Catalysis Letters</i> , 2010, 137, 69-73.	1.4	19
382	Development of a weak-base docetaxel derivative that can be loaded into lipid nanoparticles. <i>Journal of Controlled Release</i> , 2010, 144, 332-340.	4.8	78

#	ARTICLE	IF	CITATIONS
383	Identification, SAR Studies, and X-ray Crystallographic Analysis of a Novel Furanopyrimidine Aurora Kinase Inhibitor. <i>ChemMedChem</i> , 2010, 5, 255-267.	1.6	27
384	Novel Imatinib Derivatives with Altered Specificity between Bcr-Abl and FMS, KIT, and PDGF Receptors. <i>ChemMedChem</i> , 2010, 5, 130-139.	1.6	17
385	Rationale for the development of IMC3G3, a fully human immunoglobulin G subclass 1 monoclonal antibody targeting the platelet-derived growth factor receptor β . <i>Cancer</i> , 2010, 116, 1018-1026.	2.0	54
386	The 1,3-Diaminobenzene-Derived Aminophosphine Palladium Pincer Complex $\{C_6H_3[NHP(piperidinyl)]_2Pd(Cl)\}$ - A Highly Active Suzuki-Miyaura Catalyst with Excellent Functional Group Tolerance. <i>Advanced Synthesis and Catalysis</i> , 2010, 352, 1075-1080.	2.1	60
387	Dichlorobis(aminophosphine) Complexes of Palladium: Highly Convenient, Reliable and Extremely Active Suzuki-Miyaura Catalysts with Excellent Functional Group Tolerance. <i>Chemistry - A European Journal</i> , 2010, 16, 4075-4081.	1.7	62
388	An Efficient Low-Temperature Stille-Migita Cross-Coupling Reaction for Heteroaromatic Compounds by Pd-PEPPSI-Pent. <i>Chemistry - A European Journal</i> , 2010, 16, 4279-4283.	1.7	97
389	$[Pd(Cl)_2\{P(NC_5H_{10})(C_6H_{11})_2\}_2]$ - A Highly Effective and Extremely Versatile Palladium-Based Negishi Catalyst that Efficiently and Reliably Operates at Low Catalyst Loadings. <i>Chemistry - A European Journal</i> , 2010, 16, 11072-11081.	1.7	44
390	Proteus in the World of Proteins: Conformational Changes in Protein Kinases. <i>Archiv Der Pharmazie</i> , 2010, 343, 193-206.	2.1	72
391	Synthesis and microwave-assisted catalytic activity of novel bis-benzimidazole salts bearing furfuryl and thenyl moieties in Heck and Suzuki cross-coupling reactions. <i>Applied Organometallic Chemistry</i> , 2010, 24, 414-420.	1.7	14
392	Regioselective addition reactions at C-2 of 3,4-dihydropyrimidinones. Synthesis and evaluation of multifunctionalized tetrahydropyrimidines. <i>Tetrahedron</i> , 2010, 66, 8175-8180.	1.0	13
393	Dithiocarbamate and DBU-promoted amide bond formation under microwave condition. <i>Tetrahedron Letters</i> , 2010, 51, 899-902.	0.7	32
394	Synthesis of biologically potent new 3-(heteroaryl)aminocoumarin derivatives via Buchwald-Hartwig C-N coupling. <i>Tetrahedron Letters</i> , 2010, 51, 1099-1102.	0.7	26
395	Efficient synthesis of 1,4-disubstituted polyfunctional piperazines via a sequential one-pot Ugi/nucleophilic addition five-component reaction. <i>Tetrahedron Letters</i> , 2010, 51, 3277-3279.	0.7	23
396	Convenient preparation of 4-aryl-2-(heteroaryl-amino)pyrimidines and 4-anilino-2-(heteroaryl-amino)pyrimidines. <i>Tetrahedron Letters</i> , 2010, 51, 3259-3262.	0.7	4
397	Probing the Probes: Fitness Factors For Small Molecule Tools. <i>Chemistry and Biology</i> , 2010, 17, 561-577.	6.2	253
398	Potent activity against K562 cells by polyamide-seco-CBI conjugates targeting histone H4 genes. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 168-174.	1.4	10
399	Preparation and characterization of novel 4-bromo-3,4-dimethyl-1-phenyl-2-phospholene 1-oxide and the analogous phosphorus heterocycles or phospho sugars. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 5943-5946.	1.0	21
400	Structural Analysis of DFG-in and DFG-out Dual Src-Abl Inhibitors Sharing a Common Vinyl Purine Template. <i>Chemical Biology and Drug Design</i> , 2010, 75, 18-28.	1.5	26

#	ARTICLE	IF	CITATIONS
401	Contribution of BCR-ABL-independent activation of ERK1/2 to acquired imatinib resistance in K562 chronic myeloid leukemia cells. <i>Cancer Science</i> , 2010, 101, 137-142.	1.7	27
402	Combination of <i>KIT</i> gene silencing and tocopherol succinate may offer improved therapeutic approaches for human mastocytosis. <i>British Journal of Haematology</i> , 2010, 148, 59-68.	1.2	3
403	Novel pyrrolo-1,5-benzoxazepine compounds display significant activity against resistant chronic myeloid leukaemia cells in vitro, in ex vivo patient samples and in vivo. <i>British Journal of Cancer</i> , 2010, 102, 1474-1482.	2.9	22
404	PKC and the control of localized signal dynamics. <i>Nature Reviews Molecular Cell Biology</i> , 2010, 11, 103-112.	16.1	407
405	Microreview: Type IV secretion in the obligatory intracellular bacterium <i>Anaplasma phagocytophilum</i> . <i>Cellular Microbiology</i> , 2010, 12, 1213-1221.	1.1	44
408	Chemotherapy and Experimental Medical Therapies for Meningiomas. , 2010, , 667-679.		1
409	Molecular Characterization of c-Abl/c-Src Kinase Inhibitors Targeted against Murine Tumour Progenitor Cells that Express Stem Cell Markers. <i>PLoS ONE</i> , 2010, 5, e14143.	1.1	19
410	Pulmonary hypertension: advances in pathogenesis and treatment. <i>British Medical Bulletin</i> , 2010, 94, 21-32.	2.7	21
411	Preparation and Characterization of Phospha Sugar Analogues, 2,3-Dibromo-3-methyl-1-phenylphospholane 1-Oxide Derivatives, as Novel Anticancer Agents. <i>Phosphorus, Sulfur and Silicon and the Related Elements</i> , 2010, 185, 2286-2291.	0.8	8
412	Synthesis of Some 1-Aryl-2,3-dibromophospholanes as Novel Anti-Cancer Agents. <i>Heterocyclic Communications</i> , 2010, 16, .	0.6	3
413	Therapy directed against c-kit (CD117) and PDGF transmembrane receptor tyrosine kinases. <i>Progress in Respiratory Research</i> , 2010, , 279-282.	0.1	0
414	Tyrosine-Phosphorylated Caveolin-1 Blocks Bacterial Uptake by Inducing Vav2-RhoA-Mediated Cytoskeletal Rearrangements. <i>PLoS Biology</i> , 2010, 8, e1000457.	2.6	32
415	Anti-Angiogenic Therapies for Children with Cancer. <i>Current Cancer Drug Targets</i> , 2010, 10, 879-889.	0.8	6
416	Specificity in the Interaction of Natural Products with their Target Proteins- A Biochemical and Structural Insight. <i>Mini-Reviews in Medicinal Chemistry</i> , 2010, 10, 540-549.	1.1	8
417	Metal-Free Regioselective Oxidative Biaryl Coupling Leading to Head-to-Tail Bithiophenes: Reactivity Switching, a Concept Based on the Iodonium(III) Intermediate. <i>Organic Letters</i> , 2010, 12, 3804-3807.	2.4	88
419	Proteomics Analysis of Cellular Imatinib Targets and their Candidate Downstream Effectors. <i>Journal of Proteome Research</i> , 2010, 9, 6033-6043.	1.8	27
420	Natural Products Version 2.0: Connecting Genes to Molecules. <i>Journal of the American Chemical Society</i> , 2010, 132, 2469-2493.	6.6	407
421	Discovery of 3-[2-(Imidazo[1,2- <i>b</i>]pyridazin-3-yl)ethynyl]-4-methyl- <i>N</i> -{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a Potent, Orally Active Pan-Inhibitor of Breakpoint Cluster Region-Abelson (BCR-ABL) Kinase Including the T315I Gatekeeper Mutant. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 4701-4719.	2.9	315

#	ARTICLE	IF	CITATIONS
422	p21Cip1 Confers resistance to imatinib in human chronic myeloid leukemia cells. <i>Cancer Letters</i> , 2010, 292, 133-139.	3.2	20
423	BRAF Inhibitors Based on an Imidazo[4,5]pyridin-2-one Scaffold and a Meta Substituted Middle Ring. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 1964-1978.	2.9	19
424	Toward the Development of Innovative Bifunctional Agents To Induce Differentiation and To Promote Apoptosis in Leukemia: Clinical Candidates and Perspectives. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 6779-6810.	2.9	24
425	Chronic myelogenous leukemia (CML). , 2010, , 117-152.		0
426	Protein Kinases: Docking and Homology Modeling Reliability. <i>Journal of Chemical Information and Modeling</i> , 2010, 50, 1432-1441.	2.5	58
427	Analysis of Imatinib and Sorafenib Binding to p38 β Compared with c-Abl and b-Raf Provides Structural Insights for Understanding the Selectivity of Inhibitors Targeting the DFG-Out Form of Protein Kinases. <i>Biochemistry</i> , 2010, 49, 3611-3618.	1.2	63
428	New drugs and targets for asthma and COPD. <i>Progress in Respiratory Research</i> , 2010, , 3-23.	0.1	5
429	Biochemical Mechanisms of Resistance to Small-Molecule Protein Kinase Inhibitors. <i>ACS Chemical Biology</i> , 2010, 5, 121-138.	1.6	55
430	Chemical Proteomic Technologies for Drug Target Identification. <i>Annual Reports in Medicinal Chemistry</i> , 2010, , 345-360.	0.5	9
431	Biomarkers for rheumatoid arthritis: Making it personal. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2010, 70, 79-84.	0.6	40
432	PdCl ₂ (dppf)-catalyzed in situ coupling of 2-hydroxypyridines with aryl boronic acids mediated by PyBroP and the one-pot chemo- and regioselective construction of two distinct aryl-aryl bonds. <i>Chemical Communications</i> , 2011, 47, 12840.	2.2	43
433	Negishi cross-coupling reaction catalyzed by an aliphatic, phosphine based pincer complex of palladium. biaryl formation via cationic pincer-type PdIV intermediates. <i>Dalton Transactions</i> , 2011, 40, 8996.	1.6	30
434	Alpha7 Helix Plays an Important Role in the Conformational Stability of PTP1B. <i>Journal of Biomolecular Structure and Dynamics</i> , 2011, 28, 675-693.	2.0	28
435	Role of Hetero-Halogen (F \cdots X, X = Cl, Br, and I) or Homo-Halogen (X \cdots X, X = F, Cl, Br, and I) Interactions in Substituted Benzanilides. <i>Crystal Growth and Design</i> , 2011, 11, 1578-1596.	1.4	103
436	Proteome profiling reveals potential cellular targets of staurosporine using a clickable cell-permeable probe. <i>Chemical Communications</i> , 2011, 47, 11306.	2.2	68
437	From Old Competence Destruction to New Competence Access: Evidence from the Comparison of Two Discontinuities in Anticancer Drug Discovery. <i>Organization Science</i> , 2011, 22, 1500-1516.	3.0	45
438	Biomarker Definition and Validation During Drug Development. , 2011, , 223-244.		1
439	The Evolving War on Cancer. <i>Cell</i> , 2011, 145, 19-24.	13.5	197

#	ARTICLE	IF	CITATIONS
440	Oxygen-promoted PdCl ₂ -catalyzed ligand-free Suzuki reaction in aqueous media. <i>Organic and Biomolecular Chemistry</i> , 2011, 9, 1054-1060.	1.5	83
441	Anticancer Activities of Some New Synthesized Thiazolo[3,2-a]Pyrido[4,3-d]Pyrimidine Derivatives. <i>American Journal of Biochemistry and Biotechnology</i> , 2011, 7, 43-54.	0.1	24
443	RNAi Screening Identifies TAK1 as a Potential Target for the Enhanced Efficacy of Topoisomerase Inhibitors. <i>Current Cancer Drug Targets</i> , 2011, 11, 976-986.	0.8	36
444	Niche contributions to oncogenesis: emerging concepts and implications for the hematopoietic system. <i>Haematologica</i> , 2011, 96, 1041-1048.	1.7	64
445	Pericytes promote endothelial cell survival through induction of autocrine VEGF-A signaling and Bcl-w expression. <i>Blood</i> , 2011, 118, 2906-2917.	0.6	253
446	Association of SLCO1B3 Polymorphism with Intracellular Accumulation of Imatinib in Leukocytes in Patients with Chronic Myeloid Leukemia. <i>Biological and Pharmaceutical Bulletin</i> , 2011, 34, 114-119.	0.6	35
447	Deltonin Isolated from <i>Dioscorea zingiberensis</i> Inhibits Cancer Cell Growth through Inducing Mitochondrial Apoptosis and Suppressing Akt and Mitogen Activated Protein Kinase Signals. <i>Biological and Pharmaceutical Bulletin</i> , 2011, 34, 1231-1239.	0.6	25
448	The role of stem cell factor and c-KIT in keloid pathogenesis: do tyrosine kinase inhibitors have a potential therapeutic role?. <i>British Journal of Dermatology</i> , 2011, 164, 372-386.	1.4	19
449	Analysis of KIT expression and KIT exon 11 mutations in canine oral malignant melanomas. <i>Veterinary and Comparative Oncology</i> , 2011, 9, 219-224.	0.8	42
450	High-Throughput Analysis of an RNAi Library Identifies Novel Kinase Targets in <i>Trypanosoma brucei</i> . <i>Chemical Biology and Drug Design</i> , 2011, 78, 454-463.	1.5	33
451	The eye of <i>Drosophila</i> as a model system for studying intracellular signaling in ontogenesis and pathogenesis. <i>Biochemistry (Moscow)</i> , 2011, 76, 1556-1581.	0.7	9
452	Regulation of hTERT by BCR-ABL at multiple levels in K562 cells. <i>BMC Cancer</i> , 2011, 11, 512.	1.1	23
453	MeSHy: Mining unanticipated PubMed information using frequencies of occurrences and concurrences of MeSH terms. <i>Journal of Biomedical Informatics</i> , 2011, 44, 919-926.	2.5	25
454	Selection of cyclic-peptide inhibitors targeting Aurora kinase A: Problems and solutions. <i>Bioorganic and Medicinal Chemistry</i> , 2011, 19, 6743-6749.	1.4	13
455	A General Framework for Inhibitor Resistance in Protein Kinases. <i>Chemistry and Biology</i> , 2011, 18, 966-975.	6.2	49
456	The Methylation Effect in Medicinal Chemistry. <i>Chemical Reviews</i> , 2011, 111, 5215-5246.	23.0	671
457	Contemporary Approaches to Kinase Lead Generation. <i>RSC Drug Discovery Series</i> , 2011, , 54-78.	0.2	0
458	Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. <i>Blood</i> , 2011, 117, e75-e87.	0.6	202

#	ARTICLE	IF	CITATIONS
459	Molecular Dynamics Simulation and Free Energy Calculation Studies of the Binding Mechanism of Allosteric Inhibitors with p38 β MAP Kinase. <i>Journal of Chemical Information and Modeling</i> , 2011, 51, 3235-3246.	2.5	67
460	Palladium-catalyzed coupling of functionalized primary and secondary amines with aryl and heteroaryl halides: two ligands suffice in most cases. <i>Chemical Science</i> , 2011, 2, 57-68.	3.7	315
462	How were new medicines discovered?. <i>Nature Reviews Drug Discovery</i> , 2011, 10, 507-519.	21.5	1,516
463	Molecular imaging with SPECT as a tool for drug development. <i>Advanced Drug Delivery Reviews</i> , 2011, 63, 547-554.	6.6	88
464	Transcriptional activation of the Axl and PDGFR β by c-Met through a ras- and Src-independent mechanism in human bladder cancer. <i>BMC Cancer</i> , 2011, 11, 139.	1.1	67
465	Involvement of mast cells in monocrotaline-induced pulmonary hypertension in rats. <i>Respiratory Research</i> , 2011, 12, 60.	1.4	66
466	Synthesis and antiviral activity of new substituted pyrimidine glycosides. <i>Journal of Heterocyclic Chemistry</i> , 2011, 48, 1028-1038.	1.4	29
467	Highly Efficient Suzuki -- Miyaura Coupling of Aryl Tosylates and Mesylates Catalyzed by Stable, Cost -- Effective [1,3 -- Bis(diphenylphosphino)propane]nickel(II) Chloride [Ni(dppp)Cl -- 2] with only 1 -- mol% Loading. <i>Advanced Synthesis and Catalysis</i> , 2011, 353, 309-314.	2.1	42
468	Synthesis and Antimicrobial Activity of 2 -- Methyl -- 5 -- Nitroaniline Derivatives: A Structure -- Activity Relationship Study. <i>Chinese Journal of Chemistry</i> , 2011, 29, 102-108.	2.6	1
469	Prognostic but not predictive role of platelet -- derived growth factor receptors in patients with recurrent glioblastoma. <i>International Journal of Cancer</i> , 2011, 128, 1981-1988.	2.3	44
470	Structural Requirements for the Antiproliferative Activity of Pre -- mRNA Splicing Inhibitor FR901464. <i>Chemistry - A European Journal</i> , 2011, 17, 895-904.	1.7	78
471	Negishi Cross -- Coupling Reactions Catalyzed by an Aminophosphine -- Based Nickel System: A Reliable and General Applicable Reaction Protocol for the High -- Yielding Synthesis of Biaryls. <i>Chemistry - A European Journal</i> , 2011, 17, 11893-11904.	1.7	29
472	Hybrid compounds as new Bcr/Abl inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 1965-1968.	1.0	17
473	Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR -- ABL including the T3151 gatekeeper mutant. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 3743-3748.	1.0	17
474	Synthesis, molecular modeling and bio-evaluation of cycloalkyl fused 2-aminopyrimidines as antitubercular and antidiabetic agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 4404-4408.	1.0	36
475	Silica supported palladium-phosphine complex: recyclable catalyst for Suzuki -- Miyaura cross-coupling reactions at ambient temperature. <i>Tetrahedron</i> , 2011, 67, 318-325.	1.0	61
476	BCR-ABL Inhibitors in Chronic Myeloid Leukemia: Process Chemistry and Biochemical Profile. <i>Current Medicinal Chemistry</i> , 2011, 18, 2943-2959.	1.2	12
477	Targeting Oncogenic Protein-Protein Interactions by Diversity Oriented Synthesis and Combinatorial Chemistry Approaches. <i>Molecules</i> , 2011, 16, 4408-4427.	1.7	20

#	ARTICLE	IF	CITATIONS
478	p73 as a Pharmaceutical Target for Cancer Therapy. <i>Current Pharmaceutical Design</i> , 2011, 17, 578-590.	0.9	33
479	Abelson Family Tyrosine Kinases Regulate the Function of Nicotinic Acetylcholine Receptors and Nicotinic Synapses on Autonomic Neurons. <i>Molecular Pharmacology</i> , 2011, 80, 97-109.	1.0	7
480	Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain. <i>Expert Reviews in Molecular Medicine</i> , 2011, 13, e17.	1.6	266
481	Preparation of Phospha Sugar Analogues and Their Evaluation as Novel Molecular Targeting Anticancer Agents. <i>Phosphorus, Sulfur and Silicon and the Related Elements</i> , 2011, 186, 936-944.	0.8	3
483	Antenatal imatinib treatment reduces pulmonary vascular remodeling in a rat model of congenital diaphragmatic hernia. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2012, 302, L1159-L1166.	1.3	29
484	Enhanced intracellular accumulation of a non-nucleoside anti-cancer agent via increased uptake of its valine ester prodrug through amino acid transporters. <i>Xenobiotica</i> , 2012, 42, 603-613.	0.5	29
485	Synthesis, Reactions and Evaluation of the Antimicrobial Activity of Some 4-(p-Halophenyl)-4H-naphthopyran, Pyranopyrimidine and Pyranotriazolopyrimidine Derivatives. <i>Pharmaceuticals</i> , 2012, 5, 745-757.	1.7	41
486	Role of Src Tyrosine Kinases in Experimental Pulmonary Hypertension. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2012, 32, 1354-1365.	1.1	108
487	Molecular Pathogenesis of Granulosa Cell Tumors of the Ovary. <i>Endocrine Reviews</i> , 2012, 33, 109-144.	8.9	164
488	STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 2860-2865.	3.3	69
489	Cell biology: A key driver of therapeutic innovation. <i>Journal of Cell Biology</i> , 2012, 199, 571-575.	2.3	2
490	Small Molecule Tyrosine Kinase Inhibitors: The New Dawn for Cancer Therapy. <i>Letters in Drug Design and Discovery</i> , 2012, 9, 84-125.	0.4	4
491	Identification of Disease-Relevant Genes for Molecularly-Targeted Drug Discovery. <i>Current Cancer Drug Targets</i> , 2012, 12, 1-13.	0.8	13
492	Design, Synthesis and Cancer Cell Line Activities of Pyrazolo[3,4- <i>b</i>]pyridine Derivatives. <i>Open Journal of Medicinal Chemistry</i> , 2012, 02, 78-88.	0.7	25
493	Novel Benzothiazole, Benzimidazole and Benzoxazole Derivatives as Potential Antitumor Agents: Synthesis and Preliminary in Vitro Biological Evaluation. <i>Molecules</i> , 2012, 17, 873-883.	1.7	64
494	A Hemodialysis Patient with Primary Extra-gastrointestinal Stromal Tumor: Favorable Outcome with Imatinib Mesylate. <i>Internal Medicine</i> , 2012, 51, 1561-1565.	0.3	4
495	A therapeutic renaissance: emergence of novel targeted agents for metastatic melanoma. <i>Clinical Investigation</i> , 2012, 2, 883-893.	0.0	1
496	Vascular Endothelial Growth Factor (VEGF) Receptors: Drugs and New Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 10797-10822.	2.9	158

#	ARTICLE	IF	CITATIONS
497	Simultaneous measurement of imatinib, nilotinib and dasatinib in dried blood spot by ultra high performance liquid chromatography tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2012, 903, 150-156.	1.2	58
498	<i>Drug Discovery.</i> , 2012, , 507-515.		2
499	Evaluation of deoxyhypusine synthase inhibitors targeting BCR-ABL positive leukemias. <i>Investigational New Drugs</i> , 2012, 30, 2274-2283.	1.2	9
500	Silica Tethered Pd ^{II} -DABCO Complex: An Efficient and Reusable Catalyst for Suzuki-Miyaura Reaction. <i>Catalysis Letters</i> , 2012, 142, 1388-1396.	1.4	23
501	Identification of common inhibitors of wild-type and T315I mutant of BCR-ABL through the parallel structure-based virtual screening. <i>Journal of Computer-Aided Molecular Design</i> , 2012, 26, 983-992.	1.3	7
502	RELATIONSHIP BETWEEN THE CALCULATED PHYSICO-CHEMICAL PARAMETERS AND REVERSED-PHASE THIN-LAYER CHROMATOGRAPHIC RETENTION BEHAVIOR OF ALKOXY-PHENYLBENZAMIDE DERIVATIVES. <i>Journal of Liquid Chromatography and Related Technologies</i> , 2012, 35, 1314-1324.	0.5	2
503	Direct Binding Assay for the Detection of Type IV Allosteric Inhibitors of Abl. <i>Journal of the American Chemical Society</i> , 2012, 134, 9138-9141.	6.6	34
504	Cell-Based Proteome Profiling of Potential Dasatinib Targets by Use of Affinity-Based Probes. <i>Journal of the American Chemical Society</i> , 2012, 134, 3001-3014.	6.6	204
505	BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia. <i>Nature Chemical Biology</i> , 2012, 8, 285-293.	3.9	158
506	The secret ally: immunostimulation by anticancer drugs. <i>Nature Reviews Drug Discovery</i> , 2012, 11, 215-233.	21.5	591
507	System-based drug discovery within the human kinome. <i>Expert Opinion on Drug Discovery</i> , 2012, 7, 1053-1070.	2.5	32
508	Targeting the RAS pathway in melanoma. <i>Trends in Molecular Medicine</i> , 2012, 18, 27-35.	3.5	70
509	Imatinib (Gleevec®) conformations observed in single crystals, protein-imatinib co-crystals and molecular dynamics: Implications for drug selectivity. <i>Journal of Molecular Structure</i> , 2012, 1018, 107-112.	1.8	5
510	Suzuki-Miyaura cross-coupling reaction of aryl bromides catalyzed by palladium(II) pyridoxal hydrazone complexes. <i>Journal of Organometallic Chemistry</i> , 2012, 708-709, 18-24.	0.8	38
511	Development and clinical application of a LC-MS/MS method for simultaneous determination of various tyrosine kinase inhibitors in human plasma. <i>Clinica Chimica Acta</i> , 2012, 413, 143-149.	0.5	90
512	Genetic and proteomic approaches to identify cancer drug targets. <i>British Journal of Cancer</i> , 2012, 106, 254-261.	2.9	31
513	Room-temperature Suzuki-Miyaura Coupling of Heteroaryl Chlorides and Tosylates. <i>European Journal of Organic Chemistry</i> , 2012, 2012, 6248-6259.	1.2	99
514	Heterocycles and Medicine. <i>Progress in Heterocyclic Chemistry</i> , 2012, , 1-53.	0.5	48

#	ARTICLE	IF	CITATIONS
515	Advancing cancer drug discovery towards more agile development of targeted combination therapies. <i>Future Medicinal Chemistry</i> , 2012, 4, 87-105.	1.1	19
516	Biomarker development for myasthenia gravis. <i>Annals of the New York Academy of Sciences</i> , 2012, 1275, 101-106.	1.8	20
517	In vitro efficacy of the anticancer drug imatinib on <i>Echinococcus multilocularis</i> larvae. <i>International Journal of Antimicrobial Agents</i> , 2012, 40, 458-462.	1.1	56
518	Synthesis and evaluation of small libraries of triazolylmethoxy chalcones, flavanones and 2-aminopyrimidines as inhibitors of mycobacterial FAS-II and PknG. <i>Bioorganic and Medicinal Chemistry</i> , 2012, 20, 5150-5163.	1.4	49
519	PET imaging with small-molecule tyrosine kinase inhibitors: TKI-PET. <i>Drug Discovery Today</i> , 2012, 17, 1175-1187.	3.2	64
520	The catalytic activity of a novel recyclable alkoxypalladium complex in Suzuki reaction. <i>Tetrahedron</i> , 2012, 68, 8502-8508.	1.0	12
521	An efficient entry to highly substituted chiral 2-oxopiperazines from $\hat{\text{L}}\pm$ -amino acids via iodocyclization. <i>Tetrahedron</i> , 2012, 68, 10114-10121.	1.0	23
522	Molecular simulations of drug-receptor complexes in anticancer research. <i>Future Medicinal Chemistry</i> , 2012, 4, 1961-1970.	1.1	5
523	Anaplastic Lymphoma Kinase Inhibitors for the Treatment of ALK-Positive Cancers. <i>Annual Reports in Medicinal Chemistry</i> , 2012, 47, 281-293.	0.5	12
524	New tools for classification and monitoring of autoimmune diseases. <i>Nature Reviews Rheumatology</i> , 2012, 8, 317-328.	3.5	81
525	The Different Flexibility of c-Src and c-Abl Kinases Regulates the Accessibility of a Druggable Inactive Conformation. <i>Journal of the American Chemical Society</i> , 2012, 134, 2496-2499.	6.6	91
526	Preparation of copper(II) oxide bound on polystyrene beads and its application in the aryl aminations: synthesis of Imatinib. <i>Tetrahedron Letters</i> , 2012, 53, 6657-6661.	0.7	14
527	Bruton's Tyrosine Kinase Inhibitors: Approaches to Potent and Selective Inhibition, Preclinical and Clinical Evaluation for Inflammatory Diseases and B Cell Malignancies. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 4539-4550.	2.9	75
528	Design, Synthesis, and Biological Evaluation of 3-(1 <i>H</i> -1,2,3-Triazol-1-yl)benzamide Derivatives as Potent Pan Bcr-Abl Inhibitors Including the Threonine ³¹⁵ $\hat{\text{A}}$ Isoleucine ³¹⁵ Mutant. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 10033-10046.	2.9	34
529	Dasatinib as a Bone-Modifying Agent: Anabolic and Anti-Resorptive Effects. <i>PLoS ONE</i> , 2012, 7, e34914.	1.1	61
530	Oxidative Stress: A Pathogenic Mechanism for Niemann-Pick Type C Disease. <i>Oxidative Medicine and Cellular Longevity</i> , 2012, 2012, 1-11.	1.9	74
531	Cytostatic and cytotoxic effects of tyrphostin AG1296 on RMS cells. <i>Wspolczesna Onkologia</i> , 2012, 1, 1-5.	0.7	4
532	Identifying Multiple-target Ligands via Computational Chemogenomics Approaches. <i>Current Topics in Medicinal Chemistry</i> , 2012, 12, 1363-1375.	1.0	8

#	ARTICLE	IF	CITATIONS
533	Discovery of potent, orally active compounds of tyrosine kinase and Serine/threonine-protein kinase inhibitor with anti-tumor activity in preclinical assays. <i>Tropical Journal of Obstetrics and Gynaecology</i> , 2012, 9, 431-9.	0.3	4
534	A simple metal-free synthesis of 2-substituted pyridine-4,5-dicarboxylates and their N-oxides. <i>Tetrahedron</i> , 2012, 68, 4719-4731.	1.0	31
535	De novo design, synthesis and pharmacological evaluation of new azaindole derivatives as dual inhibitors of Abl and Src kinases. <i>MedChemComm</i> , 2012, 3, 788.	3.5	6
536	Chemical proteomics and its impact on the drug discovery process. <i>Expert Review of Proteomics</i> , 2012, 9, 281-291.	1.3	10
537	An automated method for the measurement of a range of tyrosine kinase inhibitors in human plasma or serum using turbulent flow liquid chromatography-tandem mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2012, 403, 1685-1695.	1.9	68
538	Double Suzuki cross-coupling reaction of pyrimidine boronic acid: synthesis of new versatile dielectrophile. <i>Applied Organometallic Chemistry</i> , 2012, 26, 330-334.	1.7	10
539	Palladium-catalyzed Suzuki-Miyaura coupling with aryl and heteroaryl bromides using tetra(diphenylphosphinomethyl)ethylenediamine. <i>Applied Organometallic Chemistry</i> , 2012, 26, 342-346.	1.7	16
540	Life Beyond Kinases: Structure-Based Discovery of Sorafenib as Nanomolar Antagonist of 5-HT Receptors. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 5749-5759.	2.9	68
541	Highly specific, bisubstrate-competitive Src inhibitors from DNA-templated macrocycles. <i>Nature Chemical Biology</i> , 2012, 8, 366-374.	3.9	61
542	<i>Plasmodium falciparum</i> possesses a unique dual-specificity serine/threonine and tyrosine kinase, Pfnek3. <i>Cellular and Molecular Life Sciences</i> , 2012, 69, 1523-1535.	2.4	9
543	Structural Biology and Drug Discovery of Difficult Targets: The Limits of Ligandability. <i>Chemistry and Biology</i> , 2012, 19, 42-50.	6.2	191
544	Identification of new amino acid amides containing the imidazo[2,1-b]benzothiazol-2-ylphenyl moiety as inhibitors of tumorigenesis by oncogenic Met signaling. <i>European Journal of Medicinal Chemistry</i> , 2012, 47, 239-254.	2.6	70
545	Key strongylid nematodes of animals – Impact of next-generation transcriptomics on systems biology and biotechnology. <i>Biotechnology Advances</i> , 2012, 30, 469-488.	6.0	37
546	Synthesis and biological activities of Schiff bases of gabapentin with different aldehydes and ketones: a structure-activity relationship study. <i>Medicinal Chemistry Research</i> , 2012, 21, 1-9.	1.1	23
547	Antitumor and antileishmanial evaluation of novel heterocycles derived from quinazoline scaffold: a molecular modeling approach. <i>Medicinal Chemistry Research</i> , 2013, 22, 2207-2221.	1.1	14
548	A Miniaturized Chemical Proteomic Approach for Target Profiling of Clinical Kinase Inhibitors in Tumor Biopsies. <i>Journal of Proteome Research</i> , 2013, 12, 4005-4017.	1.8	15
549	Structure-activity relationship study of intervenolin derivatives: synthesis, antitumor, and anti- <i>Helicobacter pylori</i> activities. <i>Tetrahedron</i> , 2013, 69, 7608-7617.	1.0	13
550	Polypharmacology – Foe or Friend?. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 8955-8971.	2.9	399

#	ARTICLE	IF	CITATIONS
551	Molecularly targeted therapies for nonmelanoma skin cancers. <i>International Journal of Dermatology</i> , 2013, 52, 654-665.	0.5	21
552	Anticancer activities of some newly synthesized pyrazole and pyrimidine derivatives. <i>Archives of Pharmacal Research</i> , 2013, 36, 1055-1065.	2.7	31
553	Computational Analysis of the Binding Specificity of Gleevec to Abl, c-Kit, Lck, and c-Src Tyrosine Kinases. <i>Journal of the American Chemical Society</i> , 2013, 135, 14741-14753.	6.6	49
554	FOXO1 (Forkhead box O1) in Tumorigenesis. <i>Advances in Cancer Research</i> , 2013, 119, 191-419.	1.9	146
555	Synthesis, characterization and in vitro screening on bacterial, fungal and malarial strain of piprazinyl cyano biphenyl based compounds. <i>Bioorganic Chemistry</i> , 2013, 51, 16-23.	2.0	5
556	An efficient synthetic approach for N-C bond formation from (S)-amino acids: an easy access to cis-2,5-disubstituted chiral piperazines. <i>RSC Advances</i> , 2013, 3, 18332.	1.7	16
557	Mechanisms of resistance to BCR-ABL and other kinase inhibitors. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2013, 1834, 1449-1459.	1.1	51
558	Antimicrobial activity of medicinal plants and induction of defense related compounds in banana fruits cv. Robusta against crown rot pathogens. <i>Biological Control</i> , 2013, 64, 16-25.	1.4	29
559	Clinical Relevance of Target Identity and Biology. <i>Journal of Biomolecular Screening</i> , 2013, 18, 1164-1185.	2.6	7
560	An Easily Prepared Tetracosphosphine and Its Use in the Palladium-Catalyzed Suzuki-Miyaura Coupling of Aryl Chlorides. <i>Catalysis Letters</i> , 2013, 143, 1214-1219.	1.4	7
562	Characterization of a membrane-active anti-tumor agent, UA8967. <i>Investigational New Drugs</i> , 2013, 31, 576-586.	1.2	0
564	Design, synthesis and structure-activity relationship of novel quinoxaline derivatives as cancer chemopreventive agent by inhibition of tyrosine kinase receptor. <i>European Journal of Medicinal Chemistry</i> , 2013, 69, 115-124.	2.6	38
565	Development and validation of an high performance liquid chromatography-tandem mass spectrometry method for the determination of imatinib in rat tissues. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2013, 73, 103-107.	1.4	17
566	Personalizing medicine for autoimmune and inflammatory diseases. <i>Nature Immunology</i> , 2013, 14, 106-109.	7.0	35
567	The synthesis of Bcr-Abl inhibiting anticancer pharmaceutical agents imatinib, nilotinib and dasatinib. <i>Organic and Biomolecular Chemistry</i> , 2013, 11, 1766-1800.	1.5	54
568	Application of next generation sequencing to human gene fusion detection: computational tools, features and perspectives. <i>Briefings in Bioinformatics</i> , 2013, 14, 506-519.	3.2	102
569	New Trial Designs and Potential Therapies for Pulmonary Artery Hypertension. <i>Journal of the American College of Cardiology</i> , 2013, 62, D82-D91.	1.2	113
570	Loss of O6-methylguanine-DNA methyltransferase confers collateral sensitivity to carmustine in topoisomerase II-mediated doxorubicin resistant triple negative breast cancer cells. <i>Biochemical Pharmacology</i> , 2013, 85, 186-196.	2.0	31

#	ARTICLE	IF	CITATIONS
571	Remarkable catalytic activity of [PdCl ₂ (CH ₃ CN) ₂] in Suzuki–Miyaura cross-coupling reaction in aqueous media under mild conditions. <i>Journal of Molecular Catalysis A</i> , 2013, 371, 118-124.	4.8	22
572	New triarylpyrazoles as broad-spectrum anticancer agents: Design, synthesis, and biological evaluation. <i>European Journal of Medicinal Chemistry</i> , 2013, 65, 315-322.	2.6	23
573	Complete Cytogenetic Response and Major Molecular Response as Surrogate Outcomes for Overall Survival in First-Line Treatment of Chronic Myelogenous Leukemia: A Case Study for Technology Appraisal on the Basis of Surrogate Outcomes Evidence. <i>Value in Health</i> , 2013, 16, 1081-1090.	0.1	21
574	Design, synthesis, and evaluation of substituted 6-amide-4-anilinoquinazoline derivatives as c-Src inhibitors. <i>RSC Advances</i> , 2013, 3, 26230.	1.7	7
576	Structure-based design of flavone-based inhibitors of wild-type and T315I mutant of ABL. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 4324-4327.	1.0	8
577	New aminopyrimidine derivatives as inhibitors of the TAM family. <i>European Journal of Medicinal Chemistry</i> , 2013, 70, 789-801.	2.6	11
578	The reduction of tumor interstitial fluid pressure by liposomal imatinib and its effect on combination therapy with liposomal doxorubicin. <i>Biomaterials</i> , 2013, 34, 2277-2288.	5.7	74
579	Bladder interstitial cells: an updated review of current knowledge. <i>Acta Physiologica</i> , 2013, 207, 7-15.	1.8	48
580	Density functional investigation of the molecular structures, vibrational spectra and molecular properties of sulfonated pyridyl imine ligands and their palladium complexes. <i>Computational and Theoretical Chemistry</i> , 2013, 1013, 109-115.	1.1	12
581	Feasibility of Using Molecular Docking-Based Virtual Screening for Searching Dual Target Kinase Inhibitors. <i>Journal of Chemical Information and Modeling</i> , 2013, 53, 982-996.	2.5	27
582	Communication between the active site and the allosteric site in class A beta-lactamases. <i>Computational Biology and Chemistry</i> , 2013, 43, 1-10.	1.1	13
583	Rapid Discovery of a Novel Series of Abl Kinase Inhibitors by Application of an Integrated Microfluidic Synthesis and Screening Platform. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 3033-3047.	2.9	118
584	Systems Biology Approaches for Discovering Biomarkers for Traumatic Brain Injury. <i>Journal of Neurotrauma</i> , 2013, 30, 1101-1116.	1.7	55
585	A Palladium Bipyridyl Complex Grafted onto Nanosized MCM-41 as a Heterogeneous Catalyst for Negishi Coupling. <i>ChemCatChem</i> , 2013, 5, 1011-1019.	1.8	14
587	Imatinib and Nilotinib inhibit Bcr–Abl-induced ROS through targeted degradation of the NADPH oxidase subunit p22phox. <i>Leukemia Research</i> , 2013, 37, 183-189.	0.4	23
588	Discovery of New Benzothiazole-Based Inhibitors of Breakpoint Cluster Region-Abelson Kinase Including the T315I Mutant. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 3531-3545.	2.9	32
589	Malarial Kinases: Novel Targets for In Silico Approaches to Drug Discovery. <i>Methods in Molecular Biology</i> , 2013, 993, 205-229.	0.4	8
590	Phenotypic vs. Target-Based Drug Discovery for First-in-Class Medicines. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 93, 299-301.	2.3	344

#	ARTICLE	IF	CITATIONS
591	Modified zeolite immobilized palladium for ligand-free Suzuki–Miyaura cross-coupling reaction. <i>Journal of Organometallic Chemistry</i> , 2013, 738, 29-34.	0.8	32
592	Protein kinase inhibitors: breakthrough medicines and the next generation. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 675-678.	1.9	9
593	Discovery of Picomolar ABL Kinase Inhibitors Equipotent for Wild Type and T315I Mutant via Structure-Based de Novo Design. <i>Journal of the American Chemical Society</i> , 2013, 135, 8227-8237.	6.6	34
594	Infrared and NMR spectra, tautomerism, vibrational assignment, normal coordinate analysis, and quantum mechanical calculations of 4-amino-5-pyrimidinecarbonitrile. <i>Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy</i> , 2013, 111, 277-289.	2.0	10
595	Study of polymorphism in imatinib mesylate: A quantum chemical approach using electronic and vibrational spectra. <i>Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy</i> , 2013, 103, 325-332.	2.0	16
596	Repurposing as a strategy for orphan drug development, evidence from European approvals. <i>Expert Opinion on Orphan Drugs</i> , 2013, 1, 473-480.	0.5	8
598	Prognosis research strategy (PROGRESS) 4: Stratified medicine research. <i>BMJ, The</i> , 2013, 346, e5793-e5793.	3.0	367
599	Synthesis and Antimicrobial Activity of Pyrimidine Salts with Chloranilic and Picric Acids. <i>Journal of Chemistry</i> , 2013, 2013, 1-5.	0.9	2
600	Identification of Autophosphorylation Inhibitors of the Inositol-Requiring Enzyme 1 Alpha (IRE1 α) by High-Throughput Screening Using a DELFIA Assay. <i>Journal of Biomolecular Screening</i> , 2013, 18, 298-308.	2.6	13
601	Quantitative determination of imatinib stability under various stress conditions. <i>Journal of Pharmacy and Bioallied Sciences</i> , 2013, 5, 49.	0.2	8
602	Synthesis, Characterization, and Antimicrobial Activity of Methyl-2-aminopyridine-4-carboxylate Derivatives. <i>Journal of Chemistry</i> , 2013, 2013, 1-5.	0.9	4
603	A36-dependent Actin Filament Nucleation Promotes Release of Vaccinia Virus. <i>PLoS Pathogens</i> , 2013, 9, e1003239.	2.1	34
604	Beyond the diagnosis of idiopathic pulmonary fibrosis; the growing role of systems biology and stratified medicine. <i>Current Opinion in Pulmonary Medicine</i> , 2013, 19, 460-465.	1.2	34
605	The impact of molecular targets in cancer drug development: major hurdles and future strategies. <i>Expert Review of Clinical Pharmacology</i> , 2013, 6, 23-34.	1.3	19
606	Novel approaches to glioma drug design and drug screening. <i>Expert Opinion on Drug Discovery</i> , 2013, 8, 1135-1151.	2.5	38
607	Synthesis and Antioxidant Activity of 2-Amino-5-methylthiazol Derivatives Containing 1,3,4-Oxadiazole-2-thiol Moiety. <i>ISRN Organic Chemistry</i> , 2013, 2013, 1-8.	1.0	26
608	Therapeutic implications of endothelin and thrombin G-protein-coupled receptor transactivation of tyrosine and serine/threonine kinase cell surface receptors. <i>Journal of Pharmacy and Pharmacology</i> , 2013, 65, 465-473.	1.2	24
609	Good Intentions, Stubborn Practice: A critical appraisal of a public event on cancer genomics. <i>International Journal of Science Education, Part B: Communication and Public Engagement</i> , 2013, 3, 1-24.	0.9	5

#	ARTICLE	IF	CITATIONS
610	That which does not kill me makes me stronger; combining <scp>ERK</scp>1/2 pathway inhibitors and <scp>BH</scp>3 mimetics to kill tumour cells and prevent acquired resistance. <i>British Journal of Pharmacology</i> , 2013, 169, 1708-1722.	2.7	19
611	Explaining why Gleevec is a specific and potent inhibitor of Abl kinase. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 1664-1669.	3.3	136
612	Development of a Specific and Sensitive Enzyme-Linked Immunosorbent Assay for the Quantification of Imatinib. <i>Biological and Pharmaceutical Bulletin</i> , 2013, 36, 1964-1968.	0.6	12
613	Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes. <i>Blood</i> , 2013, 121, 5192-5202.	0.6	75
615	Dopamine signaling negatively regulates striatal phosphorylation of Cdk5 at tyrosine 15 in mice. <i>Frontiers in Cellular Neuroscience</i> , 2013, 7, 12.	1.8	16
616	The drug discovery process. , 2013, , 43-56.		0
617	Evolution of microRNAs as Therapeutic Targets for Malignant Gliomas. , 0, , .		1
618	Human ABC transporter ABCG2/BCRP expression in chemoresistance: basic and clinical perspectives for molecular cancer therapeutics. <i>Pharmacogenomics and Personalized Medicine</i> , 2014, 7, 53.	0.4	106
619	c-Src Binds to the Cancer Drug Ruxolitinib with an Active Conformation. <i>PLoS ONE</i> , 2014, 9, e106225.	1.1	27
620	Solvent-free synthesis, spectral studies, antimicrobial activities of some (E)-N-(substituted) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50	0.2	0
622	Differential effects of ketoconazole, itraconazole and voriconazole on the pharmacokinetics of imatinib and its main metabolite GCP74588 in rat. <i>Drug Development and Industrial Pharmacy</i> , 2014, 40, 1616-1622.	0.9	18
623	Chloroquine and hydroxychloroquine for cancer therapy. <i>Molecular and Cellular Oncology</i> , 2014, 1, e29911.	0.3	154
624	A Structural Atlas of Kinases Inhibited by Clinically Approved Drugs. <i>Methods in Enzymology</i> , 2014, 548, 23-67.	0.4	44
625	Multitarget drug discovery projects in CNS diseases: quantitative systems pharmacology as a possible path forward. <i>Future Medicinal Chemistry</i> , 2014, 6, 1757-1769.	1.1	13
626	Corporate Structure, Indirect Bankruptcy Costs, and the Advantage of De Novo Firms: The Case of Gene Therapy Research. <i>Organization Science</i> , 2014, 25, 850-867.	3.0	7
627	Mutual action of anticancer and antiparasitic drugs: are there any shared targets?. <i>Future Oncology</i> , 2014, 10, 2529-2539.	1.1	21
628	Androgen Receptor Antagonists and Anti-Prostate Cancer Activities of Some Newly Synthesized Substituted Fused Pyrazolo-, Triazolo- and Thiazolo-Pyrimidine Derivatives. <i>International Journal of Molecular Sciences</i> , 2014, 15, 21587-21602.	1.8	16
629	The discovery of medicines for rare diseases. <i>Future Medicinal Chemistry</i> , 2014, 6, 987-1002.	1.1	22

#	ARTICLE	IF	CITATIONS
630	A room-temperature synthesis of 2,2'-bisoxazoles through palladium-catalyzed oxidative coupling of α -isocyanoacetamides. <i>Organic Chemistry Frontiers</i> , 2014, 1, 1285-1288.	2.3	37
631	Mangromicins A and B: structure and antitrypanosomal activity of two new cyclopentadecane compounds from <i>Lechevalieria aerocolonigenes</i> K10-0216. <i>Journal of Antibiotics</i> , 2014, 67, 253-260.	1.0	42
632	Enzyme Inhibition and Inactivation. , 2014, , 207-274.		2
633	Discovery of novel Bcr-Abl inhibitors targeting myristoyl pocket and ATP site. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 6876-6884.	1.4	6
634	Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study. <i>Arthritis Research and Therapy</i> , 2014, 16, R144.	1.6	88
636	<i>In Silico</i> Molecular Docking and <i>In Vitro</i> Antidiabetic Studies of Dihydropyrimido[4,5- <i>a</i>]acridin-2-amines. <i>BioMed Research International</i> , 2014, 2014, 1-10.	0.9	20
637	Crystal structure of 4-bromo-N-(2-hydroxyphenyl)benzamide. <i>Acta Crystallographica Section E: Structure Reports Online</i> , 2014, 70, o1261-o1262.	0.2	1
639	Targeting Survivin in Cancer: Novel Drug Development Approaches. <i>BioDrugs</i> , 2014, 28, 27-39.	2.2	70
640	Targeting tumour-supportive cellular machineries in anticancer drug development. <i>Nature Reviews Drug Discovery</i> , 2014, 13, 179-196.	21.5	202
641	Mechanisms of resistance to imatinib mesylate in KIT-positive metastatic uveal melanoma. <i>Clinical and Experimental Metastasis</i> , 2014, 31, 553-64.	1.7	11
642	Synthesis and kinase inhibitory activity of new sulfonamide derivatives of pyrazolo[4,3- <i>e</i>][1,2,4]triazines. <i>European Journal of Medicinal Chemistry</i> , 2014, 78, 217-224.	2.6	27
643	Protonation effects on the UV/Vis absorption spectra of imatinib: A theoretical and experimental study. <i>Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy</i> , 2014, 129, 326-332.	2.0	24
644	Small molecule compounds targeting the p53 pathway: are we finally making progress?. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2014, 19, 1055-1068.	2.2	60
645	A highly efficient and recyclable ligand-free protocol for the Suzuki coupling reaction of potassium aryltrifluoroborates in water. <i>Green Chemistry</i> , 2014, 16, 2185.	4.6	42
646	A Targeted Next-Generation Sequencing Assay Detects a High Frequency of Therapeutically Targetable Alterations in Primary and Metastatic Breast Cancers: Implications for Clinical Practice. <i>Oncologist</i> , 2014, 19, 453-458.	1.9	53
647	An experimental and theoretical study of the kinetics and mechanism of hydroxyl radical reaction with 2-aminopyrimidine. <i>RSC Advances</i> , 2014, 4, 14157.	1.7	17
649	Polystyrene-supported palladium(II) N,N-dimethylethylenediamine complex: A recyclable catalyst for Suzuki-Miyaura cross-coupling reactions in water. <i>Inorganica Chimica Acta</i> , 2014, 423, 95-100.	1.2	8
650	More than just a GPCR ligand: structure-based discovery of thioridazine derivatives as Pim-1 kinase inhibitors. <i>MedChemComm</i> , 2014, 5, 507-511.	3.5	9

#	ARTICLE	IF	CITATIONS
651	Recently targeted kinases and their inhibitors—the path to clinical trials. <i>Current Opinion in Pharmacology</i> , 2014, 17, 58-63.	1.7	49
652	General Suzuki Coupling of Heteroaryl Bromides by Using Tri- <i>tert</i> -butylphosphine as a Supporting Ligand. <i>European Journal of Organic Chemistry</i> , 2014, 2014, 5901-5905.	1.2	41
653	Targeting Matrix Metalloproteinases: Exploring the Dynamics of the S1 ^{h2} Pocket in the Design of Selective, Small Molecule Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 10205-10219.	2.9	85
654	Somatic alterations as the basis for resistance to targeted therapies. <i>Journal of Pathology</i> , 2014, 232, 244-254.	2.1	31
655	Green conditions for the Suzuki reaction using microwave irradiation and a new HNT-supported ionic liquid-like phase (HNT-SILLP) catalyst. <i>Applied Organometallic Chemistry</i> , 2014, 28, 234-238.	1.7	47
656	Advances in kinase targeting: current clinical use and clinical trials. <i>Trends in Pharmacological Sciences</i> , 2014, 35, 604-620.	4.0	178
657	A new series of diarylamides possessing quinoline nucleus: Synthesis, <i>in vitro</i> anticancer activities, and kinase inhibitory effect. <i>European Journal of Medicinal Chemistry</i> , 2014, 87, 484-492.	2.6	27
658	Conjugation-free, visual, and quantitative evaluation of inhibitors on protein tyrosine kinases and phosphatases with a luminescent Tb(III) complex. <i>Analytical and Bioanalytical Chemistry</i> , 2014, 406, 2957-2964.	1.9	9
659	Application of a peptide-based assay to characterize inhibitors targeting protein kinases from yeast. <i>Current Genetics</i> , 2014, 60, 193-200.	0.8	6
660	Phenotypic screening in cancer drug discovery — past, present and future. <i>Nature Reviews Drug Discovery</i> , 2014, 13, 588-602.	21.5	403
661	Modern Cancer Drug Discovery. , 2014, , 3-53.		8
662	[Bmim]PF ₆ -Promoted Ligandless Suzuki–Miyaura Coupling Reaction of Potassium Aryltrifluoroborates in Water. <i>Journal of Organic Chemistry</i> , 2014, 79, 7193-7198.	1.7	38
663	Protein–ligand interaction databases: advanced tools to mine activity data and interactions on a structural level. <i>Wiley Interdisciplinary Reviews: Computational Molecular Science</i> , 2014, 4, 562-575.	6.2	14
664	Cationic Lipid-Assisted Polymeric Nanoparticle Mediated GATA2 siRNA Delivery for Synthetic Lethal Therapy of KRAS Mutant Non-Small-Cell Lung Carcinoma. <i>Molecular Pharmaceutics</i> , 2014, 11, 2612-2622.	2.3	30
665	Development and validation of a non-aqueous capillary electrophoresis method for the determination of imatinib, codeine and morphine in human urine. <i>Analytical Methods</i> , 2014, 6, 3842.	1.3	13
666	LC-ESI-MS/MS determination of simotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor: Application to a pharmacokinetic study. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2014, 947-948, 168-172.	1.2	3
667	Polystyrene supported thiopseudourea Pd(II) complex: Applications for Sonogashira, Suzuki-Miyaura, Heck, Hiyama and Larock heteroannulation reactions. <i>Journal of Organometallic Chemistry</i> , 2014, 765, 31-38.	0.8	34
668	The multidrug resistance pumps are inhibited by silibinin and apoptosis induced in K562 and KCL22 leukemia cell lines. <i>Leukemia Research</i> , 2014, 38, 575-580.	0.4	10

#	ARTICLE	IF	CITATIONS
669	Imatinib inhibits the expression of SCO2 and FRATAxin genes that encode mitochondrial proteins in human Bcr-Abl+ leukemia cells. <i>Blood Cells, Molecules, and Diseases</i> , 2014, 53, 84-90.	0.6	4
670	Structural Mechanisms Determining Inhibition of the Collagen Receptor DDR1 by Selective and Multi-Targeted Type II Kinase Inhibitors. <i>Journal of Molecular Biology</i> , 2014, 426, 2457-2470.	2.0	77
671	Palladium-Catalyzed C-H Homocoupling of Furans and Thiophenes Using Oxygen as the Oxidant. <i>Organic Letters</i> , 2014, 16, 2732-2735.	2.4	77
672	Effect of atmospheric gas plasmas on cancer cell signaling. <i>International Journal of Cancer</i> , 2014, 134, 1517-1528.	2.3	147
673	Folate receptor-targeted liposomes enhanced the antitumor potency of imatinib through the combination of active targeting and molecular targeting. <i>International Journal of Nanomedicine</i> , 2014, 9, 2167.	3.3	45
674	Studying the impact of presence of point mutation, insertion mutation and additional chromosomal abnormalities in chronic myeloid leukemia patients treated with imatinib mesylate in the State of Qatar. <i>QScience Connect</i> , 2014, 2014, .	0.2	6
676	Diarylureas and Diarylamides with Pyrrolo[2,3-d]pyrimidine Scaffold as Broad-Spectrum Anticancer Agents. <i>Chemical and Pharmaceutical Bulletin</i> , 2014, 62, 25-34.	0.6	11
677	Translocation t(2;11) in CLL cells results in CXCR4/MAML2 fusion oncogene. <i>Blood</i> , 2014, 124, 259-262.	0.6	11
678	Advances in kinase inhibition. <i>Current Opinion in Rheumatology</i> , 2014, 26, 237-243.	2.0	15
679	Targeting kinases with anilinopyrimidines: discovery of N-phenyl-N ⁴ -[4-(pyrimidin-4-ylamino)phenyl]urea derivatives as selective inhibitors of class III receptor tyrosine kinase subfamily. <i>Scientific Reports</i> , 2015, 5, 16750.	1.6	53
681	Special Review. <i>Cancer Journal (Sudbury, Mass)</i> , 2015, 21, 441-447.	1.0	13
683	Design, Synthesis, and Characterization of a Photoactivatable Caged Prodrug of Imatinib. <i>ChemMedChem</i> , 2015, 10, 1335-1338.	1.6	27
684	Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology. <i>Angewandte Chemie - International Edition</i> , 2015, 54, 8717-8721.	7.2	33
685	Tyrosine Kinase Inhibitors as Potential Therapeutic Agents in the Treatment of Granulosa Cell Tumors of the Ovary. <i>International Journal of Gynecological Cancer</i> , 2015, 25, 1224-1231.	1.2	11
686	Recent Advances in the Development and Application of Radiolabeled Kinase Inhibitors for PET Imaging. <i>Molecules</i> , 2015, 20, 22000-22027.	1.7	25
687	Quantitative real-time polymerase chain reaction as an efficient molecular tool for detecting minimal residual disease in Moroccan chronic myeloid leukemia patients. <i>Genetics and Molecular Research</i> , 2015, 14, 1044-1055.	0.3	0
688	Review Computational characterisation of cancer molecular profiles derived using next generation sequencing. <i>Wspolczesna Onkologia</i> , 2015, 1A, 78-91.	0.7	4
689	Tyrphostin AG 1296 induces glioblastoma cell apoptosis in vitro and in vivo. <i>Oncology Letters</i> , 2015, 10, 3429-3433.	0.8	5

#	ARTICLE	IF	CITATIONS
690	Evolution and intelligent design in drug development. <i>Frontiers in Molecular Biosciences</i> , 2015, 2, 27.	1.6	10
691	The Wnt signaling network in cancer. , 0, , 222-255.		0
693	Predicting Effectiveness of Imatinib Mesylate in Tumors Expressing Platelet-Derived Growth Factors (PDGF-AA, PDGF-BB), Stem Cell Factor Ligands and Their Respective Receptors (PDGFR- α , PDGFR- β , and c-kit). <i>Journal of Gastrointestinal Cancer</i> , 2015, 46, 272-283.	0.6	10
694	Three-dimensional structures in the design of therapeutics targeting parasitic protozoa: reflections on the past, present and future. <i>Acta Crystallographica Section F, Structural Biology Communications</i> , 2015, 71, 485-499.	0.4	6
695	STI571 protects neuronal cells from neurotoxic prion protein fragment-induced apoptosis. <i>Neuropharmacology</i> , 2015, 93, 191-198.	2.0	33
696	Ohmic Heating-Assisted Synthesis of 3-Arylquinolin-4(1 <i>H</i>)-ones by a Reusable and Ligand-Free Suzuki-Miyaura Reaction in Water. <i>Journal of Organic Chemistry</i> , 2015, 80, 6649-6659.	1.7	26
697	BRD4 Structure-Activity Relationships of Dual PLK1 Kinase/BRD4 Bromodomain Inhibitor BI-2536. <i>ACS Medicinal Chemistry Letters</i> , 2015, 6, 764-769.	1.3	74
698	Development of Alkyne-Containing Pyrazolopyrimidines To Overcome Drug Resistance of Bcr-Abl Kinase. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 9228-9237.	2.9	26
700	Small molecule kinase inhibitors in veterinary oncology. <i>Veterinary Journal</i> , 2015, 205, 122-123.	0.6	2
701	Prion degradation pathways: Potential for therapeutic intervention. <i>Molecular and Cellular Neurosciences</i> , 2015, 66, 12-20.	1.0	33
702	Recent Advances in Cancer Therapeutics. <i>Progress in Medicinal Chemistry</i> , 2015, 54, 1-63.	4.1	32
703	Direct amination of pyrimidin-2-yl tosylates with aqueous ammonia under metal-free and mild conditions. <i>Chinese Chemical Letters</i> , 2015, 26, 667-671.	4.8	4
704	Recent Advances in Tumor Targeting Approaches. <i>Advances in Delivery Science and Technology</i> , 2015, , 41-112.	0.4	6
706	Multiplex Imaging and Cellular Target Identification of Kinase Inhibitors via an Affinity-Based Proteome Profiling Approach. <i>Scientific Reports</i> , 2015, 5, 7724.	1.6	34
707	Copper(I) carboxylate catalyzed C-N coupling of 2-amino pyrimidines with aryl halides to selectively generate secondary and tertiary amines. <i>Tetrahedron</i> , 2015, 71, 2113-2118.	1.0	13
708	Green chemistry approaches as sustainable alternatives to conventional strategies in the pharmaceutical industry. <i>RSC Advances</i> , 2015, 5, 26686-26705.	1.7	51
709	Hybrid pyrimidine alkynyls inhibit the clinically resistance related Bcr-AblT315I mutant. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 3458-3463.	1.0	13
710	VEGFR2-Targeted Contrast-Enhanced Ultrasound to Distinguish between Two Anti-Angiogenic Treatments. <i>Ultrasound in Medicine and Biology</i> , 2015, 41, 2202-2211.	0.7	23

#	ARTICLE	IF	CITATIONS
711	Pharmacophore Identification and Pseudo-Receptor Modeling. , 2015, , 489-510.		6
712	Protein Crystallography and Drug Discovery. , 2015, , 511-537.		3
713	Preparation of imatinib base loaded human serum albumin for application in the treatment of glioblastoma. RSC Advances, 2015, 5, 62214-62219.	1.7	32
714	A historical overview of protein kinases and their targeted small molecule inhibitors. Pharmacological Research, 2015, 100, 1-23.	3.1	391
715	Drugs That Inhibit Signaling Pathways for Tumor Cell Growth and Proliferation. , 2015, , 391-491.		5
716	General Aspects of Cancer Chemotherapy. , 2015, , 1-22.		5
717	An efficient and reusable catalyst for Suzuki cross-coupling reactions in aqueous solutionâ€”hollow palladiumâ€”ferrum bimetallic magnetic spheres. RSC Advances, 2015, 5, 38264-38270.	1.7	6
718	ABL kinase inhibitory and antiproliferative activity of novel picolinamide based benzothiazoles. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 2162-2168.	1.0	21
719	N,N,Nâ€™2,Nâ€™2-tetra(diphenylphosphinomethyl)pyridine-2,6-diamine/palladium catalyzed Suzukiâ€”Miyaura coupling of aryl and heteroaryl halides. Catalysis Communications, 2015, 66, 87-90.	1.6	16
720	Emerging Therapies and Future Directions in Pulmonary Arterial Hypertension. Canadian Journal of Cardiology, 2015, 31, 489-501.	0.8	29
721	Simple aminobenzoic acid promoted palladium catalyzed room temperature Suzukiâ€”Miyaura cross-coupling reaction in aqueous media. Tetrahedron Letters, 2015, 56, 2906-2909.	0.7	14
722	Structure-based function analysis of putative conserved proteins with isomerase activity from Haemophilus influenzae. 3 Biotech, 2015, 5, 741-763.	1.1	14
723	Dynamics of Protein Kinases: Insights from Nuclear Magnetic Resonance. Accounts of Chemical Research, 2015, 48, 1106-1114.	7.6	34
724	Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 93, 52-79.	2.0	1,278
725	Synthesis and broad-spectrum antiproliferative activity of diarylamides and diarylureas possessing 1,3,4-oxadiazole derivatives. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 1692-1699.	1.0	33
726	Cancer treatment-induced bone loss (CTIBL): Pathogenesis and clinical implications. Cancer Treatment Reviews, 2015, 41, 798-808.	3.4	85
727	Solvent-free, scalable and expeditious synthesis of benzanilides under microwave irradiation using clay doped with palladium nanoparticles as a recyclable and efficient catalyst. Green Chemistry Letters and Reviews, 2015, 8, 1-8.	2.1	31
728	A Phase I study of MEDI-575, a PDGFRÎ± monoclonal antibody, in Japanese patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2015, 76, 631-639.	1.1	5

#	ARTICLE	IF	CITATIONS
729	Targeted therapy and promising novel agents for the treatment of advanced soft tissue sarcomas. Expert Opinion on Investigational Drugs, 2015, 24, 1409-1418.	1.9	4
730	Palladium ^{II} quaternary phosphonium phase transfer catalyst brush assembly as reusable and environmentally benign catalyst for coupling of aryl halides and sodium tetraphenylborate in neat water. Applied Organometallic Chemistry, 2015, 29, 712-717.	1.7	4
731	A method to quantify several tyrosine kinase inhibitors in plasma by micellar liquid chromatography and validation according to the European Medicines Agency guidelines. Talanta, 2015, 144, 1287-1295.	2.9	28
732	Targeting the platelet-derived growth factor signalling in cardiovascular disease. Clinical and Experimental Pharmacology and Physiology, 2015, 42, 1221-1224.	0.9	40
733	Trends in Modern Drug Discovery. Handbook of Experimental Pharmacology, 2015, 232, 3-22.	0.9	38
734	Cancer targeted therapeutics: From molecules to drug delivery vehicles. Journal of Controlled Release, 2015, 219, 632-643.	4.8	89
735	Targeting Conformational Plasticity of Protein Kinases. ACS Chemical Biology, 2015, 10, 190-200.	1.6	87
736	Synthesis of N2-arylaminopyrimidine-5-carbonitrile derivatives via SNAr amination reaction. Chinese Chemical Letters, 2015, 26, 152-156.	4.8	5
738	Robust Suzuki-Miyaura Cross-Coupling on DNA-Linked Substrates. ACS Combinatorial Science, 2015, 17, 1-4.	3.8	103
739	Efficient and Easy One-Pot Synthesis of New 3,5-Dioxo-4-thiazolo[2,3-c]pyrimidine-6-carbonitrile and 4,6-Dioxo-pyrimido[2,1-b][1,3]thiazine-7-carbonitrile Derivatives. Journal of Heterocyclic Chemistry, 2015, 52, 1269-1272.	1.4	5
740	Identification of novel tyrosine kinase inhibitors for drug resistant T315I mutant BCR-ABL: a virtual screening and molecular dynamics simulations study. Scientific Reports, 2014, 4, 6948.	1.6	59
741	A convenient synthesis and molecular modeling study of novel pyrazolo[3,4-d]pyrimidine and pyrazole derivatives as anti-tumor agents. Journal of Enzyme Inhibition and Medicinal Chemistry, 2015, 30, 396-405.	2.5	19
742	Enantioselective Synthesis of β -Secondary and β -Tertiary Piperazine-2-ones and Piperazines by Catalytic Asymmetric Allylic Alkylation. Angewandte Chemie - International Edition, 2015, 54, 179-183.	7.2	80
743	Synthesis and anti-proliferative activity evaluation of sorafenib derivatives with a 3-arylacryloyl hydrazide unit. Medicinal Chemistry Research, 2015, 24, 1733-1743.	1.1	6
744	Reversal of Human Multi-Drug Resistance Leukaemic Cells by Stemofoline Derivatives via Inhibition of P-glycoprotein Function. Basic and Clinical Pharmacology and Toxicology, 2015, 116, 390-397.	1.2	15
745	Synthesis, docking studies, and in silico ADMET predictions of some new derivatives of pyrimidine as potential KSP inhibitors. Medicinal Chemistry Research, 2015, 24, 304-315.	1.1	10
746	Structure-based functional annotation of putative conserved proteins having lyase activity from Haemophilus influenzae. 3 Biotech, 2015, 5, 317-336.	1.1	15
747	Pantoprazole, an FDA-approved proton-pump inhibitor, suppresses colorectal cancer growth by targeting T-cell-originated protein kinase. Oncotarget, 2016, 7, 22460-22473.	0.8	59

#	ARTICLE	IF	CITATIONS
748	Selective Sensing of Tyrosine Phosphorylation in Peptides Using Terbium(III) Complexes. <i>International Journal of Analytical Chemistry</i> , 2016, 2016, 1-14.	0.4	13
749	c-Abl Inhibitors Enable Insights into the Pathophysiology and Neuroprotection in Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2016, 8, 254.	1.7	33
750	Telomerase Activation in Hematological Malignancies. <i>Genes</i> , 2016, 7, 61.	1.0	25
751	Biologic Therapy in Inflammatory Immunomediated Systemic Diseases: Safety Profile. <i>Current Drug Safety</i> , 2016, 11, 44-46.	0.3	0
752	A Novel and Efficient Five-Component Synthesis of Pyrazole Based Pyrido[2,3-d]pyrimidine-diones in Water: A Triply Green Synthesis. <i>Molecules</i> , 2016, 21, 441.	1.7	33
753	Use of a Catalytic-Cosolvent, <i>N,N</i> -Dimethyl Octanamide, Allows the Flow Synthesis of Imatinib with no Solvent Switch. <i>Angewandte Chemie - International Edition</i> , 2016, 55, 2531-2535.	7.2	52
754	Reduction of Blood Amyloid- β^2 Oligomers in Alzheimer's Disease Transgenic Mice by c-Abl Kinase Inhibition. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 1193-1205.	1.2	23
755	Quercetin suppresses lung cancer growth by targeting Aurora B kinase. <i>Cancer Medicine</i> , 2016, 5, 3156-3165.	1.3	56
757	Highly efficient palladium catalysts supported on nitrogen contained polymers for Suzuki-Miyaura reaction. <i>Catalysis Communications</i> , 2016, 82, 24-28.	1.6	27
758	Dual leucine zipper kinase (MAP3K12) modulators: a patent review (2010-2015). <i>Expert Opinion on Therapeutic Patents</i> , 2016, 26, 607-616.	2.4	6
759	Innovative computer-aided methods for the discovery of new kinase ligands. <i>Future Medicinal Chemistry</i> , 2016, 8, 509-526.	1.1	16
760	Metal free C-H functionalization of diazines and related heteroarenes with organoboron species and its application in the synthesis of a CDK inhibitor, meriolin 1. <i>Organic and Biomolecular Chemistry</i> , 2016, 14, 4312-4320.	1.5	18
761	Advanced molecular dynamics simulation methods for kinase drug discovery. <i>Future Medicinal Chemistry</i> , 2016, 8, 545-566.	1.1	21
762	Antineoplastic Agents. , 2016, , 495-547.		13
763	Design, synthesis, broad-spectrum antiproliferative activity, and kinase inhibitory effect of triarylpyrazole derivatives possessing arylamides or arylureas moieties. <i>European Journal of Medicinal Chemistry</i> , 2016, 119, 122-131.	2.6	20
764	Palladium-Catalyzed Defluorinative Coupling of <i>1</i> -Aryl- <i>2,2</i> -Difluoroalkenes and Boronic Acids: Stereoselective Synthesis of Monofluorostilbenes. <i>Angewandte Chemie</i> , 2016, 128, 11801-11804.	1.6	51
765	Protective Effects of Imatinib on Ischemia/Reperfusion Injury in Rat Lung. <i>Annals of Thoracic Surgery</i> , 2016, 102, 1717-1724.	0.7	11
766	Dehydrosulfurative C-N Cross-Coupling and Concomitant Oxidative Dehydrogenation for One-Step Synthesis of 2-Aryl(alkyl)aminopyrimidines from 3,4-Dihydropyrimidin-1 <i>H</i> -2-thiones. <i>Organic Letters</i> , 2016, 18, 5154-5157.	2.4	20

#	ARTICLE	IF	CITATIONS
767	Upregulation of INS-IGF2 read-through expression and identification of a novel INS-IGF2 splice variant in insulinomas. <i>Oncology Reports</i> , 2016, 36, 2653-2662.	1.2	8
768	Molecular Mechanisms of Disease: The RET Proto-oncogene. , 2016, , 47-63.		0
769	A novel inhibitor of BCL2, Disarib abrogates tumor growth while sparing platelets, by activating intrinsic pathway of apoptosis. <i>Biochemical Pharmacology</i> , 2016, 122, 10-22.	2.0	18
770	Palladium Supported on Fluorite Structured Redox CeZrO ₄ for Heterogeneous Suzuki Coupling in Water: A Green Protocol. <i>ChemistrySelect</i> , 2016, 1, 2673-2681.	0.7	20
771	Multi-target therapeutics for neuropsychiatric and neurodegenerative disorders. <i>Drug Discovery Today</i> , 2016, 21, 1886-1914.	3.2	42
772	Palladium-Catalyzed Defluorinative Coupling of Aryl-2-Fluoroalkenes and Boronic Acids: Stereoselective Synthesis of Monofluorostilbenes. <i>Angewandte Chemie - International Edition</i> , 2016, 55, 11629-11632.	7.2	161
773	Precision medicine, genomics and drug discovery: Table 1.. <i>Human Molecular Genetics</i> , 2016, 25, R166-R172.	1.4	43
774	The development of agents targeting the BCR-ABL tyrosine kinase as Philadelphia chromosome-positive acute lymphoblastic leukemia treatment. <i>Expert Opinion on Drug Discovery</i> , 2016, 11, 1061-1070.	2.5	9
775	A Quality by Design Approach to Developing and Manufacturing Polymeric Nanoparticle Drug Products. <i>AAPS Journal</i> , 2016, 18, 1354-1365.	2.2	42
776	Small Molecule Kinase Inhibitors for the Treatment of Brain Cancer. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 10030-10066.	2.9	106
777	Synthesis, in vitro potential and computational studies on 2-amino-1, 4-dihydropyrimidines as multitarget antibacterial ligands. <i>Medicinal Chemistry Research</i> , 2016, 25, 1877-1894.	1.1	18
778	Design and Performance Validation of a Conductively Heated Sealed-Vessel Reactor for Organic Synthesis. <i>Journal of Organic Chemistry</i> , 2016, 81, 11788-11801.	1.7	39
779	Exploiting Nanocarriers for Combination Cancer Therapy. <i>Fundamental Biomedical Technologies</i> , 2016, , 375-402.	0.2	1
780	Conformational Selection and Induced Fit Mechanisms in the Binding of an Anticancer Drug to the c-Src Kinase. <i>Scientific Reports</i> , 2016, 6, 24439.	1.6	53
781	Non-Specificity of Drug-Target Interactions – Consequences for Drug Discovery. <i>ACS Symposium Series</i> , 2016, , 91-142.	0.5	2
782	Imatinib and Nilotinib increase glioblastoma cell invasion via Abl-independent stimulation of p130Cas and FAK signalling. <i>Scientific Reports</i> , 2016, 6, 27378.	1.6	37
783	Use of a Catalytic-Cosolvent, N,N-Dimethyl Octanamide, Allows the Flow Synthesis of Imatinib with no Solvent Switch. <i>Angewandte Chemie</i> , 2016, 128, 2577-2581.	1.6	17
784	Evaluation of the potential synergism of imatinib-related poly kinase inhibitors using growth factor stimulated proteoglycan synthesis as a model response. <i>Journal of Pharmacy and Pharmacology</i> , 2016, 68, 368-378.	1.2	8

#	ARTICLE	IF	CITATIONS
785	Phenotypic Assessment and the Discovery of Topiramate. <i>ACS Medicinal Chemistry Letters</i> , 2016, 7, 662-665.	1.3	16
786	An optimized approach in the synthesis of imatinib intermediates and analogues. <i>RSC Advances</i> , 2016, 6, 61458-61467.	1.7	7
787	Anticancer metal drugs and immunogenic cell death. <i>Journal of Inorganic Biochemistry</i> , 2016, 165, 71-79.	1.5	107
788	Synthesis of new diarylamides with pyrimidinyl pyridine scaffold and evaluation of their anti-proliferative effect on cancer cell lines. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 1301-1304.	1.0	11
789	Transcriptional response networks for elucidating mechanisms of action of multitargeted agents. <i>Drug Discovery Today</i> , 2016, 21, 1063-1075.	3.2	28
790	Palladium NPs supported on novel imino-pyridine-functionalized MWCNTs: efficient and highly reusable catalysts for the Suzuki-Miyaura and Sonogashira coupling reactions. <i>New Journal of Chemistry</i> , 2016, 40, 4945-4951.	1.4	27
791	Metabolic characterization of imatinib-resistant BCR-ABL T315I chronic myeloid leukemia cells indicates down-regulation of glycolytic pathway and low ROS production. <i>Leukemia and Lymphoma</i> , 2016, 57, 2180-2188.	0.6	14
792	Chemical Methods for Encoding and Decoding of Posttranslational Modifications. <i>Cell Chemical Biology</i> , 2016, 23, 86-107.	2.5	73
793	Conformation-Selective Analogues of Dasatinib Reveal Insight into Kinase Inhibitor Binding and Selectivity. <i>ACS Chemical Biology</i> , 2016, 11, 1296-1304.	1.6	58
794	A clinically relevant pharmacokinetic interaction between cyclosporine and imatinib. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 719-723.	0.8	19
795	Open Access Could Transform Drug Discovery: A Case Study of JQ1. <i>Expert Opinion on Drug Discovery</i> , 2016, 11, 321-332.	2.5	28
796	Topoisomerase II α mediates TCF-dependent epithelial-mesenchymal transition in colon cancer. <i>Oncogene</i> , 2016, 35, 4990-4999.	2.6	23
797	Trial Watch—Small molecules targeting the immunological tumor microenvironment for cancer therapy. <i>Oncotarget</i> , 2016, 5, e1149674.	2.1	46
798	The origin of the stereoselective alkylation of 3-substituted-2-oxopiperazines: A computational investigation. <i>Computational and Theoretical Chemistry</i> , 2016, 1078, 1-8.	1.1	0
799	Rho Kinase (ROCK) Inhibitors and Their Therapeutic Potential. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 2269-2300.	2.9	284
800	The use of novel selectivity metrics in kinase research. <i>BMC Bioinformatics</i> , 2017, 18, 17.	1.2	35
801	Systems biology driving drug development: from design to the clinical testing of the anti-ErbB3 antibody seribantumab (MM-121). <i>Npj Systems Biology and Applications</i> , 2017, 3, 16034.	1.4	61
802	Computational polypharmacology: a new paradigm for drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2017, 12, 279-291.	2.5	86

#	ARTICLE	IF	CITATIONS
803	Novel Pieces for the Emerging Picture of Sulfoximines in Drug Discovery: Synthesis and Evaluation of Sulfoximine Analogues of Marketed Drugs and Advanced Clinical Candidates. <i>ChemMedChem</i> , 2017, 12, 487-501.	1.6	151
804	Gastric cancer management: Kinases as a target therapy. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2017, 44, 613-622.	0.9	24
805	Synthesis and antitumor activity of novel N-(5-benzyl-4-(tert-butyl)thiazol-2-yl)-2-(piperazin-1-yl)acetamides. <i>Research on Chemical Intermediates</i> , 2017, 43, 4833-4850.	1.3	6
806	One-pot hydrothermal synthesis of magnetically recoverable palladium/reduced graphene oxide nanocomposites and its catalytic applications in cross-coupling reactions. <i>Journal of Colloid and Interface Science</i> , 2017, 497, 83-92.	5.0	33
807	Combination antitumor therapy with targeted dual-nanomedicines. <i>Advanced Drug Delivery Reviews</i> , 2017, 115, 23-45.	6.6	111
808	Inhibition of PDGFR signaling prevents muscular fatty infiltration after rotator cuff tear in mice. <i>Scientific Reports</i> , 2017, 7, 41552.	1.6	29
809	Synergistic anti-cancer effects of epigenetic drugs on medulloblastoma cells. <i>Cellular Oncology (Dordrecht)</i> , 2017, 40, 263-279.	2.1	18
810	Osajin Inhibits Solar UV-Induced Cyclooxygenase-2 Expression Through Direct Inhibition of RSK2. <i>Journal of Cellular Biochemistry</i> , 2017, 118, 4080-4087.	1.2	6
811	An ultra-specific and sensitive sandwich ELISA for imatinib using two anti-imatinib antibodies. <i>Analytica Chimica Acta</i> , 2017, 969, 72-78.	2.6	25
812	Shades of chemical beauty: An overview of synthetic routes to some anticancer drugs. <i>Synthetic Communications</i> , 2017, 47, 1415-1433.	1.1	4
814	The Roles of Water in the Protein Matrix: A Largely Untapped Resource for Drug Discovery. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 6781-6827.	2.9	111
815	Pharmaceutical Industry Performance. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2017, , 3-25.	0.2	0
816	Nano-Fe ₃ O ₄ @SiO ₂ supported Pd(0) as a magnetically recoverable nanocatalyst for Suzuki coupling reaction in the presence of waste eggshell as low-cost natural base. <i>Tetrahedron</i> , 2017, 73, 5624-5633.	1.0	72
817	Synthesis, Molecular Docking, Molecular Dynamics Studies, and Biological Evaluation of 4 <i>H</i> -Chromone-1,2,3,4-tetrahydropyrimidine-5-carboxylate Derivatives as Potential Antileukemic Agents. <i>Journal of Chemical Information and Modeling</i> , 2017, 57, 1246-1257.	2.5	28
818	Effectiveness of imatinib mesylate over etoposide in the treatment of sensitive and resistant chronic myeloid leukaemia cells in vitro. <i>Experimental and Therapeutic Medicine</i> , 2017, 13, 3209-3216.	0.8	4
819	Targeting ABL-IRE1 α Signaling Spares ER-Stressed Pancreatic β Cells to Reverse Autoimmune Diabetes. <i>Cell Metabolism</i> , 2017, 25, 883-897.e8.	7.2	149
820	Molecular Mechanism of Drug Resistance. , 2017, , 47-110.		14
821	Influence of MDR1 and CYP3A5 genetic polymorphisms on trough levels and therapeutic response of imatinib in newly diagnosed patients with chronic myeloid leukemia. <i>Pharmacological Research</i> , 2017, 120, 138-145.	3.1	23

#	ARTICLE	IF	CITATIONS
822	Synthesis and identification of GZD856 as an orally bioavailable Bcr-Abl ^{T315I} inhibitor overcoming acquired imatinib resistance. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2017, 32, 331-336.	2.5	6
823	Monitoring Cell-surface N-Glycoproteome Dynamics by Quantitative Proteomics Reveals Mechanistic Insights into Macrophage Differentiation. <i>Molecular and Cellular Proteomics</i> , 2017, 16, 770-785.	2.5	41
824	Do polymorphisms in <i>MDR1</i> and <i>CYP3A5</i> genes influence the risk of cytogenetic relapse in patients with chronic myeloid leukemia on imatinib therapy?. <i>Leukemia and Lymphoma</i> , 2017, 58, 2218-2226.	0.6	5
825	Treatment-Induced Mutagenesis and Selective Pressures Sculpt Cancer Evolution. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2017, 7, a026617.	2.9	59
826	Design, Synthesis, and Evaluation of the Kinase Inhibition Potential of Pyridylpyrimidinylaminophenyl Derivatives. <i>Archiv Der Pharmazie</i> , 2017, 350, 1600390.	2.1	4
827	Identification of a selective inhibitor of transforming growth factor β -activated kinase 1 by biosensor-based screening of focused libraries. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 1031-1036.	1.0	1
828	Chemotherapeutics. , 2017, , 295-313.		17
829	Click Chemistry: Novel Applications in Cell Biology and Drug Discovery. <i>Angewandte Chemie - International Edition</i> , 2017, 56, 15504-15505.	7.2	26
830	Trends in GPCR drug discovery: new agents, targets and indications. <i>Nature Reviews Drug Discovery</i> , 2017, 16, 829-842.	21.5	1,773
831	Oxidative Annulations Involving DMSO and Formamide: $K_2S_2O_8$ Mediated Syntheses of Quinolines and Pyrimidines. <i>Organic Letters</i> , 2017, 19, 5673-5676.	2.4	87
832	Dehydrosulfurative arylation with concomitant oxidative dehydrogenation for rapid access to pyrimidine derivatives. <i>Tetrahedron</i> , 2017, 73, 6604-6613.	1.0	11
833	CRISPR-Cas9-mediated saturated mutagenesis screen predicts clinical drug resistance with improved accuracy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 11751-11756.	3.3	50
834	Design, Synthesis, and Biological Evaluation of Novel Type I ₂ p38 β MAP Kinase Inhibitors with Excellent Selectivity, High Potency, and Prolonged Target Residence Time by Interfering with the R-Spine. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 8027-8054.	2.9	24
835	Synthesis, antibacterial and antitubercular activity of novel Schiff bases of 2-(1-benzofuran-2-yl)quinoline-4-carboxylic acid derivatives. <i>Russian Journal of General Chemistry</i> , 2017, 87, 1843-1849.	0.3	11
836	Small-Molecule Screens: A Gateway to Cancer Therapeutic Agents with Case Studies of Food and Drug Administration-Approved Drugs. <i>Pharmacological Reviews</i> , 2017, 69, 479-496.	7.1	58
837	Application of PDX Cancer Models in Co-clinical Trials and Personalized/Precision Medicine. <i>Molecular and Translational Medicine</i> , 2017, , 177-192.	0.4	1
839	Neue Anwendungen der Klick-Chemie in Zellbiologie und Wirkstoffentwicklung. <i>Angewandte Chemie</i> , 2017, 129, 15709-15711.	1.6	7
840	Dual protein kinase and nucleoside kinase modulators for rationally designed polypharmacology. <i>Nature Communications</i> , 2017, 8, 1420.	5.8	18

#	ARTICLE	IF	CITATIONS
842	Approved and Experimental Small-Molecule Oncology Kinase Inhibitor Drugs: A Mid-2016 Overview. <i>Medicinal Research Reviews</i> , 2017, 37, 314-367.	5.0	65
843	Search for new compounds from Kitasato microbial library by physicochemical screening. <i>Biochemical Pharmacology</i> , 2017, 134, 42-55.	2.0	31
844	The oxidative stress theory of disease: levels of evidence and epistemological aspects. <i>British Journal of Pharmacology</i> , 2017, 174, 1784-1796.	2.7	126
845	Stirring-controlled solidified floating solid-liquid drop microextraction as a new solid phase-enhanced liquid-phase microextraction method by exploiting magnetic carbon nanotube-nickel hybrid. <i>Analytica Chimica Acta</i> , 2017, 951, 78-88.	2.6	19
846	Role and Function of the Type IV Secretion System in <i>Anaplasma</i> and <i>Ehrlichia</i> Species. <i>Current Topics in Microbiology and Immunology</i> , 2017, 413, 297-321.	0.7	38
847	RNA-seq: Applications and Best Practices. , 0, , .		17
848	Polypharmacology in Precision Oncology: Current Applications and Future Prospects. <i>Current Pharmaceutical Design</i> , 2017, 22, 6935-6945.	0.9	65
849	PDGFA/PDGFR α -regulated GOLM1 promotes human glioma progression through activation of AKT. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017, 36, 193.	3.5	35
850	Standard of care of patients with Chronic Myeloid Leukemia (CML) treated in community based oncology group practices between 2001-2015 in Rhineland-Palatinate (Germany). <i>Applied Cancer Research</i> , 2017, 37, .	1.0	4
851	Drug discovery. , 2017, , 183-279.		1
852	Selective Kinase Inhibitors in Cancer. , 2017, , 39-75.		4
853	Structure-based drug design approach to target toll-like receptor signaling pathways for disease treatment. <i>Tropical Journal of Pharmaceutical Research</i> , 2017, 16, 2297.	0.2	1
854	Overview of Drug Polypharmacology and Multitargeted Molecular Design. , 2017, , 259-275.		4
855	Pd(II)/Pd(0) anchored to magnetic nanoparticles (Fe ₃ O ₄) modified with biguanidine-chitosan polymer as a novel nanocatalyst for Suzuki-Miyaura coupling reactions. <i>International Journal of Biological Macromolecules</i> , 2018, 113, 186-194.	3.6	132
856	Combined inhibition of EGFR and c-ABL suppresses the growth of fulvestrant-resistant breast cancer cells through miR-375-autophagy axis. <i>Biochemical and Biophysical Research Communications</i> , 2018, 498, 559-565.	1.0	30
857	RAS \rightarrow MAPK Reactivation Facilitates Acquired Resistance in <i>FGFR1</i> -Amplified Lung Cancer and Underlies a Rationale for Upfront <i>FGFR</i> \rightarrow MEK Blockade. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1526-1539.	1.9	39
858	Evaluation of kinase-inhibitors nilotinib and everolimus against alveolar echinococcosis <i>in vitro</i> and in a mouse model. <i>Experimental Parasitology</i> , 2018, 188, 65-72.	0.5	10
859	An Active Palladium Colloidal Catalyst for the Selective Oxidative Heterocoupling of (Hetero)Aryl Boronic Acids. <i>Chemistry - an Asian Journal</i> , 2018, 13, 2489-2498.	1.7	7

#	ARTICLE	IF	CITATIONS
860	Orphan drugs: trends and issues in drug development. <i>Journal of Basic and Clinical Physiology and Pharmacology</i> , 2018, 29, 437-446.	0.7	3
861	Catalyst- and solvent-free approach to 2-arylated quinolines via [5 + 1] annulation of 2-methylquinolines with diynones. <i>RSC Advances</i> , 2018, 8, 4584-4587.	1.7	10
862	Triple Angiokinase Inhibitor Nintedanib Directly Inhibits Tumor Cell Growth and Induces Tumor Shrinkage via Blocking Oncogenic Receptor Tyrosine Kinases. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2018, 364, 494-503.	1.3	85
863	Using Genome Sequence to Enable the Design of Medicines and Chemical Probes. <i>Chemical Reviews</i> , 2018, 118, 1599-1663.	23.0	64
864	An Efficient and Practical Method for the Enantioselective Synthesis of Tertiary Trifluoromethyl Carbinols. <i>Advanced Synthesis and Catalysis</i> , 2018, 360, 1273-1279.	2.1	21
865	Allosteric modulation of the farnesoid X receptor by a small molecule. <i>Scientific Reports</i> , 2018, 8, 6846.	1.6	15
866	The First Pentacyclic Triterpenoid Gypsogenin Derivative Exhibiting Anti-ABL1 Kinase and Anti-chronic Myelogenous Leukemia Activities. <i>Biological and Pharmaceutical Bulletin</i> , 2018, 41, 570-574.	0.6	33
867	The potential and benefits of repurposing existing drugs to treat rare muscular dystrophies. <i>Expert Opinion on Orphan Drugs</i> , 2018, 6, 259-271.	0.5	10
868	Quantitative investigation of intermolecular interactions in dimorphs of 3-Chloro-N-(2-fluorophenyl)benzamide and 2-Iodo-N-(4-bromophenyl)benzamide. <i>Journal of Chemical Sciences</i> , 2018, 130, 1.	0.7	2
869	Boric Ester and Thiourea as Coupling Partners in a Copper-Mediated Oxidative Dehydrosulfurative Carbon-Oxygen Cross-Coupling Reaction. <i>Organic Letters</i> , 2018, 20, 1961-1965.	2.4	14
870	The impact of structural biology in medicine illustrated with four case studies. <i>Journal of Molecular Medicine</i> , 2018, 96, 9-19.	1.7	7
871	Early clinical observations on the use of imatinib mesylate in FOP: A report of seven cases. <i>Bone</i> , 2018, 109, 276-280.	1.4	34
872	Fe ₃ O ₄ /SiO ₂ nanoparticles coated with polydopamine as a novel magnetite reductant and stabilizer sorbent for palladium ions: Synthetic application of Fe ₃ O ₄ /SiO ₂ @PDA/Pd for reduction of 4-nitrophenol and Suzuki reactions. <i>Journal of Industrial and Engineering Chemistry</i> , 2018, 60, 114-124.	2.9	124
873	1,4-Disubstituted-5-hydroxy-3-methylpyrazoles and some derived ring systems as cytotoxic and DNA binding agents. Synthesis, in vitro biological evaluation and in silico ADME study. <i>Medicinal Chemistry Research</i> , 2018, 27, 442-457.	1.1	5
874	Imatinib-induced ophthalmological side-effects in GIST patients are associated with the variations of EGFR, SLC22A1, SLC22A5 and ABCB1. <i>Pharmacogenomics Journal</i> , 2018, 18, 460-466.	0.9	16
875	Intracellular signal transduction pathways as potential drug targets for ischemia-reperfusion injury in lung transplantation. <i>Journal of Thoracic Disease</i> , 2018, 10, S3965-S3969.	0.6	3
876	TQuest, A Web-Based Platform to Enable Precision Medicine by Linking a Tumor's Genetic Defects to Therapeutic Options. <i>JCO Clinical Cancer Informatics</i> , 2018, 2, 1-13.	1.0	1
877	Modulating ROS to overcome multidrug resistance in cancer. <i>Drug Resistance Updates</i> , 2018, 41, 1-25.	6.5	420

#	ARTICLE	IF	CITATIONS
878	Heterobiaryl synthesis by contractive C–C coupling via P(V) intermediates. <i>Science</i> , 2018, 362, 799-804.	6.0	145
879	Discovery of (E)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)propanamide (CHMFL-ABL-121) as a highly potent ABL kinase inhibitor capable of overcoming a variety of ABL mutants including T315I for chronic myeloid leukemia. <i>European Journal of Medicinal Chemistry</i> , 2018, 160, 61-81.	2.6	7
880	Targeted therapy for gynecologic cancers: Toward the era of precision medicine. <i>International Journal of Gynecology and Obstetrics</i> , 2018, 143, 131-136.	1.0	17
881	Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis. <i>Blood Advances</i> , 2018, 2, 444-453.	2.5	115
882	Direct synthesis of benzylic amines by palladium-catalyzed carbonylative aminohomologation of aryl halides. <i>Communications Chemistry</i> , 2018, 1, .	2.0	10
883	Pd/Cu-assisted C–S activation and N–H insertion: highly versatile synthesis of 2-aminopyrimidines from 3,4-dihydropyrimidine-2(1H)-thiones. <i>Chemistry of Heterocyclic Compounds</i> , 2018, 54, 375-378.	0.6	3
884	Micelle-Enabled Suzuki–Miyaura Cross-Coupling of Heteroaryl Boronate Esters. <i>Journal of Organic Chemistry</i> , 2018, 83, 7523-7527.	1.7	31
885	Decarboxylative cross-couplings of 2-aminopyrimidine-5-carboxylic acids. <i>Tetrahedron</i> , 2018, 74, 3843-3851.	1.0	3
886	Discovery of Potent, Selective, and Peripherally Restricted Pan-Trk Kinase Inhibitors for the Treatment of Pain. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 6779-6800.	2.9	27
887	What is Cancer?. , 2018, , 307-310.		0
888	Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy. <i>Journal of Hematology and Oncology</i> , 2018, 11, 84.	6.9	241
889	Synthesis, in vitro antiproliferative activity, and kinase inhibitory effects of pyrazole-containing diarylureas and diarylamides. <i>European Journal of Medicinal Chemistry</i> , 2018, 156, 230-239.	2.6	15
890	Kinase-targeted cancer therapies: progress, challenges and future directions. <i>Molecular Cancer</i> , 2018, 17, 48.	7.9	796
891	Co-fuse: a new class discovery analysis tool to identify and prioritize recurrent fusion genes from RNA-sequencing data. <i>Molecular Genetics and Genomics</i> , 2018, 293, 1217-1229.	1.0	0
892	Molecular dynamics simulations provide insights into the origin of gleevec™s selectivity toward human tyrosine kinases. <i>Journal of Biomolecular Structure and Dynamics</i> , 2019, 37, 2733-2744.	2.0	17
893	Novel N-thioamide analogues of pyrazolopyrimidine based piperazine: Design, synthesis, characterization, in-silico molecular docking study and biological evaluation. <i>Journal of Molecular Structure</i> , 2019, 1175, 551-565.	1.8	9
894	A Pyridine–Pyridine Cross-Coupling Reaction via Dearomatized Radical Intermediates. <i>Angewandte Chemie - International Edition</i> , 2019, 58, 14882-14886.	7.2	61
895	Application of metal oxide semiconductors in light-driven organic transformations. <i>Catalysis Science and Technology</i> , 2019, 9, 5186-5232.	2.1	143

#	ARTICLE	IF	CITATIONS
896	Modular Continuous Flow Synthesis of Imatinib and Analogues. <i>Organic Letters</i> , 2019, 21, 6112-6116.	2.4	36
897	Personalized medicine: From diagnostic to adaptive. <i>Biomedical Journal</i> , 2022, 45, 132-142.	1.4	8
898	Design and synthesis of novel phenylaminopyrimidines with antiproliferative activity against colorectal cancer. <i>RSC Advances</i> , 2019, 9, 21578-21586.	1.7	5
899	Type 2 inhibitor leads of human tropomyosin receptor kinase (hTrkA). <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 126624.	1.0	5
900	A Pyridine-Pyridine Cross-Coupling Reaction via Dearomatized Radical Intermediates. <i>Angewandte Chemie</i> , 2019, 131, 15024-15028.	1.6	10
901	Development of Kinase Inactive PD173955 Analogues for Reducing Production of A β Peptides. <i>ACS Medicinal Chemistry Letters</i> , 2019, 10, 1430-1435.	1.3	1
902	Design, synthesis, <i>in vitro</i> potent antiproliferative activity, and kinase inhibitory effects of new triarylpyrazole derivatives possessing different heterocycle terminal moieties. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2019, 34, 1534-1543.	2.5	7
903	Towards a global health practice based on the liberation and sovereignty of populations under siege: a theoretical analysis. <i>Lancet, The</i> , 2019, 393, S48.	6.3	0
904	Lead identification and characterization of hTrkA type 2 inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 126680.	1.0	5
905	Polymeric Nanomaterials. , 2019, , 1-66.		25
906	Beneficial Effects of Imatinib in a Patient with Suspected Pulmonary Veno-Occlusive Disease. <i>Tohoku Journal of Experimental Medicine</i> , 2019, 247, 69-73.	0.5	11
907	Updates to Binding MOAD (Mother of All Databases): Polypharmacology Tools and Their Utility in Drug Repurposing. <i>Journal of Molecular Biology</i> , 2019, 431, 2423-2433.	2.0	62
908	Crystal structure of 1,1-dibenzyl-3,3-dicyano-1,4,4-tetrahydro-4-bipyridine, C ₂₆ H ₂₂ N ₄ . <i>Zeitschrift Fur Kristallographie - New Crystal Structures</i> , 2019, 234, 793-794.	0.1	0
909	Late stage functionalization of heterocycles using hypervalent iodine(<i>III</i>) reagents. <i>Organic and Biomolecular Chemistry</i> , 2019, 17, 6326-6341.	1.5	63
910	Discovery of novel Bcr-AblT315I inhibitors with flexible linker. Part 1: Confirmation optimization of phenyl-1H-indazol-3-amine as hinge binding moiety. <i>European Journal of Medicinal Chemistry</i> , 2019, 178, 232-242.	2.6	4
911	Rational Design of Multitarget-Directed Ligands: Strategies and Emerging Paradigms. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 8881-8914.	2.9	164
912	Novel Tetrahydroquinazolinamines as Selective Histamine 3 Receptor Antagonists for the Treatment of Obesity. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 4638-4655.	2.9	12
913	Antitumor efficacy of arsenic/interferon in preclinical models of chronic myeloid leukemia resistant to tyrosine kinase inhibitors. <i>Cancer</i> , 2019, 125, 2818-2828.	2.0	14

#	ARTICLE	IF	CITATIONS
914	A Perspective on Extreme Open Science: Companies Sharing Compounds without Restriction. <i>SLAS Discovery</i> , 2019, 24, 505-514.	1.4	13
915	Proteochemometric Modeling for Drug Repositioning. , 2019, , 281-302.		7
916	Diosgenin-conjugated PCL-MPEG polymeric nanoparticles for the co-delivery of anticancer drugs: design, optimization, <i>in vitro</i> drug release and evaluation of anticancer activity. <i>New Journal of Chemistry</i> , 2019, 43, 6622-6635.	1.4	20
917	Development of Gleevec Analogues for Reducing Production of β -Amyloid Peptides through Shifting β -Cleavage of Amyloid Precursor Proteins. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 3122-3134.	2.9	4
918	BCR-ABL Inhibitors as Sensitizing Agents for Cancer Chemotherapy. , 2019, , 13-27.		0
919	Computational algorithms for <i>in silico</i> profiling of activating mutations in cancer. <i>Cellular and Molecular Life Sciences</i> , 2019, 76, 2663-2679.	2.4	11
920	Design, synthesis, cytotoxicity, and molecular modeling study of 2,4,6-trisubstituted pyrimidines with anthranilate ester moiety. <i>Medicinal Chemistry Research</i> , 2019, 28, 545-558.	1.1	16
921	FDA and the medical device clinical drug trials. , 2019, , 301-357.		0
922	Molecular Requirements for the Expression of Antiplatelet Effects by Synthetic Structural Optimized Analogues of the Anticancer Drugs Imatinib and Nilotinib. <i>Drug Design, Development and Therapy</i> , 2019, Volume 13, 4225-4238.	2.0	3
923	KIT as a therapeutic target for non-oncological diseases. , 2019, 197, 11-37.		14
924	Evolution of Small Molecule Kinase Drugs. <i>ACS Medicinal Chemistry Letters</i> , 2019, 10, 153-160.	1.3	27
925	How Structural Biologists and the Protein Data Bank Contributed to Recent FDA New Drug Approvals. <i>Structure</i> , 2019, 27, 211-217.	1.6	65
926	Structural versatility that serves the function of the HRD motif in the catalytic loop of protein tyrosine kinase, Src. <i>Protein Science</i> , 2019, 28, 533-542.	3.1	3
927	Advances in the Solid-Phase Synthesis of Pyrimidine Derivatives. <i>ACS Combinatorial Science</i> , 2019, 21, 35-68.	3.8	18
928	Sonochemical <i>in situ</i> immobilization of Pd nanoparticles on green tea extract coated Fe ₃ O ₄ nanoparticles: An efficient and magnetically recyclable nanocatalyst for synthesis of biphenyl compounds under ultrasound irradiations. <i>Materials Science and Engineering C</i> , 2019, 98, 584-593.	3.8	102
929	Cancer therapeutic targeting using mutant p53-specific siRNAs. <i>Oncogene</i> , 2019, 38, 3415-3427.	2.6	29
930	Journey on Greener Pathways via Synthesis of Pd/KB Polymeric Nanocomposite as a Recoverable Catalyst for the Ligand-Free Oxidative Hydroxylation of Phenylboronic Acid and Suzuki-Miyaura Coupling Reaction in Green Solvents. <i>Catalysis Letters</i> , 2019, 149, 169-179.	1.4	27
931	Small molecule tyrosine kinase inhibitors and pancreatic cancer: Trials and troubles. <i>Seminars in Cancer Biology</i> , 2019, 56, 149-167.	4.3	23

#	ARTICLE	IF	CITATIONS
932	Therapeutic advances for blocking heterotopic ossification in fibrodysplasia ossificans progressiva. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1180-1187.	1.1	53
933	Discovery of Allosteric, Potent, Subtype Selective, and Peripherally Restricted TrkA Kinase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 247-265.	2.9	44
934	Open-Label Phase II Evaluation of Imatinib in Primary Inoperable or Incompletely Resected and Recurrent Glioblastoma. <i>Oncology</i> , 2020, 98, 16-22.	0.9	23
935	Nanoformulations of small molecule protein tyrosine kinases inhibitors potentiate targeted cancer therapy. <i>International Journal of Pharmaceutics</i> , 2020, 573, 118785.	2.6	21
936	Stafioaâ€1: a STAT5aâ€Selective Inhibitor Developed via Dockingâ€Based Screening of in Silico Oâ€Phosphorylated Fragments. <i>Chemistry - A European Journal</i> , 2020, 26, 148-154.	1.7	12
937	How does evolution design functional free energy landscapes of proteins? A case study on the emergence of regulation in the Cyclin Dependent Kinase family. <i>Molecular Systems Design and Engineering</i> , 2020, 5, 392-400.	1.7	1
938	Design, synthesis, and biological evaluations of novel 3-amino-4-ethynyl indazole derivatives as Bcr-Abl kinase inhibitors with potent cellular antileukemic activity. <i>European Journal of Medicinal Chemistry</i> , 2020, 207, 112710.	2.6	10
939	Chemical strategies to overcome resistance against targeted anticancer therapeutics. <i>Nature Chemical Biology</i> , 2020, 16, 817-825.	3.9	41
940	Calcium-/Calmodulin-Dependent Protein Kinase IV (CAMKIV): A Multifunctional Enzyme and Its Role in Various Cancer: An Update. <i>Current Molecular Biology Reports</i> , 2020, 6, 139-147.	0.8	7
942	Emerging antenatal therapies for congenital diaphragmatic hernia-induced pulmonary hypertension in preclinical models. <i>Pediatric Research</i> , 2021, 89, 1641-1649.	1.1	5
943	c-Abl Inhibition Activates TFEB and Promotes Cellular Clearance in a Lysosomal Disorder. <i>IScience</i> , 2020, 23, 101691.	1.9	30
944	2-Anilinoquinoline based arylamides as broad spectrum anticancer agents with B-RAFV600E/C-RAF kinase inhibitory effects: Design, synthesis, in vitro cell-based and oncogenic kinase assessments. <i>European Journal of Medicinal Chemistry</i> , 2020, 208, 112756.	2.6	10
945	Oxidative Dehydrosulfurative Azolation of 3,4-Dihydropyrimidinâ€1 <i>H</i> -thiones. <i>Bulletin of the Korean Chemical Society</i> , 2020, 41, 881-883.	1.0	2
946	Applications of Machine Learning in Drug Discovery I: Target Discovery and Small Molecule Drug Design. , 2020, .		2
947	Recent developments in anticancer kinase inhibitors based on the pyrazolo[3,4- <i>d</i>]pyrimidine scaffold. <i>RSC Medicinal Chemistry</i> , 2020, 11, 1112-1135.	1.7	36
948	Antimycobacterial and PknB Inhibitory Activities of Venezuelan Medicinal Plants. <i>International Journal of Microbiology</i> , 2020, 2020, 1-7.	0.9	1
949	Demystifying Oxidative Stress. <i>Handbook of Experimental Pharmacology</i> , 2020, 264, 3-26.	0.9	10
950	Personalized Medicine, Disruptive Innovation, and â€Trailblazerâ€Guidelines: Case Study and Theorization of an Unsuccessful Change Effort. <i>Milbank Quarterly</i> , 2020, 98, 581-617.	2.1	17

#	ARTICLE	IF	CITATIONS
951	Detergent Titration as an Efficient Method for NMR Resonance Assignments of Membrane Proteins in Lipid Bilayer Nanodiscs. <i>Analytical Chemistry</i> , 2020, 92, 7786-7793.	3.2	8
952	In Search of Advanced Tumor Diagnostics and Treatment: Achievements and Perspectives of Carbonic Anhydrase IX Targeted Delivery. <i>Molecular Pharmaceutics</i> , 2020, 17, 1800-1815.	2.3	10
953	Phosphine Oxides from a Medicinal Chemist's Perspective: Physicochemical and <i>in Vitro</i> Parameters Relevant for Drug Discovery. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 7081-7107.	2.9	80
954	Synthesis of medically important heterocycles inside the nanoreactors built-in nonconventional reaction media. , 2020, , 181-229.		0
955	Photocatalytic synthesis of 2-amino-4,6-diarylpyrimidines using nanoTiO ₂ . <i>Journal of Photochemistry and Photobiology A: Chemistry</i> , 2020, 399, 112648.	2.0	3
956	Molecular insights and novel approaches for targeting tumor metastasis. <i>International Journal of Pharmaceutics</i> , 2020, 585, 119556.	2.6	55
957	Ligand-free Suzuki coupling reaction with highly recyclable ionic palladium catalyst, Ti _{1-x} Pd _x O _{2-x} (x = 0.03). <i>Applied Catalysis A: General</i> , 2020, 596, 117516.	2.2	15
958	Oxidative Dehydrosulfurative Cross-Coupling of 3,4-Dihydropyrimidine-2-thiones with Alkynes for Access to 2-Alkynylpyrimidines. <i>Journal of Organic Chemistry</i> , 2020, 85, 5087-5096.	1.7	6
959	Solvent Effects on Protonation Constants of Imatinib in Different Aqueous Solutions of Methanol at T = 298.15 K. <i>Russian Journal of Physical Chemistry A</i> , 2020, 94, 88-94.	0.1	1
960	Advances in covalent kinase inhibitors. <i>Chemical Society Reviews</i> , 2020, 49, 2617-2687.	18.7	160
961	Novel HSP90-PI3K Dual Inhibitor Suppresses Melanoma Cell Proliferation by Interfering with HSP90-EGFR Interaction and Downstream Signaling Pathways. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1845.	1.8	21
962	Palladium-catalyzed remote C-H functionalization of 2-aminopyrimidines. <i>Chemical Communications</i> , 2020, 56, 4284-4287.	2.2	6
963	Exploring different approaches to improve the success of drug discovery and development projects: a review. <i>Future Journal of Pharmaceutical Sciences</i> , 2020, 6, .	1.1	81
964	Acetylene Group, Friend or Foe in Medicinal Chemistry. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 5625-5663.	2.9	76
965	Large-Scale Virtual Screening Against the MET Kinase Domain Identifies a New Putative Inhibitor Type. <i>Molecules</i> , 2020, 25, 938.	1.7	7
966	Targeting BCL-2 as a Therapeutic Strategy for Primary ^{p210} BCR-ABL1-positive B-ALL Cells. <i>In Vivo</i> , 2020, 34, 511-516.	0.6	8
967	Visible-Light-Induced C-C Coupling Reaction to Synthesize Bipyridine From 3-Cyano-1,4-Dihydropyridines. <i>Frontiers in Chemistry</i> , 2019, 7, 940.	1.8	5
968	Integrative X-ray Structure and Molecular Modeling for the Rationalization of Procaspace-8 Inhibitor Potency and Selectivity. <i>ACS Chemical Biology</i> , 2020, 15, 575-586.	1.6	5

#	ARTICLE	IF	CITATIONS
969	2-Anilinopyrimidine derivatives: Design, synthesis, in vitro anti-proliferative activity, EGFR and ARO inhibitory activity, cell cycle analysis and molecular docking study. <i>Bioorganic Chemistry</i> , 2020, 99, 103798.	2.0	26
970	Identifying GPCR-drug interaction based on wordbook learning from sequences. <i>BMC Bioinformatics</i> , 2020, 21, 150.	1.2	10
971	Use of BODIPY-Labeled ATP Analogues in the Development and Validation of a Fluorescence Polarization-Based Assay for Screening of Kinase Inhibitors. <i>ACS Omega</i> , 2020, 5, 9064-9070.	1.6	4
972	Systems Biology and Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 695-703.	2.2	15
973	Turning liabilities into opportunities: Off-target based drug repurposing in cancer. <i>Seminars in Cancer Biology</i> , 2021, 68, 209-229.	4.3	39
974	Design, synthesis, and biological evaluation of Bcr-Abl PROTACs to overcome T315I mutation. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 1315-1328.	5.7	14
975	Biotechnology and drugs. , 2021, , 397-415.		2
976	E1 Enzymes as Therapeutic Targets in Cancer. <i>Pharmacological Reviews</i> , 2021, 73, 1-56.	7.1	60
977	Catalytic Asymmetric Total Synthesis of Leucinostatin A. <i>Chemical Record</i> , 2021, 21, 175-187.	2.9	2
978	Repositioning antispasmodic drug Papaverine for the treatment of chronic myeloid leukemia. <i>Pharmacological Reports</i> , 2021, 73, 615-628.	1.5	7
979	Synthesis and Structure-Activity Relationship Study of Intervenolin, an Antitumor and Anti-Helicobacter pylori Quinolone Natural Product. <i>Heterocycles</i> , 2021, 102, 1894.	0.4	0
980	Computational Prediction of Chemical Tools for Identification and Validation of Synthetic Lethal Interaction Networks. <i>Methods in Molecular Biology</i> , 2021, 2381, 333-358.	0.4	0
981	Protein Structure, Dynamics and Assembly: Implications for Drug Discovery. , 2021, , 91-122.		1
982	Impact of structural biologists and the Protein Data Bank on small-molecule drug discovery and development. <i>Journal of Biological Chemistry</i> , 2021, 296, 100559.	1.6	23
983	Compound Screening. , 2021, , .		0
984	Elucidating the anticancer activities of guanidinium-functionalized amphiphilic random copolymers by varying the structure and composition in the hydrophobic monomer. <i>Theranostics</i> , 2021, 11, 8977-8992.	4.6	3
985	Cooperativity between the orthosteric and allosteric ligand binding sites of ROR β . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	26
986	Future Approaches for Treating Chronic Myeloid Leukemia: CRISPR Therapy. <i>Biology</i> , 2021, 10, 118.	1.3	9

#	ARTICLE	IF	CITATIONS
987	Proton Pump Inhibitors and Oncologic Treatment Efficacy: A Practical Review of the Literature for Oncologists. <i>Current Oncology</i> , 2021, 28, 783-799.	0.9	29
988	Challenges and Opportunities for Drug Repositioning in Fibrodysplasia Ossificans Progressiva. <i>Biomedicines</i> , 2021, 9, 213.	1.4	8
989	Targeting autophagy using small-molecule compounds to improve potential therapy of Parkinson's disease. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 3015-3034.	5.7	54
990	Agro-Waste Generated Pd/CAP-Ash Catalyzed Ligand-Free Approach for Suzuki–Miyaura Coupling Reaction. <i>Catalysis Letters</i> , 2021, 151, 3617-3631.	1.4	4
991	Oxidative Dehydrosulfurative Carbon–Oxygen Cross-Coupling of 3,4-Dihydropyrimidine-2-thiones with Aryl Alcohols. <i>Journal of Organic Chemistry</i> , 2021, 86, 5423-5430.	1.7	6
992	Targeting loss of heterozygosity for cancer-specific immunotherapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	39
993	An Overview on the Therapeutics of Neglected Infectious Diseases—Leishmaniasis and Chagas Diseases. <i>Frontiers in Chemistry</i> , 2021, 9, 622286.	1.8	58
994	ABCG2 Single Nucleotide Polymorphism Affects Imatinib Pharmacokinetics in Lower Alpha-1-Acid Glycoprotein Levels in Humans. <i>Frontiers in Pharmacology</i> , 2021, 12, 658039.	1.6	0
995	Cellular Signal Transductions and Their Inhibitors Derived from Deep-Sea Organisms. <i>Marine Drugs</i> , 2021, 19, 205.	2.2	3
997	Tumour neoantigen mimicry by microbial species in cancer immunotherapy. <i>British Journal of Cancer</i> , 2021, 125, 313-323.	2.9	29
998	Directed evolution in mammalian cells. <i>Nature Methods</i> , 2021, 18, 346-357.	9.0	43
999	Green catalyst Cu(II)-enzyme-mediated eco-friendly synthesis of 2-pyrimidinamines as potential larvicides against <i>Culex quinquefasciatus</i> mosquito and toxicity investigation against non-target aquatic species. <i>Bioorganic Chemistry</i> , 2021, 109, 104697.	2.0	5
1000	Discovery of a Candidate Containing an (<i>S</i>)-3,3-Difluoro-1-(4-methylpiperazin-1-yl)-2,3-dihydro-1<i>H</i>-inden Scaffold as a Highly Potent Pan-Inhibitor of the BCR-ABL Kinase Including the T315I-Resistant Mutant for the Treatment of Chronic Myeloid Leukemia. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 7434-7452.	2.9	7
1001	Bioinformatics Approach on Biososterism Softwares to be Used in Drug Discovery and Development. <i>Current Bioinformatics</i> , 2022, 17, 19-30.	0.7	2
1002	Tyrosine kinases in the pathogenesis of tissue fibrosis in systemic sclerosis and potential therapeutic role of their inhibition. <i>Translational Research</i> , 2021, 231, 139-158.	2.2	20
1003	Design, Synthesis, Anticancer Evaluation, and Molecular Docking Studies of Thiazole–Pyrimidine Linked Amide Derivatives. <i>Polycyclic Aromatic Compounds</i> , 2022, 42, 5368-5384.	1.4	8
1004	Imatinib (STI571) Inhibits the Expression of Angiotensin-Converting Enzyme 2 and Cell Entry of the SARS-CoV-2-Derived Pseudotyped Viral Particles. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6938.	1.8	7
1005	Nickel(II)-catalyzed Suzuki–Miyaura cross-coupling of aryl boronic acids with aryl halides in water. <i>Applied Organometallic Chemistry</i> , 2021, 35, e6378.	1.7	5

#	ARTICLE	IF	CITATIONS
1006	Pharmacological inhibitors of anaplastic lymphoma kinase (ALK) induce immunogenic cell death through on-target effects. <i>Cell Death and Disease</i> , 2021, 12, 713.	2.7	29
1007	Betulin, a Newly Characterized Compound in <i>Acacia auriculiformis</i> Bark, Is a Multi-Target Protein Kinase Inhibitor. <i>Molecules</i> , 2021, 26, 4599.	1.7	5
1008	Drugging the Undruggable: How Isoquinolines and PKA Initiated the Era of Designed Protein Kinase Inhibitor Therapeutics. <i>Biochemistry</i> , 2021, 60, 3470-3484.	1.2	5
1010	Advanced Cancer as a Chronic Disease: Introduction. <i>Seminars in Oncology Nursing</i> , 2021, 37, 151176.	0.7	7
1011	Chemical Probes for Understudied Kinases: Challenges and Opportunities. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 1132-1170.	2.9	15
1012	1,3-Aza-Brook Rearrangement of Aniline Derivatives: In Situ Generation of 3-Aminoaryne via 1,3-C-(sp ²)-to-N Silyl Migration. <i>Organic Letters</i> , 2021, 23, 7545-7549.	2.4	7
1013	Bioisosteres of the Phenyl Ring: Recent Strategic Applications in Lead Optimization and Drug Design. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 14046-14128.	2.9	171
1014	Off-on-off-on use of imatinib in three children with fibrodysplasia ossificans progressiva. <i>Bone</i> , 2021, 150, 116016.	1.4	6
1015	Recent Advances about the Applications of Click Reaction in Chemical Proteomics. <i>Molecules</i> , 2021, 26, 5368.	1.7	9
1016	Synthesis, spectroscopic characterization, structural studies, thermal analysis and molecular docking of <i>N</i> -(2-methyl-5-nitrophenyl)-4-(pyridin-2-yl)pyrimidin-2-amine, a precursor for drug design against chronic myeloid leukemia. <i>Acta Crystallographica Section C, Structural Chemistry</i> , 2021, 77, 621-632.	0.2	0
1017	Positioning imatinib for pulmonary arterial hypertension: A phase I/II design comprising dose finding and single-arm efficacy. <i>Pulmonary Circulation</i> , 2021, 11, 1-12.	0.8	5
1018	Structure of benzothiadiazine at zwitterionic phospholipid cell membranes. <i>Journal of Chemical Physics</i> , 2021, 155, 154303.	1.2	8
1019	Translational research—from basic science to an approved therapeutic—an overview. , 2021, , 663-681.		1
1020	Type 2 Diabetes, Obesity, and Cancer Share Some Common and Critical Pathways. <i>Frontiers in Oncology</i> , 2020, 10, 600824.	1.3	20
1022	Molecular Imaging and Applications for Pharmaceutical R&D. , 0, , 1211-1241.		3
1023	The drug discovery process. , 2005, 62, 1-14.		6
1024	Magnetic resonance and fluorescence based molecular imaging technologies. , 2005, 62, 83-115.		33
1025	Targeting the Tumor Microenvironment (Stroma) for Treatment of Metastasis. , 2008, , 259-270.		1

#	ARTICLE	IF	CITATIONS
1026	Hunting for Peripheral Biomarkers to Support Drug Development in Psychiatry. , 2008, , 405-426.		2
1027	Toward Personalized Therapy for Cancer. , 2008, , 411-425.		1
1028	A Drosophila Based Cancer Drug Discovery Framework. Advances in Experimental Medicine and Biology, 2019, 1167, 237-248.	0.8	8
1029	Targeting the Cancer Epigenome with Histone Deacetylase Inhibitors in Osteosarcoma. Advances in Experimental Medicine and Biology, 2020, 1258, 55-75.	0.8	4
1030	Anti-cancer Drugs: Discovery, Development and Therapy. , 2015, , 81-94.		1
1031	Chemogenomics in Drug Discovery. , 2006, , 1-19.		29
1032	Natural Products in Cancer Chemoprevention and Chemotherapy. , 2009, , 153-171.		9
1033	Why R&D into Rare Diseases Matter. Communications in Medical and Care Compunetics, 2014, , 3-20.	0.2	2
1034	Structural Biology Contributions to the Discovery of Drugs to Treat Chronic Myelogenous Leukemia. NATO Science for Peace and Security Series A: Chemistry and Biology, 2009, , 37-61.	0.5	2
1035	Malignant Gliomas: Role of Platelet-Derived Growth Factor Receptor A (PDGFRA). , 2011, , 109-118.		1
1036	Drugs to Treat Head and Neck Cancers: Mechanisms of Action. , 2013, , 861-913.		1
1037	Imatinib: Basic Results. , 2017, , 11-31.		1
1038	Development of a Ligand-Targeted Therapeutic Agent for Neurokinin-1 Receptor Expressing Cancers. Molecular Pharmaceutics, 2017, 14, 3859-3865.	2.3	8
1039	Biotechnology and Drug Discovery: From Bench to Bedside. Southern Medical Journal, 2003, 96, 1174-1186.	0.3	17
1040	N-(2-Methylphenyl)-2-nitrobenzamide. Acta Crystallographica Section E: Structure Reports Online, 2008, 64, o521-o521.	0.2	2
1041	N-(2-Chloro-4-nitrophenyl)-2-nitrobenzamide. Acta Crystallographica Section E: Structure Reports Online, 2008, 64, o705-o705.	0.2	3
1042	N-(4-Chlorophenyl)-3,4,5-trimethoxybenzamide. Acta Crystallographica Section E: Structure Reports Online, 2008, 64, o1625-o1625.	0.2	3
1043	4-Chloro-N-(2-chlorophenyl)benzamide. Acta Crystallographica Section E: Structure Reports Online, 2008, 64, o1934-o1934.	0.2	8

#	ARTICLE	IF	CITATIONS
1044	Imatinibium dipicrate. Acta Crystallographica Section E: Structure Reports Online, 2010, 66, o411-o412.	0.2	6
1045	Allele-specific RNA interference prevents neuropathy in Charcot-Marie-Tooth disease type 2D mouse models. Journal of Clinical Investigation, 2019, 129, 5568-5583.	3.9	47
1046	Stable expression of small interfering RNA sensitizes TEL-PDGFR to inhibition with imatinib or rapamycin. Journal of Clinical Investigation, 2004, 113, 1784-1791.	3.9	50
1047	Autocrine PDGFR signaling promotes mammary cancer metastasis. Journal of Clinical Investigation, 2006, 116, 1561-1570.	3.9	307
1048	Reversal of experimental pulmonary hypertension by PDGF inhibition. Journal of Clinical Investigation, 2005, 115, 2811-2821.	3.9	917
1049	Structural reengineering of imatinib to decrease cardiac risk in cancer therapy. Journal of Clinical Investigation, 2007, 117, 3650-3653.	3.9	33
1050	Tumours of the central nervous system. , 2004, , 287-322.		4
1051	Recent advances in phenotypic drug discovery. F1000Research, 2020, 9, 944.	0.8	37
1052	Towards a Molecular Understanding of the Link between Imatinib Resistance and Kinase Conformational Dynamics. PLoS Computational Biology, 2015, 11, e1004578.	1.5	59
1053	Functions of Paracrine PDGF Signaling in the Proangiogenic Tumor Stroma Revealed by Pharmacological Targeting. PLoS Medicine, 2008, 5, e19.	3.9	383
1054	RIN3 Is a Negative Regulator of Mast Cell Responses to SCF. PLoS ONE, 2012, 7, e49615.	1.1	42
1055	Gleevec, an Abl Family Inhibitor, Produces a Profound Change in Cell Shape and Migration. PLoS ONE, 2013, 8, e52233.	1.1	15
1056	Hyperplastic Growth of Pulmonary Artery Smooth Muscle Cells from Subjects with Pulmonary Arterial Hypertension Is Activated through JNK and p38 MAPK. PLoS ONE, 2015, 10, e0123662.	1.1	36
1057	Pregnancy outcomes of women whom spouse fathered children after tyrosine kinase inhibitor therapy for chronic myeloid leukemia: A systematic review. PLoS ONE, 2020, 15, e0243045.	1.1	8
1058	RWCFusion: identifying phenotype-specific cancer driver gene fusions based on fusion pair random walk scoring method. Oncotarget, 2016, 7, 61054-61068.	0.8	4
1059	Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia. Oncotarget, 2016, 7, 79842-79853.	0.8	22
1060	Integrated Technology Platform Protein Kinases for Drug Development in Oncology. BioTechniques, 2002, 33, S101-S106.	0.8	9
1061	Human Disease and Drug Pharmacology, Complex as Real Life. Current Medicinal Chemistry, 2013, 20, 1623-1634.	1.2	33

#	ARTICLE	IF	CITATIONS
1062	Recent Advances and Strategies in Tumor Vasculature Targeted Nano-Drug Delivery Systems. <i>Current Pharmaceutical Design</i> , 2015, 21, 3066-3075.	0.9	17
1063	Neuroprotective Mechanisms Mediated by CDK5 Inhibition. <i>Current Pharmaceutical Design</i> , 2016, 22, 527-534.	0.9	57
1064	Abelson Tyrosine-Protein Kinase 1 as Principal Target for Drug Discovery Against Leukemias. Role of the Current Computer-Aided Drug Design Methodologies. <i>Current Topics in Medicinal Chemistry</i> , 2013, 12, 2745-2762.	1.0	15
1065	Chemical Intuition in Drug Design and Discovery. <i>Current Topics in Medicinal Chemistry</i> , 2019, 19, 1679-1693.	1.0	10
1066	Computational Approaches for the Design of (Mutant-)Selective Tyrosine Kinase Inhibitors: State-of-the-Art and Future Prospects. <i>Current Topics in Medicinal Chemistry</i> , 2020, 20, 1564-1575.	1.0	4
1067	The Dual Role of Microglia in Blood-Brain Barrier Dysfunction after Stroke. <i>Current Neuropharmacology</i> , 2020, 18, 1237-1249.	1.4	41
1068	Therapeutic targeting of JAKs: from hematology to rheumatology and from the first to the second generation of JAK inhibitors. <i>Mediterranean Journal of Rheumatology</i> , 2020, 31, 105.	0.3	13
1069	Synthesis of New N-Arylpyrimidin-2-amine Derivatives Using a Palladium Catalyst. <i>Molecules</i> , 2008, 13, 818-830.	1.7	11
1070	Docking Methodologies and Recent Advances. , 2017, , 804-828.		1
1071	Antibacterial Activities of New Schiff Bases and Intermediate Silyl Compounds Synthesized from 5-Substituted-1,10-phenanthroline- 2,9-dialdehyde. <i>Advances in Microbiology</i> , 2014, 04, 1140-1153.	0.3	5
1072	Fibroblasts as therapeutic targets in rheumatoid arthritis and cancer. <i>Swiss Medical Weekly</i> , 2012, 142, w13529.	0.8	36
1073	Reaction of 1-(3,5-Bis(trifluoromethyl)phenyl)-3-(4-(Pyridin-3-yl)pyrimidin-2-yl) urea with Methyl Iodide and X-ray Crystallographic Structure of Its Derivative. <i>Bulletin of the Korean Chemical Society</i> , 2008, 29, 1421-1423.	1.0	2
1074	New Phenylaminopyrimidine (PAP) Anticancer Lead Compound with High Efficacy: Design, Synthesis, and in vitro Screening. <i>Bulletin of the Korean Chemical Society</i> , 2010, 31, 1848-1858.	1.0	3
1075	Design, Synthesis, and Preliminary Cytotoxicity Evaluation of New Diarylureas and Diarylamides Possessing 1,3,4-Triarylpyrazole Scaffold. <i>Bulletin of the Korean Chemical Society</i> , 2012, 33, 2991-2998.	1.0	12
1076	Synthesis and Preliminary Cytotoxicity Evaluation of New Diarylamides and Diarylureas Possessing 2,3-Dihydropyrrolo[3,2-b]quinoline Scaffold. <i>Bulletin of the Korean Chemical Society</i> , 2013, 34, 2480-2486.	1.0	8
1077	Theoretical Characterization of Binding Mode of Organosilicon Inhibitor with p38: Docking, MD Simulation and MM/GBSA Free Energy Approach. <i>Bulletin of the Korean Chemical Society</i> , 2014, 35, 2494-2504.	1.0	1
1078	Multi-Nuclear NMR Investigation of Nickel(II), Palladium(II), Platinum(II) and Ruthenium(II) Complexes of an Asymmetrical Ditertiary Phosphine. <i>Journal of the Korean Chemical Society</i> , 2013, 57, 726-730.	0.2	1
1079	An Efficient Palladium Nanoparticles Catalytic System for Suzuki Coupling Reactions. <i>Chinese Journal of Organic Chemistry</i> , 2019, 39, 3207.	0.6	1

#	ARTICLE	IF	CITATIONS
1080	Angiogenesis Inhibition – A promising approach to combat Cancer. IOSR Journal of Pharmacy and Biological Sciences, 2013, 7, 52-54.	0.1	1
1081	Supported phosphine free bis-NHC palladium pincer complex: An efficient reusable nanocatalyst for Suzuki-Miyaura coupling reaction. Molecular Catalysis, 2021, 515, 111928.	1.0	5
1082	Small Molecule Kinase Inhibitor Drugs (1995–2021): Medical Indication, Pharmacology, and Synthesis. Journal of Medicinal Chemistry, 2022, 65, 1047-1131.	2.9	114
1083	Activation of Oncogenic Protein Kinases. , 2003, , 441-449.		0
1084	Drug Discovery Opportunities. , 2003, , 1-10.		0
1085	Clinical Pharmacology Overview. , 2004, , 111-127.		1
1086	Signal Transduction and Apoptosis Pathways as Therapeutic Targets. Progress in Molecular and Subcellular Biology, 2004, 36, 307-323.	0.9	0
1089	Pharmacoproteomics. , 2006, , 35-50.		0
1090	Emerging Molecular Therapies: Drugs Interfering With Signal Transduction Pathways. , 2008, , 317-365.		0
1091	N-(2-Methoxyphenyl)-2-nitrobenzamide. Acta Crystallographica Section E: Structure Reports Online, 2008, 64, o603-o603.	0.2	0
1092	2,4-Dichloro-N-cyclohexylbenzamide. Acta Crystallographica Section E: Structure Reports Online, 2008, 64, o773-o773.	0.2	3
1096	Novel anti-proliferative strategies. , 2011, , 368-378.		0
1097	Treatment of Chronic Myeloid Leukaemia: Current Practice and Future Prospects. , 0, , .		0
1099	Emerging Potential of Nanoparticles for the Treatment of Solid Tumors and Metastasis. , 2013, , 1-28.		0
1100	Chemical Genomic Approaches to Eradicate Leukemia Stem Cells. Stem Cells and Cancer Stem Cells, 2014, , 93-101.	0.1	0
1101	Anticancer Clinical Pharmacology Overview. Cancer Drug Discovery and Development, 2014, , 141-157.	0.2	1
1102	Research Methods for Clinical Trials in Personalized Medicine: A Systematic Review. , 2014, , 659-684.		1
1103	Docking Methodologies and Recent Advances. Advances in Medical Technologies and Clinical Practice Book Series, 2016, , 295-319.	0.3	0

#	ARTICLE	IF	CITATIONS
1104	Small Molecule Inhibitors. , 2017, , 771-795.		2
1105	Apoptosis and Autophagy. , 2017, , 75-113.		1
1107	Anti-cancer Drugs " Discovery, Development and Therapy. , 2019, , 95-111.		2
1108	Cancer Therapy. , 2019, , 7-76.		0
1110	A unique mutator phenotype reveals complementary oncogenic lesions leading to acute leukemia. JCI Insight, 2019, 4, .	2.3	4
1111	An atom-economical addition of methyl azaarenes with aromatic aldehydes via benzylic C(sp ³)-H bond functionalization under solvent- and catalyst-free conditions. Beilstein Journal of Organic Chemistry, 2020, 16, 3093-3103.	1.3	0
1112	An Efficient And Catalytically Free Chemical Transformation of Pyrimidin-2(1H)-one to 2-(N-Arylamino)pyrimidines and their in vitro Cytotoxicity Evaluation. Asian Journal of Organic & Medicinal Chemistry, 2020, 5, 133-137.	0.1	0
1113	Phenotypic Drug Discovery: History, Evolution, Future. RSC Drug Discovery Series, 2020, , 1-19.	0.2	4
1114	Chemical Probes for Kinases. Chemical Biology, 2020, , 182-213.	0.1	0
1115	Current and Future Therapeutic Targets of the Tumour-Host Microenvironment. , 2005, , 345-367.		0
1118	Stable expression of small interfering RNA sensitizes TEL-PDGFR to inhibition with imatinib or rapamycin. Journal of Clinical Investigation, 2004, 113, 1784-1791.	3.9	30
1121	Platelet-derived growth factor as a therapeutic target for systemic autoimmune diseases. Drug Target Insights, 2007, 2, 239-47.	0.9	4
1123	Targeting eradication of chronic myeloid leukemia using chimeric oncolytic adenovirus to drive IL-24 expression. International Journal of Clinical and Experimental Pathology, 2015, 8, 3775-84.	0.5	2
1124	The use of dynamic nuclear polarization (13)C-pyruvate MRS in cancer. American Journal of Nuclear Medicine and Molecular Imaging, 2015, 5, 548-60.	1.0	32
1125	Bridging academic science and clinical research in the search for novel targeted anti-cancer agents. Cancer Biology and Medicine, 2015, 12, 316-27.	1.4	5
1126	The Effects of Imatinib Mesylate on Cellular Viability, Platelet Derived Growth Factor and Stem Cell Factor in Mouse Testicular Normal Leydig Cells. Journal of Reproduction and Infertility, 2016, 17, 82-7.	1.0	2
1127	Modulating the dysregulated migration of pulmonary arterial hypertensive smooth muscle cells with motif mimicking cell permeable peptides. Current Topics in Peptide and Protein Research, 2015, 16, 1-17.	1.0	5
1129	Continuous Flow Synthesis of Anticancer Drugs. Molecules, 2021, 26, 6992.	1.7	5

#	ARTICLE	IF	CITATIONS
1130	Design and synthesis of novel urea derivatives of pyrimidine-pyrazoles as anticancer agents. <i>Journal of Molecular Structure</i> , 2022, 1251, 131937.	1.8	10
1131	Modulating undruggable targets to overcome cancer therapy resistance. <i>Drug Resistance Updates</i> , 2022, 60, 100788.	6.5	15
1132	Aptamers: an emerging navigation tool of therapeutic agents for targeted cancer therapy. <i>Journal of Materials Chemistry B</i> , 2021, 10, 20-33.	2.9	19
1134	Understanding flow chemistry for the production of active pharmaceutical ingredients. <i>IScience</i> , 2022, 25, 103892.	1.9	16
1135	Defining clinical outcome pathways. <i>Drug Discovery Today</i> , 2022, 27, 1671-1678.	3.2	5
1136	Self-Assembly of Podophyllotoxin-Loaded Lipid Bilayer Nanoparticles for Highly Effective Chemotherapy and Immunotherapy via Downregulation of Programmed Cell Death Ligand 1 Production. <i>ACS Nano</i> , 2022, 16, 3943-3954.	7.3	14
1137	Allosteric Regulation of Cyclic Nucleotide Dependent Protein Kinases. <i>Canadian Journal of Chemistry</i> , 0, , .	0.6	0
1138	Synthesis, crystal structure and negative hyperconjugation study of quinoxaline derivatives containing piperazine. <i>Journal of the Indian Chemical Society</i> , 2022, , 100453.	1.3	1
1139	Why medicines work. , 2022, 238, 108175.		1
1140	Commercial SARS-CoV-2 Targeted, Protease Inhibitor Focused and Protein-Protein Interaction Inhibitor Focused Molecular Libraries for Virtual Screening and Drug Design. <i>International Journal of Molecular Sciences</i> , 2022, 23, 393.	1.8	11
1141	Molecular Classification and Therapeutic Targets in Ependymoma. <i>Cancers</i> , 2021, 13, 6218.	1.7	22
1142	High-throughput metabolomics predicts drug-target relationships for eukaryotic proteins. <i>Molecular Systems Biology</i> , 2022, 18, e10767.	3.2	16
1147	A parallelized, perfused 3D triculture model of leukemia for in vitro drug testing of chemotherapeutics. <i>Biofabrication</i> , 2022, 14, 035011.	3.7	4
1148	Imatinib Mesylate Reduces Neurotrophic Factors and pERK and pAKT Expression in Urinary Bladder of Female Mice With Cyclophosphamide-Induced Cystitis. <i>Frontiers in Systems Neuroscience</i> , 2022, 16, 884260.	1.2	2
1149	The Synergistic Cooperation between TGF- β ² and Hypoxia in Cancer and Fibrosis. <i>Biomolecules</i> , 2022, 12, 635.	1.8	17
1150	Imatinib Mesylate Reduces Voiding Frequency in Female Mice With Acute Cyclophosphamide-Induced Cystitis. <i>Frontiers in Systems Neuroscience</i> , 2022, 16, .	1.2	2
1151	Comparative photo-oxidative degradation of etodolac, febuxostat and imatinib mesylate by UV-C/H ₂ O ₂ and UV-C/S ₂ O ₈ ²⁻ processes: Modeling, treatment optimization and biodegradability enhancement. <i>Environmental Research</i> , 2022, 212, 113385.	3.7	2
1152	Phenotypic drug discovery: recent successes, lessons learned and new directions. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 899-914.	21.5	81

#	ARTICLE	IF	CITATIONS
1153	Trial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy. <i>Oncolmmunology</i> , 2022, 11, .	2.1	9
1154	Affinities and Kinetics Detection of Proteinâ€™Small Molecule Interactions with a Monolayer MoS ₂ â€™Based Optical Imaging Platform. <i>Small</i> , 0, , 2202622.	5.2	0
1156	The piperazine scaffold for novel drug discovery efforts: the evidence to date. <i>Expert Opinion on Drug Discovery</i> , 2022, 17, 969-984.	2.5	9
1157	Trimethylsilyl chloride catalyzed synthesis of fluoro substituted tetrahydropyrimidines: Molecular docking and antidiabetic studies. <i>Chemical Data Collections</i> , 2022, 41, 100904.	1.1	4
1158	Dual Inhibition of <i>RET</i> and <i>FGFR4</i> Restrains Medullary Thyroid Cancer Cell Growth. <i>Clinical Cancer Research</i> , 2005, 11, 1336-1341.	3.2	69
1159	Enhanced cytotoxicity of a novel family of ATPase inhibitors in colorectal cancer cells with high NAT2 activity. <i>Biochemical Pharmacology</i> , 2022, 203, 115184.	2.0	0
1160	Multi or Single-Kinase Inhibitors to Counteract Drug Resistance in Cancer: What is New?. <i>Current Medicinal Chemistry</i> , 2023, 30, 776-782.	1.2	5
1161	Designing Novel BCR-ABL Inhibitors for Chronic Myeloid Leukemia with Improved Cardiac Safety. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 10898-10919.	2.9	7
1162	Plant Metabolites as SARS-CoV-2 Inhibitors Candidates: In Silico and In Vitro Studies. <i>Pharmaceuticals</i> , 2022, 15, 1045.	1.7	9
1163	Pyridine ring as an important scaffold in anticancer drugs. , 2023, , 375-410.		1
1164	The multitarget approach as a green tool in medicinal chemistry. , 2022, , 457-492.		1
1165	Molecular Docking: Metamorphosis in Drug Discovery. , 0, , .		2
1166	Drug Hunting at the Nexus of Medicinal Chemistry and Chemical Biology and the Discovery of Novel Therapeutic Modalities. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 13594-13613.	2.9	3
1167	Novel pyrazolo[3,4-d]pyrimidines as potential anticancer agents: Synthesis, VEGFR-2 inhibition, and mechanisms of action. <i>Biomedicine and Pharmacotherapy</i> , 2022, 156, 113948.	2.5	12
1168	Exploratory Clinical Development: From First in Humans to Phase 3 Ready. <i>Pediatric Oncology</i> , 2022, , 41-49.	0.5	0
1169	Addition of Benzyne to 2-Hydroxypyrimidine to Synthesize 2-Aryloxypyrimidine Derivatives under Mild Conditions. <i>Chinese Journal of Organic Chemistry</i> , 2022, 42, 3835.	0.6	0
1170	Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy. <i>Molecular Biomedicine</i> , 2022, 3, .	1.7	29
1171	Considering the Oral Bioavailability of Protein Kinase Inhibitors: Essential in Assessing the Extent of Drugâ€™Drug Interaction and Improving Clinical Practice. <i>Clinical Pharmacokinetics</i> , 2023, 62, 55-66.	1.6	3

#	ARTICLE	IF	CITATIONS
1172	Detection and Quantification of the Abelson Tyrosine Kinase Domains of the bcr-abl Gene Translocation in Chronic Myeloid Leukaemia Using Genomic Quantitative Real-time Polymerase Chain Reaction. <i>Annals of the Academy of Medicine, Singapore</i> , 2006, 35, 680-687.	0.2	0
1173	Evaluation of separation performance for eggshell-based reversed-phase HPLC columns by controlling particle size and application in quantitative therapeutic drug monitoring. <i>Analytical Methods</i> , 2023, 15, 1790-1796.	1.3	0
1174	Drug discovery: Chaos can be your friend or your enemy. , 2023, , 417-511.		2
1175	Overcoming the imatinib-resistant BCR-ABL mutants with new ureidobenzothiazole chemotypes endowed with potent and broad-spectrum anticancer activity. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2023, 38, .	2.5	3
1176	Imatinib blocks tyrosine phosphorylation of Smad4 and restores TGF- β 2 growth-suppressive signaling in BCR-ABL1-positive leukemia. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	3
1177	From Personalized to Precision Medicine in Oncology: A Model-Based Dosing Approach to Optimize Achievement of Imatinib Target Exposure. <i>Pharmaceutics</i> , 2023, 15, 1081.	2.0	1
1178	Prediction for Plasma Trough Concentration and Optimal Dosing of Imatinib under Multiple Clinical Situations Using Physiologically Based Pharmacokinetic Modeling. <i>ACS Omega</i> , 2023, 8, 13741-13753.	1.6	4
1179	The importance of personalized medicine in chronic myeloid leukemia management: a narrative review. <i>Egyptian Journal of Medical Human Genetics</i> , 2023, 24, .	0.5	0
1180	A comprehensive review on potential candidates for the treatment of chagas disease. <i>Chemical Biology and Drug Design</i> , 2023, 102, 587-605.	1.5	1
1181	General aspects of cancer therapy. , 2023, , 1-35.		0
1183	Target Validation for Medicinal Chemists. , 2023, , 653-681.		1
1184	Anticancer drugs acting on signaling pathways, part 1: Tyrosine kinase inhibitors. , 2023, , 493-563.		0
1185	Modern concepts of pharmaceutical biotechnology in drug development. , 2023, , 1-34.		0
1200	Clonal evolution in leukemia: preleukemia, evolutionary models, and clinical implications. <i>Genome Instability & Disease</i> , 2023, 4, 227-238.	0.5	0
1201	From signalling pathways to targeted therapies: unravelling glioblastoma's secrets and harnessing two decades of progress. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	3
1203	Management of Philadelphia Chromosome-positive Acute Lymphoblastic Leukaemia. , 2023, , 289-310.		0